UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM10-K
(Mark One)
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 20172022
or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period fromto
Commission File Number:001-35331
ACADIA HEALTHCARE COMPANY, INC.
(Exact Namename of Registrantregistrant as Specifiedspecified in Its Charter)its charter)
Delaware | 45-2492228 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
6100 Tower Circle, Suite 1000
Franklin, Tennessee 37067
(Address, including zip code, of registrant’s principal executive offices)
(615) 861-6000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each | Trading Symbol | Name of exchange on which registered | ||
Common Stock, $.01 par value | ACHC | NASDAQ Global Select Market |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationS-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of RegulationS-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form10-K or any amendment to this Form10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | Emerging growth company | ☐ | ||
Non-accelerated filer | ☐ | ||||||
Smaller reporting company | ☐ | ||||||
If an emerging growth company, indicate by check mark ofif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 30, 2017,2022, the aggregate market value of the shares of common stock of the registrant held bynon-affiliates was approximately $3.9$6.0 billion, based on the closing price of the registrant’s common stock reported on the NASDAQ Global Select Market of $49.38$67.63 per share.
As of February 27, 2018,28, 2023, there were 87,950,96591,314,616 shares of the registrant’s common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for its 20182023 annual meeting of stockholders to be held on May 3, 201818, 2023 are incorporated by reference into Part III of this Form10-K.
ACADIA HEALTHCARE COMPANY, INC.
ANNUAL REPORT ON FORM10-K
PART I
Unless the context otherwise requires, all references in this Annual Report on Form10-K to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries.
Overview
Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing quality patient care,high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At December 31, 2017,2022, we operated 582250 behavioral healthcare facilities with approximately 17,80011,000 beds in 39 states the United Kingdom (“U.K.”) and Puerto Rico. During the year ended December 31, 2017,2022, we acquired one facility and added 750 new560 beds, (exclusiveconsisting of the acquisition), including 588290 added to existing facilities and 162270 added through the opening of one wholly-owned facility and two de novo facilities. For the year ending December 31, 2018,joint venture facilities, and we expect to add more than 800 total beds exclusive of acquisitions.opened seven comprehensive treatment centers (“CTCs”).
We are the leading publicly traded pure-play provider of behavioral healthcare services with operations in the United States (“U.S.(the “U.S.”) and the U.K.. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and U.K.bed additions in existing facilities.
Acadia was formed as a limited liability companyOn January 19, 2021, we completed the sale of our operations in the StateUnited Kingdom (the “U.K.”) to RemedcoUK Limited, a company organized under the laws of DelawareEngland and Wales and owned by funds managed or advised by Waterland Private Equity Fund VII (the “U.K. Sale”). The U.K. Sale allowed us to reduce our indebtedness and focus on our U.S. operations. We report, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in 2005, and converted to a corporation on May 13, 2011. the accompanying financial statements. See “U.K. Sale” below for additional details about the U.K. Sale.
Our common stock is listed for trading on The NASDAQ Global Select Market under the symbol “ACHC.” Our principal executive offices are located at 6100 Tower Circle, Suite 1000, Franklin, Tennessee 37067, and our telephone number is(615) 861-6000.
Acquisitions
2017 Acquisition
On November 13, 2017,7, 2022, we completed the acquisition of Aspire Scotland (“Aspire”), an education facility with 36 bedsacquired four CTCs located in Scotland,Georgia from Brand New Start Treatment Centers (“Brand New Start”).
On December 31, 2021, we acquired the equity of CenterPointe Behavioral Health System, LLC and certain related entities (“CenterPointe”) for cash consideration of approximately $21.3$140 million. The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility (as defined below). At the time of the acquisition, CenterPointe operated four acute inpatient hospitals with 306 beds and ten outpatient locations primarily in Missouri.
2016 U.S. AcquisitionsU.K. Sale
On June 1, 2016,January 19, 2021, we completed the acquisitionU.K. Sale pursuant to a Share Purchase Agreement in which we sold all of Pocono Mountain Recovery Centerthe securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of our U.K. operations.The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current British Pounds (“Pocono Mountain”GBP”), an inpatient psychiatric facility with 108 beds located in Henryville, Pennsylvania, for to U.S. Dollars (“USD”) exchange rate, cash considerationretained by the buyer and transaction costs. We used the net proceeds of approximately $25.4 million.
On May 1, 2016, we completed$1,425 million (excluding cash retained by the acquisitionbuyer) along with cash from the balance sheet to reduce debt by $1,640 million during the first quarter of TrustPoint Hospital (“TrustPoint”), an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.
On April 1, 2016, we completed the acquisition of Serenity Knolls (“Serenity Knolls”), an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.
Priory
On February 16, 2016, we completed the acquisition of Priory Group No. 1 Limited (“Priory”) for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of our common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K., operating 324 facilities with approximately 7,100 beds at the acquisition date.
The Competition and Markets Authority (the “CMA”) in the U.K. reviewed our acquisition of Priory. On July 14, 2016, the CMA announced that our acquisition of Priory was referred for a phase 2 investigation unless we offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that we had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider our undertakings.
On October 18, 2016, we signed a definitive agreement with BC Partners (“BC Partners”) for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds (collectively, the “U.K. Disposal Group”). On November 10, 2016, the CMA accepted our undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concern about the impact of our acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K.2021. As a result of the CMA’s acceptanceU.K. Sale, we reported, for all periods presented, results of our undertakings, our acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, we completed the saleoperations and cash flows of the U.K. Disposal Group to BC Partners for £320 million cash (the “U.K. Divestiture”).operations as discontinued operations in the accompanying financial statements.
Our completed acquisitions1
2015 Acquisitions
During 2015, we completed the acquisition of CRC Health Group, Inc. (“CRC”), Quality Addition Management Inc., Choice Lifestyles, Pastoral Care Group, Mildmay Oaks f/k/a Vista Independent Hospital, Care UK Limited, The Manor Clinic, Belmont Behavioral Health, Southcoast Behavioral, The Danshell Group, Health and Social Care Partnerships, Manor Hall, Meadow View, Cleveland House, Duffy’s Napa Valley Rebab, Discovery House-Group Inc and MMO Behavioral Health Systems (collectively with the 2016 Acquisitions , the “2015 and 2016 Acquisitions”).
Financing Transactions
On May 10, 2017, weWe entered into a Third Repricing Amendment (the “Third Repricing Amendment”) to the Amended and Restated Credit Agreement, dated as of December 31, 2012 (the “Amended and Restated Credit Agreement”). The Third Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-1 Term Loancredit agreement establishing a new senior credit facility (the “TrancheB-1“New Credit Facility”) and the TrancheB-2 Term Loan facility (the “TrancheB-2 Facility”) from 3.0% to 2.75% in the case of Eurodollar Rate loans and from 2.0% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, the Company recordedon March 17, 2021. The New Credit Facility provides for a debt extinguishment charge of $0.8$600.0 million including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of operations.
On November 30, 2016, we entered into a Refinancing Facilities Amendment (the “Refinancing Amendment”) to the Amended and Restated Credit Agreement. The Refinancing Amendment increased our line of credit on oursenior secured revolving credit facility to $500.0(the “Revolving Facility”) and a $425.0 million from $300.0 million and reduced our Term Loan Asenior secured term loan facility (the “TLA“Term Loan Facility” and, together with the Revolving Facility, the “Senior Facilities”), each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $400.0$20.0 million from $600.6 million (together, the “Refinancing Facilities”). In addition, the Refinancing Amendment extended the maturity dateto be utilized for the Refinancing Facilities to November 30, 2021 from February 13, 2019, and lowered the effective interest rate on our lineissuance of letters of credit on our revolving creditand (ii) the availability of a swingline facility and TLA Facility by 50 basis points. In connection with the Refinancing Amendment,under which we recorded a debt extinguishment charge of $0.8 million, including thewrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.
On November 22, 2016, we entered into a Tenth Amendment (the “Tenth Amendment”)may borrow up to the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amended the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.
On September 21, 2016, we entered into a TrancheB-2 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-2 Repricing Amendment reduced the Applicable Rate with respect to our TrancheB-2 Facility from 3.75% to 3.00% in the case of Eurodollar Rate loans and 2.75% to 2.00% in the case of Base Rate Loans. In connection with the TrancheB-2 Repricing Amendment, we recorded a debt extinguishment charge of $3.4 million, including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.
On May 26, 2016, we entered into a TrancheB-1 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-1 Repricing Amendment reduced the Applicable Rate with respect to our TrancheB-1 Facility from 3.5% to 3.0% in the case of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.
On February 16, 2016, we issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. We used the net proceeds to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions.
On February 16, 2016, we entered into a Second Incremental Facility Amendment (the “Second Incremental Amendment”) to our Amended and Restated Credit Agreement. The Second Incremental Amendment activated our TrancheB-2 Facility and added $135.0 million to the TLA Facility to our Amended and Restated Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”), subject to limited conditionality provisions. Borrowings under the TrancheB-2 Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were used to pay down the majority of our $300.0 million revolving credit facility.
On January 25, 2016, we entered into the Ninth Amendment (the “Ninth Amendment”) to the Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provided increased flexibility to us in terms of our financial covenants.$20.0 million. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—LiquidityOperations —Liquidity and Capital Resources—Amended and Restated Senior Credit Facility”Resources” for additional information.information about the New Credit Facility and the Prior Credit Facility (as defined below).
As a part of the closing of the New Credit Facility on March 17, 2021, we (i) refinanced and terminated our prior credit facilities under an amended and restated credit agreement, dated as of December 31, 2012 (the “Prior Credit Facility”) and (ii) financed the redemption of all of our outstanding 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”).
In connection with the redemption of the 5.625% Senior Notes, we satisfied and discharged the indentures governing the 5.625% Senior Notes and recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.
On March 1, 2021, we satisfied and discharged the indentures governing the 6.500% Senior Notes due 2024 (“6.500% Senior Notes”). In connection with the redemption of the 6.500% Senior Notes, we recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.
On January 12, 2016,5, 2021, we completed the offeringmade a voluntary payment of 11,500,000 shares of common stock (including shares sold pursuant to the exercise$105.0 million on our Term Loan B facility Tranche B-4 of the over-allotment option thatPrior Credit Facility (the “Tranche B-4 Facility”). On January 19, 2021, we granted to the underwriters as part of the offering) at a public offering price of $61.00 per share. The net proceeds to us from the sale of the shares, after deducting the underwriting discount of $15.8 million and additional offering related costs of $0.7 million, were approximately $685.0 million. We used the net offering proceeds to fund a portion of the purchase price fornet proceeds from the acquisitionU.K. Sale to repay $311.7 million of Priory.the Term Loan A facility of the Prior Credit Facility (the “TLA Facility”) and $767.9 million of our Tranche B-4 Facility.
On September 21, 2015,October 14, 2020, we issued $275.0$475.0 million of additional 5.625%5.000% Senior Notes due 20332029 (the “5.625%“5.000% Senior Notes”).The 5.625%5.000% Senior Notes mature on FebruaryApril 15, 20232029 and bear interest at a rate of 5.625%5.000% per annum, payable semi-annually in arrears on FebruaryApril 15 and AugustOctober 15, commencing on April 15, 2021. We used the net proceeds of each year, beginning on August 15, 2015. The additional notes formed a single class of debt securities with the 5.625%5.000% Senior Notes issued in February 2015. Giving effect to this issuance, we have outstanding an aggregate of $650.0prepay approximately $453.3 million of 5.625% Senior Notes.
On September 21, 2015, we purchased approximately $88.3 million aggregate principal amountthe outstanding borrowings on our Term Loan B facility Tranche B-3 of 12.875% Senior Notes due 2018the Prior Credit Facility (the “12.875% Senior Notes”“Tranche B-3 Facility”) and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with a tender offer for any and all of the 12.875% Senior Notes. The notes purchased represented 90.6% of the outstanding $97.5 million principal amount of 12.875% Senior Notes. The 12.875% Senior Notes were purchased at a price of 107.875% of the principal amount thereof plus accrued and unpaid interest to, but not including, September 21, 2015. On September 18, 2015, we delivered a notice to redeem all $9.2 million in principal amount of the 12.875% Senior Notes remaining outstanding following the consummation of the tender offer. On November 1, 2015, we redeemed all of the outstanding $9.2 million principal amount of the 12.875% Senior Notes. As a result of this redemption, both the 12.875% Senior Notes and the indenture governing the 12.875% Senior Notes were satisfied and discharged in accordance with their terms.offering. In connection with the purchase of notes, the Company5.000% Senior Notes, we recorded a debt extinguishment charge of approximately $10.8$2.9 million, for the year ended December 31, 2015, including the premiumwrite-off of discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costscost in the consolidated statements of income.operations.
On May 11, 2015,June 24, 2020, we completed the offeringissued $450.0 million of 5,175,000 shares of common stock (including shares sold pursuant to the exercise of the over-allotment option that we granted to the underwriters as part of the offering)5.500% Senior Notes due 2028 (the “5.500% Senior Notes”). The 5.500% Senior Notes mature on July 1, 2028 and bear interest at a pricerate of $66.505.500% per share. The net proceeds to us from the saleannum, payable semi-annually in arrears on January 1 and July 1 of the shares, after deducting the underwriting discount of $12.0 million and additional offering-related costs of $0.8 million, were $331.3 million. We used the net offering proceeds to repay outstanding indebtedness and fund acquisitions.
On April 22, 2015, we entered into an Eighth Amendment (the “Eighth Amendment”) to our Amended and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.
On February 11, 2015, we issued $375.0 million of 5.625% Senior Notes.each year, commencing on January 1, 2021. We used the net proceeds to fund a portion of the consideration for5.500% Senior Notes, together with cash on hand, to redeem in full the acquisition of CRC.
On February 11, 2015, we entered into a First Incremental Facility Amendmentoutstanding 6.125% Senior Notes due 2021 (the “First Incremental Amendment”“6.125% Senior Notes”) and the 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”) and to the Amendedpay related fees and Restated Credit Agreement. The First Incremental Amendment activated our TrancheB-1 Facility that was added to the Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-1 Facility were used to fund a portion of the consideration for the acquisition of CRC.
On February 6, 2015, we entered into a Seventh Amendment (the “Seventh Amendment”) to our Amended and Restated Credit Agreement. The Seventh Amendment added Citibank, N.A. as an “L/C Issuer” under the Amended and Restated Credit Agreementexpenses in order to permit the rollover of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.connection therewith.
Competitive Strengths
Management believes the following strengths differentiate us from other providers of behavioral healthcare services:
Premier operational management team with track record of success. Our management team has approximately 160300 combined years of experience in acquiring, integrating and operating a variety of behavioral health facilities. Following the sale of Psychiatric Solutions, Inc. (“PSI”) to Universal Health Services, Inc. (“UHS”) in November 2010, certain of PSI’s key former executive officers joined Acadia in February 2011.healthcare industry. The extensive national experience and operational expertise of our management team give us what management believes to be the premier leadership team in the behavioral healthcare industry. Our management team strives to use its years of experience operating behavioral healthcare facilities to generate strong cash flow and grow a profitable business.
Favorable industry and legislative trends. According to a 20142021 survey by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services (“SAMHSA”), 18.1% of57.8 million adults in the U.S. aged 18 years or older suffered from a mental illness in the prior year and 4.1%14.1 million suffered from a serious mental illness. In addition, 29.7 million U.S. adults with mental illness received no mental health services in the past year. Further, approximately 8.1% of43.7 million people aged 12 or older in 2014 were classified with a2021 needed substance abuse disorderuse treatment in the past year. According to the National Institutea study by The Journal of Mental Health, over 20% ofAmerican Medical Association Pediatrics, an estimated 7.7 million U.S. children either currently or at some point in their life, have hadhas a seriously debilitatingtreatable mental health disorder. Management believes the market for behavioral services will continue to grow due to increased awareness of mental health and substance abuse conditions and treatment options. According to a 2014 SAMHSA report, national expenditures at substance abuse treatment facilities are expected to reach $42.1 billion in 2020, up from $24.3 billion in 2009.
2
While the growing awareness of mental health and substance abuse conditions is expected to accelerate demand for services, recent healthcare reform in the U.S. is expected to increase access to industry services as more people obtain insurance coverage. A key aspect of reform legislation is the extension of mental health parity protections established into law by the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (the “MHPAEA”). The MHPAEA requires employers who provide behavioral health and addiction benefits to provide such coverage to the same extent as other medical conditions. On December 13, 2016, then President Obama signed the 21st21st Century Cures Act. The 21st21st Century Cures Act appropriates substantial resources for the treatment of behavioral health and substance abuse disorders and contains measures intended to strengthen the MHPAEA. On October 21, 2018, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the “SUPPORT Act”) was signed into law. The SUPPORT Act expands Medicare coverage to include Opioid Treatment Programs for services provided on or after January 2, 2020. It also includes Individuals in Medicaid Deserve Care that is Appropriate and Responsible in its Execution Act, which suspends the current prohibition on using federal Medicaid funds to pay for substance use disorder treatment at inpatient treatment facilities with more than 16 beds and limits beneficiaries to no more than 30 days of inpatient treatment per 12 month period.
The mental health hospitals market in the U.K. was estimated at £15.9 billion for 2014/2015. As a result of government budget constraintsNational footprint and an increased focus on quality, the independent mental health hospitals market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K. healthcare industry. Demand for independent sector beds has grown significantly as a result of the National Health Service (the “NHS”) reducing its bed capacityscale with regional density and increasing hospitalization rates. Independent sector demand is expected to further increase in light of additional bed closures and reduction in community capacity by the NHS.
Leading platform in attractive healthcare nichepresence across multiple service lines. We are a leading behavioral healthcare platform in an industry that is undergoing consolidation in an effort to reduce costs and expand programs to better serve the growing need for inpatient behavioral healthcare services. Management expects to take advantage of several strategies that are more accessible as a result of our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. and U.K.count.
Diversified revenue and payor bases. As ofAt December 31, 2017,2022, we operated 582250 facilities in 39 states the U.K. and Puerto Rico. Our payor, patient and geographic diversity mitigates the potential risk associated with any single facility. For the year ended December 31, 2017,2022, we received 32%51% of our revenue from public funded sources in the U.K. (including the NHS, Clinical Commissioning Groups (“CCGs”) and Local Authorities), 28%continuing operations from Medicaid, 20%30% from commercial payors, 10%15% from Medicare and 10%4% from other payors. As we receive Medicaid payments from 4546 states, the District of Columbia and Puerto Rico, management does not believe that we are significantly affected by changes in reimbursement policies in any one state or territory. No facility accounted for more than 3%4% of revenue for the year ended December 31, 2017,2022, and no state or U.S. territory accounted for more than 8%14% of revenue for the year ended December 31, 2017. Our U.K. operations accounted for approximately 36% of our revenue for the year ended December 31, 2017.2022. We believe that our increased geographic diversity will mitigate the impact of any financial or budgetary pressure that may arise in a particular state or market where we operate.
Strong cash flow generationfinancial position to execute our strategy. Management believes we continue to be in a strong position for investments in our facilities, expansion into new and low capital requirements.existing markets and enhancement of our capabilities and infrastructure. We generate strong free cash flow by profitably operating our business and by actively managing our working capital. Moreover, as the behavioral healthcare business does not typically require the procurement and replacement of expensive medical equipment, our maintenance capital expenditure requirements are generally less than that of other facility-based healthcare providers. For the year ended December 31, 2017,2022, our maintenance capital expenditures amounted to approximately 3%2% of our revenue. In addition, our accounts receivable management is less complex than medical/surgical hospital providers because behavioral healthcare facilities have fewer billing codes and generally are paid on a per diem basis.
Business Strategy
Our strategy is to become the indispensable behavioral health provider for the high-acuity and complex needs patient population. We are committed to providing the communities we serve with high-quality, cost-effective behavioral healthcare services, while growing our business, increasing profitability and creating long-term value for our stockholders. To achieve these objectives, we have alignedThis strategy includes five growth pathways: expansions of existing facilities, joint venture partnerships, de novo facilities, acquisitions and expansion across our activities aroundcontinuum of care. Our core strategic priorities include:
Drive organic growth of existing facilities. We seek to increase revenue at our facilities by providing a broader range of services to new and existing patients and clients. In addition, management intends to increase bed counts in our existing facilities. We added 290 beds to existing facilities during the following growth strategies:year ended December 31, 2022, and expect to add approximately 300 beds to existing facilities for the year ending December 31, 2023. Furthermore, management believes that opportunities exist to leverage out-of-state referrals to increase volume and minimize payor concentration, especially with respect to our youth and adolescent focused services and our substance abuse services.
Increase margins by enhancing programs and improving performance at existing facilities.Management believes we can improve efficiencies and increase operating margins by utilizing our management’s expertise and experience within existing programs and their expertise in improving performance at underperforming facilities. Management believes the efficiencies can be realized by investing in growth in strong markets, addressing capital-constrained facilities that have underperformed and improving management systems. Furthermore, our recent acquisitions
3
Fuel facility growth through accelerated joint venture partnerships and referrals.
Opportunistically pursue acquisitionsde novo builds and partnerships.pursuing programmatic mergers and acquisitions. We have positioned our companythe Company as a leading provider of mental health services in the U.S. and the U.K. The behavioral healthcare industry in the U.S. and the independent behavioral healthcare industry in the U.K. areis highly fragmented, and we selectively seek opportunities to expand and diversify our base of operations by acquiring additional facilities and entering into partnerships with healthcare providers to acquire and develop additional facilities. Acadia management believes there are a number of acquisition candidates available at attractive valuations, and weWe have a number of potential joint ventures and acquisitions in various stages of development and consideration in the U.S.
During the year ended December 31, 2022, we added 270 beds through the opening of one wholly-owned facility and two joint venture facilities, and we opened seven CTCs. For the year ending December 31, 2023, we expect to open two wholly-owned facilities, two joint venture facilities and at least six CTCs.
Management believes our focus on behavioral healthcare and history of completing acquisitions provides us with a strategic advantage in sourcing, evaluating and closing acquisitions. We leverage our management team’s expertise to identify and integrate acquisitions based on a disciplined acquisition strategy that focuses on quality of service, return on investment and strategic benefits. We also have a comprehensive post-acquisition strategic plan to facilitate the integration of acquired facilities that includes improving facility operations, retaining and recruiting psychiatrists and other healthcare professionals and expanding the breadth of services offered by the facilities.
Drive organicAccelerate expansion across the care continuum, particularly for patients with opioid use and other substance use disorders. Our growth strategy includes a patient-centric approach covering the full continuum of existing facilities.care, with deep expertise in treating high needs patients. We seekfocus on the most complex patients and are also working to increase revenue atreach underserved patient populations by expanding our facilities by providing a broader rangebreadth of services toand increasing access points within new and existing metropolitan statistical areas.
COVID-19 Impact
During March 2020, the global pandemic of the novel coronavirus known as COVID-19 (“COVID-19”) began to affect our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. and U.K. economies and financial markets. At manyof our facilities, employees and/or patients have tested positive for COVID-19. We are committed to protecting the health of our communities and have been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of our patients and clients. In addition, management intends to increase bed counts inemployees. Over the last three years, all of our existing facilities. Duringfacilities have closely followed infectious disease protocols, as well as recommendations by the year ended December 31, 2017, we added 750 new beds (exclusive of the acquisition), including 588 added to existing facilitiesCenters for Disease Control and 162 added through the opening of two de novo facilities. For the year ending December 31, 2018, we expect to add more than 800 total beds exclusive of acquisitions. Furthermore, management believes that opportunities exist to leverageout-of-state referrals to increase volumePrevention (“CDC”) and minimize payor concentration in the U.S., especially with respect to our youth and adolescent focused services and our substance abuse services.local health officials.
U.S. Operations
Our U.S. facilities and services can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; CTCs; and residential treatment centers; and outpatient community-based services.centers. Outpatient programs associated with our facilities are included within each respective service line. The table below presents the percentage of our total U.S. revenue attributed to each category for the year ended December 31, 2017:2022:
Facility/Service | Revenue for the Year Ended December 31, | |||
Acute inpatient psychiatric facilities | 51 | % | ||
Specialty treatment facilities | 22 | % | ||
Comprehensive treatment centers | 16 | % | ||
Residential treatment centers | ||||
| 11 | % |
We receive payments from the following sources for services rendered in our U.S. facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”);CMS; and (iv) individual patients and clients. For the year ended December 31, 2017 in our U.S. facilities,2022, we received 43%51% of our revenue from Medicaid, 31%30% from commercial payors, 15% from Medicare and 11%4% from other payors.
At December 31, 2017,2022, our U.S. facilities included 209250 behavioral healthcare facilities with approximately 8,90011,000 beds in 39 states and Puerto Rico. Of our U.S. facilities, excluding CTCs, approximately 40%53% are acute inpatient psychiatric facilities, approximately 41%37% are specialty treatment facilities and approximately 14%10% are residential treatment centers and approximately 5% are outpatient community-based service facilities at December 31, 2017.2022. Of the 209250 behavioral healthcare facilities, 112151 are comprehensive treatment centers (“CTCs”) which is a subset of specialty treatment facilities.CTCs. Of ourthe CTCs, 1416 are owned properties and 98135 are leased properties. Of the 97 facilities that are not CTCs, 7791% of our beds are at owned properties and 209% are at leased properties. For the years ended December 31, 20172022 and 2016,2021, our U.S.continuing operations generated revenue of $1.8 billion$2,610.4 million and $1.7 billion,$2,314.4 million, respectively.
4
Acute Inpatient Psychiatric Facilities
Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides24-hour observation, daily intervention and monitoring by psychiatrists. Generally, due to shorter lengths of stay, the related higher patient turnover, and the special security and health precautions required, acute inpatient psychiatric facilities have lower average occupancy than residential treatment centers. Our facilities that offer acute care services provide evaluation and crisis stabilization of patients with severe psychiatric diagnoses through a medical delivery model that incorporates structured and intensive medical and behavioral therapies with24-hour monitoring by a psychiatrist, psychiatric trained nurses, therapists and other direct care staff. Lengths of stay for crisis stabilization and acute care range from three to five days and from five to twelve days, respectively.
Specialty Treatment Facilities
Our specialty treatment facilities include residential recovery facilities and eating disorder facilities and CTCs.facilities. We provide a comprehensive continuum of care for adults with addictive disorders andco-occurring mental disorders. Our detoxification, inpatient, partial hospitalization and outpatient treatment programs are cost-effective and give patients access to the least restrictive level of care. All programs offer individualized treatment in a supportive and nurturing environment.
The majority of our specialty treatment services are provided to patients who abuse addictive substances such as alcohol, illicit drugs or opiates, including prescription drugs. Some of our facilities also treat other addictions and behavioral disorders such as chronic pain, sexual compulsivity, compulsive gambling, mood disorders, emotional trauma and abuse. The goal of our treatment facilities is to provide the appropriate level of treatment to an individual no matter where they are in the lifecycle of their disease in order to restore the individual to a healthier, more productive life, free from dependence on illicit substances and destructive behaviors. Our treatment facilities provide a number of different treatment services such as assessment, detoxification, medication-assisted treatment, counseling, education, lectures and group therapy. We assess and evaluate the medical, psychological and emotional needs of the patient and address these needs in the treatment process. Following this assessment, an individualized treatment program is designed to provide a foundation for a lifelong recovery process. Many modalities are used in our treatment programs to support the individual, including the twelve step philosophy, cognitive/behavioral therapies, supportive therapies and continuing care.
Residential Recovery Facilities.Our inpatient facilities house and care for patients over an extended period and typically treat patients from a broadly defined regional market. We provide three basic levels of residential treatment depending on the severity of the patient’s addiction and/or behavioral disorder. Patients with the most severe dependencies are typically placed into inpatient treatment, in which the patient resides at a treatment facility. If a patient’s condition is less severe, he or she will be offered day treatment, which allows the patient to return home in the evening. The least intensive service is where the patient visits the facility for just a few hours a week to attend counseling/group sessions.
Following primary treatment, our extended care programs typically offer residential care, which allows patients to develop healthy and appropriate living skills while remaining in a safe and nurturing setting. Patients are supported in their recovery by a semi-structured living environment that allows them to begin the process of employment or to pursue educational goals and to take personal responsibility for their recovery. The structure of this treatment phase is monitored by a primary therapist who works with each patient to integrate recovery skills and build a foundation of sobriety with a strong support system. Length of stay will vary depending on the patient’s needs with a minimum stay of 30 days and could be multiple months if needed.
Our outpatient clinics serve patients that do not require inpatient treatment or are transitioning from a residential treatment program; have employment, family or school commitments; and have stabilized in their substance addiction recovery practices and are seeking ongoing continuing care.
Eating Disorder Facilities. Our eating disorder facilities provide treatment services for eating disorders and weight management, each of which may be effectively treated through a combination of medical, psychological and social treatment programs.
Our behavioral therapies are delivered in an array of treatment models that may include individual and group therapy, intensive outpatient, outpatient, partial hospitalization/day treatment, road to recovery and other programs that can be either abstinent or medication-assisted based.
Comprehensive Treatment Centers.
Our CTCs specialize in providing medication-assisted and abstinent-based treatment.treatment in an outpatient setting. Medication-assisted treatment combines behavioral therapy and medication to treat substance use disorders. CTCs utilize medication-assisted treatment to
5
individuals addicted to opiates such as opioid analgesics (prescription pain medications) and heroin.. Medication is used to normalize brain chemistry to block the euphoric effects of alcohol and opioids allowing our professional staff to provide behavioral therapy. Patients begin their treatment attending the clinic almost daily. Then, through successfully progressing in treatment, patients attend less frequently depending on individual treatment plans. The length of treatment differs from patient to patient, but typically ranges fromlasts longer than one to three years.year.
Each of our CTCs provide a range of comprehensive substance abuse treatment support services that include medical, counseling, vocational, educational, and other treatment services. Our behavioral therapies are delivered in array of treatment models that may include individual and group therapy, intensive outpatient, outpatient, partial hospitalization/day treatment, road to recovery, and other programs that can be either abstinent or medication assisted based.
Residential Treatment Centers
Residential treatment centers treat patients with behavioral disorders in anon-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities. Because the setting is less intensive, demands on staffing, security and oversight are generally lower than inpatient psychiatric facilities. In contrast to acute care psychiatric facilities, occupancy in residential treatment centers can be managed more easily given a longer length of stay. Over time, however, residential treatment centers have continued to serve increasingly severe patients who would have been treated in acute care facilities in earlier years.
We provide residential treatment care through a medical model residential treatment facility, which offers intensive, medically-driven interventions and individualized treatment regimens designed to deal with moderate to high level patient acuity. Children and adolescents admitted to these facilities typically have had multiple prior failed treatment plans, severe physical, sexual and emotional abuse, termination of parental custody, substance abuse, marked deficiencies in social, interpersonal and academic skills and a wide range of psychiatric disorders. Treatment typically is provided by an interdisciplinary team coordinating psychopharmacological, individual, group and family therapy, along with specialized accredited educational programs in both secure and unlocked environments. Lengths of stay range from three months to several years.
Certain of our residential treatment centers provide group home, therapeutic group home and therapeutic foster care programs. Our group home programs provide family-style living for youths in a single house or apartment within residential communities where supervision and support are provided by24-hour staff. The goal of a group home program is to teach family living and social skills through individual and group counseling sessions within a real life environment. The residents are encouraged to take responsibility for the home and their health as well as actively take part in community functions. Most attend an accredited and licensedon-premises school or a local public school. We also operate therapeutic group homes that provide comprehensive treatment services for seriously, emotionally disturbed adolescents. The ultimate goal is to reunite or place these children with their families or prepare them, when appropriate, for permanent placement with a relative or an adoptive family. We also manage therapeutic foster care programs, which are considered the least restrictive form of therapeutic placement for children and adolescents with emotional disorders. Children and adolescents in our therapeutic foster care programs often are part of the child welfare or juvenile justice system. Care is delivered in private homes with experienced foster parents who are trained to work with children and adolescents with special needs.
Outpatient Community-Based Services
Our community-based services can be divided into two age groups: children and adolescents (seven to 18 years of age) and young children (three months to six years of age). Community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community. Many patients who participate in community-based programs have transitioned out of a residential facility or have a disorder that does not require placement in a facility that provides24-hour care.
Community-based programs developed for these age groups provide a unique array of therapeutic services to a very high-risk population of children. These children suffer from severe congenital, neurobiological, speech/motor and early onset psychiatric disorders. These services are provided in clinics and employ a treatment model that is consistent with our interdisciplinary medical treatment approach. Depending on their individual needs and treatment plan, children receive speech, physical, occupational and psychiatric interventions that are coordinated with services provided by their referring primary care physician. The children generally receive treatment during regular business hours.
U.K. Operations
Overview
WithPrior to the Priory and Partnerships in Care acquisitions,U.K. Sale, we arewere the leading independent provider of mental health services in the U.K. operating 373345 inpatient behavioral health facilities with approximately 8,9008,200 beds as ofat December 31, 2017. The2020. Our U.K. facilities arewere located in England, Wales, Scotland and Northern Ireland. For the years ended December 31, 20172021 and 2016,2020, our U.K. operations generated revenue of $1.0 billion$62.5 million and $1.1 billion,$1,119.8 million, respectively, primarily through the operation and management of inpatient behavioral health facilities. The year ended December 31, 2016 was impacted by the acquisition of Priory on February 16, 2016
Additional information about our U.K. operations and the U.K. Divestiture on November 30, 2016.
United Kingdom Healthcare and Adult Social Care Sectors
In the U.K., central government spending on health for fiscal year 2017-2018 is budgeted at approximately £149 billion, according to the U.K. government budget. This spending is primarily delivered by the NHS, which operates as three separate national public sector bodies in England, Scotland and Wales as well as the Northern Ireland Health and Social Care Board. Local Government gross spending on adult social care for the fiscal year 2017-2018 is budgeted at approximately £25 billion and is commissioned by local authorities in England, Scotland and Wales, which we refer to as Local Authorities and by the Northern Ireland Health and Social Care Board. The NHS, Local Authorities and Northern Ireland Health and Social Care Board commissioners dominate the U.K. health and social care markets in terms of the funding of care. With the exception of the elderly residential and nursing care market, private health insurance and self-payment play a minor role in these sectors.
The mental health market in the U.K. was estimated at £15.9 billion for 2014/2015. The independent mental health market accounted for roughly £1.4 billion of that amount, or approximately 9% market share. As a result of government budget constraints and an increased focus on quality, the independent mental health market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K.’s behavioral healthcare industry.
Publicly-funded healthcare services in England are commissioned at two levels as follows: (i) nationally by NHS England which, via its Local Area Teams commissions specialized healthcare services, including specialized Mental Health Secure, Eating Disorder and Children and Adolescent (CAMHS) services, and (ii) locally by over 200 local CCGs, which commission all acute, rehabilitation and community-based healthcare services. In Scotland and Wales, all healthcare services are commissioned by Local/Regional Health Boards.
The principal distinction between healthcare and social care relates to an individual’s assessed care needs. If there is a primary health need, services are commissioned by the NHS under the general NHS principle that the services are free at the point of delivery. In the case of adult social care, individuals’ healthcare-related needs have been assessed as being of secondary importance with services being means-tested. Local Authority commissioners of adult social care provided in care homes and other community settings are responsible for undertaking financial assessments to determine the level of contributions that individuals must pay towards the cost of their care. Individuals with income or capital above set statutory thresholds must fund the full cost of their care.
In recent years, the U.K. Government has placed increasing emphasis on implementing integrated care pathways across health and social care services. Integrated care pathways provide patients with highly coordinated and personalized care overseen by relevant commissioners working together to plan, arrange and monitor patient progression through each stage of the care pathway.
Additionally, mental health commissioning trends toward moving patients more quickly down care pathways, out of higher acuity, more intensive care settings towards community focused care services have increased the demand for community and rehabilitation services in the independent mental health market. The Department of Health in England recently identified priorities for essential change in mental health that include, among other things, funding providers based on the quality of their service rather than volume of patients, allocating funds to support specialized housing for people with mental health problems and adopting a new rating system and inspection process to improve the quality of care. Increasing political focus on the provision of mental health services in the U.K. and increasing support for the rights of mental health patients are expected to lead to further increases in the size of the mental health market in the U.K. In addition, rising demand for mental health services in the U.K. coupled with a constrained mental healthcare funding environment are increasing pressure to improve operational efficiency and refer patients to single provider programs with care pathways that more appropriately reflect each patient’s specific mental health needs. As a result of these pressures and an increased focus on quality, the independent mental health market has witnessed significant expansion in the last decade, making it one of the fastest growing sectors in the U.K. healthcare industry.
Description of U.K. Facilities
In the U.K., we provide inpatient services through a variety of facilities, including mental health hospitals, clinics, care homes, schools, colleges and children’s homes. In addition to these services, we also operate a U.K. division that leverages on our clinical knowledge to provide Employee Assistance Programs (“EAP”) to organizations.
Our U.K. facilities and servicesindustry can generally be classified into the following categories: healthcare facilities, education and children’s services, adult care facilities and elderly care facilities. The table below presents the percentage of our total U.K. revenue attributed to each category for the year ended December 31, 2017:
| ||||
| ||||
| ||||
| ||||
|
We receive payments from approximately 500 public funded sources in the U.K. (including the NHS, CCGs and Local Authorities) and individual patients and clients. For the year ended December 31, 2017found in our U.K. facilities, we received 91% of our revenue from public funded sources inprior filings with the U.K. (including the NHS, CCGs and Local Authorities) and 9% from other payors.SEC.
At December 31, 2017, our U.K. facilities included 373 behavioral healthcare facilities with approximately 8,900 beds, including approximately 1,000non-residential education places, in the U.K. Of our U.K. facilities, approximately 22% are healthcare facilities, approximately 20% are education and children’s services facilities, approximately 47% are adult care facilities and approximately 11% are elderly care facilities at December 31, 2017. At December 31, 2017, 291 of our U.K. facilities are owned properties and 82 are leased properties.
Healthcare
In the U.K., mental health hospitals provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients detained under a section of the U.K.’s Mental Health Act of 1983, and whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient. The levels of dependency and risk stemming from the wide range of disorders treated at these hospitals determine the level of care provided, which are comprised of:
Other Services
Sources of Revenue
We receiveAs of December 31, 2022, we received payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and Local Authorities); and (v)(iv) individual patients and clients. Revenue is recorded inWe determine the period in which services are provided attransaction price based on established billing rates lessreduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Revenue” Operations — Critical Accounting Policies — Revenue and Accounts Receivable”
6
for additional disclosure. Other information related to our revenue, income and other operating information is provided in our Consolidated Financial Statements.
Regulation
U.S. Overview
The healthcare industry is subject to numerous laws, regulations and rules including, among others, those related to government healthcare program participation requirements, various licensure and accreditation standards, reimbursement for patient services, health information privacy and security rules, and government healthcare program fraud and abuse provisions. Providers that are found to have violated any of these laws and regulations may be excluded from participating in government healthcare programs, subjected to loss or limitation of licenses to operate, subjected to significant fines or penalties and/or required to repay amounts received from the government for previously billed patient services. Management believes that we are in substantial compliance with all applicable laws and regulations and is not aware of any material pending or threatened investigations involving allegations of wrongdoing.
Licensing, Certification and Accreditation
All of our facilities must comply with various federal, state and local licensing and certification regulations and undergo periodic inspection by licensing agencies to certify compliance with such regulations. The initial and continued licensure of our facilities and certification to participate in government healthcare programs depends upon many factors including various state licensure regulations relating to quality of care, environment of care, equipment, services, staff training, personnel and the existence of adequate policies, procedures and controls. Federal, state and local agencies survey our facilities on a regular basis to determine whether the facilities are in compliance with regulatory operating and health standards and conditions for participating in government healthcare programs.
Most of our inpatient and residential facilities maintain accreditation from private entities, such as The Joint Commission or the Commission on Accreditation of Rehabilitation Facilities (“CARF”). The Joint Commission and CARF are private organizations that have accreditation programs for a broad spectrum of healthcare facilities. The Joint Commission accredits a broad variety of healthcare organizations, including hospitals and behavioral health organizations. CARF accredits behavioral health organizations providing mental health and alcohol and drug use and addiction services, as well as opiate treatment programs, and many other types of healthcare programs. These accreditation programs are intended generally to improve the quality, safety, outcomes and value of healthcare services provided by accredited facilities. Certain federal and state licensing agencies as well as many in government and private healthcare payment programs require that providers be accredited as a condition of licensure, certification or participation. Accreditation is typically granted for a specified period, ranging from one to three years, and renewals of accreditation generally require completion of a renewal application and anon-site renewal survey.
Certificates of Need
Many of the states in which we operate facilities have enacted certificate of need (“CON”) laws that regulate the construction or expansion of certain healthcare facilities, certain capital expenditures or changes in services or bed capacity. Failure to obtain CON approval of certain activities can result in: our inability to complete an acquisition, expansion or replacement; the imposition of civil penalties; the inability to receive Medicare or Medicaid reimbursement; or the revocation of a facility’s license, any of which could harm our business.
Quality Improvement
Services provided to Medicare beneficiaries are subject to review by Quality Improvement Organizations (“QIOs”), which aim to improve the effectiveness, efficiency, economy and quality of services furnished within the Medicare program. QIOs are independent organizations that contract with CMS to perform several functions, including reviewing the appropriateness of patient admissions and discharges, the quality of care provided, the validity of diagnosis related group classifications, and the appropriateness of length of stay, as well as investigating beneficiary complaints. QIOs may recommend the imposition of sanctions against a Medicare provider found to have, among other things, provided services deemed medically unnecessary or not of a quality that meets professionally recognized standards of care. Such sanctions may include monetary assessments and exclusion from participation in government healthcare programs.
Audits
Our healthcare facilities are also subject to federal, state and commercial payor audits to validate the accuracy of claims submitted to the government healthcare programs and commercial payors. If these audits identify overpayments, we could be required to make substantial repayments, subject to various appeal rights. Several of ourOur facilities have undergoneare routinely subjected to claims audits related to their receiptin the ordinary course of payments during the last several years withbusiness. While no such audit has identified any material overpayments identified. However,overpayment liability, should a potential material overpayment liability arise from a future audits couldaudit, such overpayment liability may ultimately exceed established reserves, and any excess could potentially be substantial. Further, Medicare and Medicaid regulations, as well as commercial payor contracts, also provide for withholding or suspending payments in certain circumstances, which could adversely affect our cash flow.
The Anti-Kickback Statute, andthe Stark Law and the Eliminating Kickbacks in Recovery Act
The Anti-Kickback Statute prohibits healthcare providers and others from directly or indirectly soliciting, receiving, offering or paying any remuneration, in cash or in kind, as an inducement or reward for using, referring, ordering, recommending or arranging for such referrals or orders of services or other items paid for by a government healthcare program. The Anti-Kickback Statute may be found to have been violated if at least one purpose of the remuneration is to induce or reward referrals. A provider is not required to have actual knowledge or specific intent to commit a violation of the Anti-Kickback Statute to be found guilty of violating the law.
7
The Office of Inspector General of the Department of Health and Human Services (the “OIG”) has issued safe harbor regulations that protect certain types of common arrangements from prosecution or sanction under the Anti-Kickback Statute and there are also several statutory exceptions toward that end.Statute. The fact that conduct or a business arrangement does not fall within a safe harbor or exception does not automatically render the conduct or business arrangement illegal under the Anti-Kickback Statute. However, conduct and business arrangements falling outside the safe harbors may lead to increased scrutiny by government enforcement authorities. In December of 2020, the OIG finalized revisions to the Anti-Kickback Statute safe harbors and created new safe harbors for value-based care that became effective January 19, 2021. The new regulations are intended to improve patient care and foster innovative care models by easing regulatory burdens to coordinated and value-based care.
Although management believes that our arrangements with physicians and other referral sources comply with current law and available interpretative guidance, as a practical matter it is not always possible to structure our arrangements so as to fall squarely within an available safe harbor. Where that is the case, we cannot guarantee that applicable regulatory authorities will determine these financial arrangements do not violate the Anti-Kickback Statute or other applicable laws, including state anti-kickback laws.
In addition to the Anti-Kickback Statute, the federal Physician Self-Referral Law, also known as the Stark Law, prohibits physicians from referring Medicare patients to healthcare entities with which they or any of their immediate family members have a financial relationship for the furnishing of any “designated health services” unless certain exceptions apply. A violation of the Stark Law may result in a denial of payment; required refunds to the Medicare program; imposition of statutory civil monetary penalties of up to $24,253$15,000 for each prohibited claim up to $161,692 for circumvention schemes, and up to $19,246$100,000 for each day the entity fails to report required information;circumvention schemes; exclusion from government healthcare programs; and liability under the False Claims Act. There are ownership and compensation arrangement exceptions for many customary financial arrangements between physicians and facilities, including the employment exception, personal services exception, lease exception and certain recruitment exceptions. As part of CMS’s “regulatory sprint to coordinated care”, CMS finalized revisions to the exceptions and created new exceptions for value-based care that became effective on January 19, 2021. As with the changes made to the Anti-Kickback Statute, the new Stark exceptions are intended to improve patient care and foster innovative care models by easing regulatory burdens to coordinated and value-based care.
Management believes that our financial arrangements with physicians are structured to comply with the regulatory exceptions to the Stark Law. However, the Stark Law is a strict liability statute, meaning that no intent is required to violate the law, and even a technical violation may lead to significant penalties.
These laws and regulations are extremely complex and, in many cases, we do not have the benefit of regulatory or judicial interpretation. It is possible that different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our arrangements relating to facilities, equipment, personnel, services, capital expenditure programs and operating expenses. A determination that we have violated one or more of these laws, or the public announcement that we are being investigated for possible violations of one or more of these laws, could have a material adverse effect on our business, financial condition or results of operations. In addition, we cannot predict whether other federal or state legislation or regulations will be adopted, what form such legislation or regulations may take or what their impact on us may be.
The SUPPORT Act contains a number of provisions aimed at identifying at-risk individuals, increasing access to opioid abuse treatment, reducing overprescribing and promoting data sharing with the primary goal of reducing the use and abuse of opioids. Additionally, the SUPPORT Act attempts to address the problem of “patient brokering” in the context of addiction treatment facilities and sober living homes.
One section of the SUPPORT Act, the Eliminating Kickbacks in Recovery Act (the “EKRA”), makes it a federal crime to knowingly and willfully: (1) solicit or receive any remuneration in return for referring a patient to a recovery home, clinical treatment facility or laboratory; or (2) pay or offer any remuneration to induce such a referral or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. Each conviction under the EKRA is punishable by up to $200,000 in monetary damages, imprisonment for up to ten (10) years, or both. Unlike the Anti-Kickback Statutes, the EKRA is not limited to services reimbursable under a government healthcare program. The EKRA also contains exceptions similar to the Anti-Kickback Statute safe harbors, but those exceptions are more narrow than the Anti-Kickback Statute safe harbors such that practices that would be permissible under the Anti-Kickback Statute may violate the EKRA.
If we are deemed to have failed to comply with the Anti-Kickback Statute, the Stark Law, the EKRA or other applicable laws and regulations, we could be subjected to liabilities, including criminal penalties, civil penalties and exclusion of one or more facilities from participation in the government healthcare programs. The imposition of such penalties could have a material adverse effect on our business, financial condition or results of operations.
8
Federal False Claims Act and Other Fraud and Abuse Provisions
The federal False Claims Act provides the government a tool to pursue healthcare providers for submitting false claims or requests for payment for healthcare items or services. Under the False Claims Act, the government may fine any person or entity that, among other things, knowingly submits, or causes the submission of, false or fraudulent claims for payment to the federal government or knowingly and improperly avoids or decreases an obligation to pay money to the federal government. The federal government has widely used the False Claims Act to prosecute Medicare and other federal healthcare program fraud such as coding errors, billing for services not provided, submitting false cost reports and providing care that is not medically necessary or that is substandard in quality. Claims for services or items rendered in violation of the Anti-Kickback Statute or the Stark Law can provide a basis for liability under the False Claims Act as well. The False Claims Act is also implicated by the knowing failure to report and return an overpayment within 60 days of identifying the overpayment or by the date a corresponding cost report is due, whichever is later.
Violations of the False Claims Act are punishable by significant penalties totaling $10,957$13,508 to $21,916$27,018 for each fraudulent claim plus three times the amount of damages sustained by the government. In addition, under the qui tam, or whistleblower, provisions of the False Claims Act, private parties may bring actions under the False Claims Act on behalf of the federal government. These private parties, often referred toknown as relators, are entitled to share in any amounts recovered by the government, and, as a result, whistleblower lawsuits have increased significantly in recent years. Many states have similar false claims statutes that impose liability for the types of acts prohibited by the False Claims Act or that otherwise prohibit the submission of false or fraudulent claims to the state government or Medicaid program.
In addition to the False Claims Act, the federal government may use several criminal laws, such as the federal mail fraud, wire fraud or health carehealthcare fraud statutes, to prosecute the submission of false or fraudulent claims for payment to the federal government. Most states have also adopted generally applicable insurance fraud statutes and regulations that prohibit healthcare providers from submitting inaccurate, incorrect or misleading claims to private insurance companies. Management believes our healthcare facilities have implemented appropriate safeguards and procedures to complete claim forms and requests for payment in an accurate manner and to operate in compliance with applicable laws. However, the possibility of billing or other errors can never be completely eliminated, and we cannot guarantee that the government or a qui tam plaintiff, upon audit or review, would not take the position that billing, the quality of patient care or other deficiencies or errors, should they occur, are violations of the False Claims Act.
HIPAA Administrative Simplification and Privacy and Security Requirements
The administrative simplification provisions of the Health Insurance Portability and Accountability Act (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), require the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry. HIPAA also established federal rules protecting the privacy and security of individually identifiable protected health information (“PHI”). The privacy and security regulations control the use and disclosure of PHI and the rights of patients to be informed about and control how such PHI is used and disclosed. Violations of HIPAA can result in both criminal and civil fines and penalties.
The HIPAA security regulations require healthcare providers to implement administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of PHI. HITECH has strengthened certain HIPAA rules regarding the use and disclosure of PHI, extended certain HIPAA provisions to business associates and created security breach notification requirements including notifications to the individuals affected by the breach, the Department of Health and Human Services, and in certain cases, the media. HITECH has also increased maximum penalties for violations of HIPAA privacy rules. Management believes that we have been in material compliance with the HIPAA regulations and have developed our policies and procedures to ensure ongoing compliance, although we cannot guarantee that our facilities will not be subject to security incidents or breaches which could have a material adverse effect on our business, financial condition or results of operations.
The Emergency Medical Treatment & Labor Act
The Emergency Medical Treatment & Labor Act (“EMTALA”) is intended to ensure public access to emergency services regardless of ability to pay. Section 1867 of the Social Security Act imposes specific obligations on Medicare-participating hospitals that offer emergency services to provide a medical screening examination when a request is made for examination or treatment for an emergency medical condition regardless of an individual’s ability to pay. Hospitals are then required to provide stabilizing treatment for patients with emergency medical conditions. If a hospital is unable to stabilize a patient within its capability, or if the patient requests, an appropriate transfer must be implemented. EMTALA imposes additional obligations on hospitals with specialized capabilities, such as ours, to accept the transfer of patients in need of such specialized capabilities if those patients present in the emergency room of a hospital that does not possess the specialized capabilities.
9
Mental Health Parity Legislation
The MHPAEA was signed into law in October 2008 and requires health insurance plans that offer mental health and addiction coverage to provide that coverage on par with financial and treatment coverage offered for other illnesses. The MHPAEA has some limitations because health plans that do not already cover mental health treatments are not required to do so, and health plans are not required to provide coverage for every mental health condition published in the Diagnostic and Statistical Manual of Mental Disorders by the American Psychiatric Association. The MHPAEA also contains a cost exemption which operates to exempt a group health plan from the MHPAEA’s requirements if compliance with the MHPAEA becomes too costly.
On December 13, 2016, then President Obama signed the 21st Century Cures Act. The 21st Century Cures Act appropriated substantial resources for the treatment of behavioral health and substance abuse disorders and contained measures intended to strengthen the MHPAEA.
Patient Protection and Affordable Care Act
The Patient Protection and Affordable CareCARES Act and Other Regulatory Developments
On March 27, 2020, the Health CareCoronavirus Aid, Relief and Education ReconciliationEconomic Security Act of 2010 (collectively, “PPACA”(the “CARES Act”) dramatically alteredwas signed into law. The CARES Act is intended to provide over $2 trillion in stimulus benefits for the U.S. health care system. PPACA sought to provide coverage and access to substantially all Americans, to increase the quality of care provided, and to reduce the rate of growth in health care expenditures. PPACA attempted to achieve these goals by, amongeconomy. Among other things, requiring most Americansthe CARES Act includes additional support for small businesses, expands unemployment benefits, makes forgivable loans available to obtain health insurance, expanding the Medicare program’s use of value-based purchasing programs, bundling payments to hospitalssmall businesses, provides for certain federal income tax changes, and provides $500 billion for loans, loan guarantees, and other investments for or in U.S. businesses.
In addition, the CARES Act contains a number of provisions that are intended to assist healthcare providers reducing Medicare and Medicaid payments to providers, expanding Medicaid eligibility, and tying reimbursement toas they combat the satisfaction of certain quality criteria.
On January 20, 2017, Donald Trump became Presidenteffects of the United States. DuringCOVID-19 pandemic. Those provisions include, among others:
• | an appropriation to the Public Health and Social Services Emergency Fund (“PHSSE Fund”), also known as the Provider Relief Fund, to reimburse, through grants or other mechanisms, eligible healthcare providers and other approved entities for COVID-19-related expenses or lost revenue; |
• | the expansion of CMS’ Accelerated and Advance Payment Program; |
• | the temporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022; and |
• | waivers or temporary suspension of certain regulatory requirements. |
The U.S. government initially announced it would offer $100 billion of relief to eligible healthcare providers through the 2016 election cycle, Republicans also assumed control of both the United States Senate and House of Representatives. Shortly after his inauguration, President Trump issued an executive order that, among other things, stated that it was the intent of his administration to repeal PPACA and, pending that repeal, instructed the executive branch of the federal government to defer or delay the implementation of any provision or requirement of PPACA that would impose a fiscal burden on any state or a cost, fee, tax, or penalty on any individual, family, health care provider, or health insurer. Several bills have been introduced and voted upon in the House of Representatives and United States Senate that would either repeal and replace or simply repeal PPACA, although none have been enactedto-date.
PHSSE Fund. On October 12, 2017,April 24, 2020, then President Trump signed an executive order intendinginto law the Paycheck Protection Program and Health Care Enhancement Act (the “PPP Act”). Among other things, the PPP Act allocates $75 billion to expandeligible healthcare providers to help offset COVID-19 related losses and expenses. The $75 billion allocated under the availabilityPPP Act is in addition to the $100 billion allocated to healthcare providers for the same purposes in the CARES Act and has been disbursed to providers under terms and conditions similar to the CARES Act funds. In 2020, we received approximately $34.9 million ofso-called association health plans the funds distributed from the PHSSE Fund. During the fourth quarter of 2020, we recorded approximately $32.8 million of income from provider relief fund related to PHSSE Fund funds received in 2020.
In 2021, we received $24.2 million of additional funds from the PHSSE Fund. During the fourth quarter of 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received. During the year ended December 31, 2022, we received $7.7 million of additional funds from the PHSSE Fund and short-term plans outside PPACA’s requirements. President Trump also announced that$14.2 million from the administration would cease making cost-sharing reduction paymentsAmerican Rescue Plan (“ARP”) Rural Payments for Hospitals. During the year ended December 31, 2022, we recorded $21.5 million of income from provider relief fund related to health insurance companies that help coverout-of-pocket costs forlow-income individuals. Finally,PHSSE Fund and ARP funds received. The remaining ARP funds of $9.0 million are included in other accrued liabilities on the Tax Act (as defined and described below) effectively eliminates PPACA’s individual health insurance mandateconsolidated balance sheet as of 2018 by reducingDecember 31, 2022. We continue to zeroevaluate our compliance with the tax penalty associated with failureterms and conditions to, maintain health insurance coverage.
It is difficult to predict whether PPACA will be repealed, replaced, or modified; whatand the effect will befinancial impact of, these additional funds received, including potential repayment of the health care-related provisions in the Tax Act; or the impact that the President’s executive actions will have on the implementation and enforcementremaining balance.
Healthcare providers were required to sign an attestation confirming receipt of the provisionsProvider Relief Fund funds and agree to the terms and conditions of PPACA orpayment. Under the regulations adopted or to be adopted to implement the law or the President’s executive orders. In addition, if PPACA is replaced or modified, it remains unclear what the replacement plan or modifications would be, when the changes would become effective, or whether anyterms and conditions for receipt of the existing provisionspayment, we were allowed to use the funds to cover lost revenues and healthcare costs related to COVID-19, and we were required to properly and fully document the use of PPACA would remain in place. Even if the current administration is not successful in its efforts to repeal and replace PPACA, there have been and likely will continue to be a number of legal challenges to various provisions of the law and President Trump’s recent executive actions. Limitations on the availability of adequate insurance coverage for patients seeking services at our facilities; any reductions in government healthcare spending; and the possible repeal, replacement or modification of PPACA could have a material adverse effect on our business, financial condition, or results of operations.
U.S. Tax Reform
On December 22, 2017, Public Law115-97, informally referred to as the Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law. The Tax Act provides for significant changesthese funds to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21% for U.S. taxable income. The Tax Act requires aone-time remeasurementDepartment of deferred taxes to reflect their value at a lower tax rate of 21%Health and Human Services (“HHS”). The Tax Act includes other changes, including, but not limited to, requiring aone-time transition tax on certain unrepatriated earnings of foreign subsidiaries that is payable over eight years, a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries, a new provision designed to tax global intangiblelow-taxed income, a limitationreporting of the deduction for net operating losses, elimination of net operating loss carrybacks, immediate deductions for certain new investments instead of deductions for depreciation expense for certain qualified property, additional limitations on the deductibility of executive compensation and limitations on the deductibility of interest. The effects of the Tax Act on the Company are still being evaluated.
U.K. Overview
The regulatory environment applicable to facilities in the U.K.funds is complex and multifaceted. The regulatory regime is made up of multiple statutes, regulations and minimum standards that are subject to continuous change. The laws and regulations applicable to the U.K. facilities include, without limitation, the Mental Capacity Act of 2005, Safeguarding Vulnerable Groups Act of 2006, Mental Health Act of 2007, Health and Social Care Act of 2008 and Corporate Manslaughter and Corporate Homicide Act of 2008. These laws and regulations are predominantly protective in nature and share the same general underlying purpose to protect vulnerable persons from exploitation or harm. The regulatory requirements relevant to our facilities in the U.K. cover our operations from the initial establishments of new facilities, which are subject to registration and licensing requirements, to the recruitment and appointment of staff, occupational health and safety, duty of care to service users, clinical and educational standards, conduct of our professional and support staff and other areas.
Mental Capacity Act of 2005. The Mental Capacity Act of 2005 establishes the processfuture audit for determining whether a person lacks mental capacity at a particular time and also sets out who can make decisions in those circumstances and how they should go about this. The Act sets out when liability may arise for actions in connection with the care or treatment of persons who lack capacity to consent to such actions.
Safeguarding Vulnerable Groups Act of 2006. The Safeguarding Vulnerable Groups Act of 2006 created the Independent Safeguarding Authority (“ISA”). In December 2012, the ISA merged with the Criminal Records Bureau to form the Discharge and Barring Service (“DBS”) and is required to establish and maintain lists of persons barred from working with children and adults. It is a criminal offense for a barred person to seek to work, or work in, activities from which they are barred. It is also generally a criminal offense for an employer to allow a barred person, or person who is not appropriately registered, to work in any regulated activity. The Children Act 1989 also allocates duties to Local Authorities, courts, parents, and other agencies in the U.K. to ensure children are safeguarded and their welfare is promoted.
The Mental Health Act of 2007. The Mental Health Act of 2007 regulates the manner in which an individual can be committed or detained against his or her will. The main purpose of the legislation is to ensure that people with serious mental disorders which threaten their health or safety or the safety of the public can be treated irrespective of their consent where it is necessary to prevent them from harming themselves or others. The Act places the burden on the entity detaining a person to prove that the entity has the right to hold the detainee. This places a substantial regulatory burden on service providers to ensure compliance with the law. Thereterms and conditions. We recognized Provider Relief Fund funds to the extent we had qualifying COVID-19 expenses or lost revenues as permitted under the terms and conditions. The grant income associated with the COVID-19 expenses and
10
lost revenues incurred during the years ended December 31, 2022, 2021 and 2020 is similar legislationreflected as income from provider relief fund in Scotland, Walesour consolidated statement of operations.
During 2020, we applied for and Northern Ireland.
The Health and Social Care Act of 2008. The Health and Social Care Act of 2008 (“HSCA”), as amended by the Care Act 2014, established the Care Quality Commission (“CQC”) as the registration and regulatory body for health and adult social care in England. Under the HSCA, service providers carrying out “regulated activities” must be registered with the CQC for each separate regulated activity provided. Where the service provider isCARES Act, we received a company, each regulated activity/location must also have an individual registered as the registered manager. Registration depends both on an assessment of the fitness of the registered provider and also the individual registered manager. Regulated activities include the provision of residential accommodation together with nursing or personal care and the provision of treatment for a disease, disorder or injury by or under the supervision of a social worker or a multidisciplinary team which includes a social worker where the treatment is for a mental disorder.
The Care Act 2014. The Care Act 2014 came into force on April 1, 2015 along with a range of supporting regulations and a single set of statutory guidance. The Care Act 2014 requires Local Authorities to set personal budgets for individuals that are appropriate to meeting those individuals’ assessed eligible care and support needs. The Care Act 2014 also imposes new statutory duties upon Local Authorities to ensure the supply of diverse, good quality, local services, including a duty to plan for future demand and to ensure that services are high quality and sustainable.
The regulated activities regulations and the registration regulations issued pursuant to the HSCA place legally binding obligations on health and social care providers. Breach of certain provisions of the HSCA or the regulations is a criminal offense. In addition, a breach may lead to the CQC taking action to suspend, cancel or vary the conditions of registration of a service provider or impose a substantial fine.
Inspections by regulators2% increase in the U.K. can be carried out on both an announced and an unannounced basis depending on the specific regulatory provisions relating to the different services provided and also depending upon whether the inspection is routine orour facilities’ Medicare reimbursement rate as a result of specific information regarding the servicetemporary suspension of Medicare sequestration from May 1, 2020 to March 31, 2022, which was reduced to 1% on April 1, 2022 and was eliminated effective July 1, 2022.
The CARES Act also provides for certain federal income and other tax changes. We received a cash benefit of approximately $39.3 million for 2020 relating to the delay of payment of the employer portion of Social Security payroll taxes. We repaid half of the $39.3 million of payroll tax deferrals during the third quarter of 2021 and repaid the remaining portion in the third quarter of 2022 to eliminate the liability.
In addition to the financial and other relief that has been provided toby the regulator. Generally, however, a majority of inspections tend to be unannounced. A failure to comply with laws and regulations,federal government through the receipt of a poor inspection report rating or a lower rating, or the receipt of a negative report that leads to a determination of regulatorynon-compliance or a failure to cure any defect noted in an inspection report may result in reputational damage, fines, the revocation or suspension of the registration of any facility or a decrease in, or cessation of, the services provided at any given location.
Corporate Manslaughter and Corporate HomicideCARES Act of 2007. The Corporate Manslaughter and Corporate Homicide Act of 2007 provides liability if the way in which a provider’s activities are managed or organized causes a person’s death and amounts to a gross breach of a relevant duty of care owed to the deceased person.
Regulatory and Enforcement Bodies in the U.K.
The primary healthcare regulatory enforcement bodies in the U.K. are NHS Improvement, the CQC, Healthcare Inspectorate Wales (“HIW”), Care Inspectorate Wales (“CIW”), Healthcare Improvement Scotland (“HIS”), Social Care and Social Work Improvement Scotland (“SCSWIS”) and Regulation and Quality Improvement Authority (“RQIA”). In addition, the Office for Standards in Education, Children’s Services and Skills (“OFSTED”), Estyn, Education Scotland and other regulatory bodies regulatelegislation passed by Congress, CMS and inspect education servicesmany state governments have also issued waivers and temporary suspensions of healthcare facility licensure, certification, and reimbursement requirements in England, Walesorder to provide hospitals, physicians, and Scotland, as applicable. These enforcement bodies control and administer the registration, inspection and complaints procedures set out under the applicable laws and regulations. The enforcement bodies have the power to terminate a facility’s registration, refuse to register a facility, impose admissions holds, or impose significant fines if a service provider failsother healthcare providers with increased flexibility to meet the key minimum standardschallenges presented by the COVID-19 pandemic. For example, CMS and many state governments have temporarily eased regulatory requirements prescribedand burdens for delivering and being reimbursed for healthcare services provided remotely through telemedicine. CMS has also temporarily waived many provisions of the Stark law, including many of the provisions affecting our relationships with physicians. Many states have also suspended the enforcement of certain regulatory requirements to ensure that healthcare providers have sufficient capacity to treat COVID-19 patients. These regulatory changes are temporary, with most slated to expire at the end of the COVID-19 public health emergency, expected in May 2023.
We are continuing to evaluate the terms and conditions and financial impact of funds received under the various lawsCARES Act and regulations. See “Riskother government relief programs.
Corporate Integrity Agreement
During the second quarter of 2019, we entered into a corporate integrity agreement (the “CIA”) with the OIG imposing certain compliance obligations on us and our subsidiary, CRC Health. For further discussion of the background of this matter and the CIA, see “Item 1A. Risk Factors— IfWe could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.”
Our primary regulators continually review their regulatory regimes and may extend their enforcement powers with the intention of holding parent companies and senior executives accountable for material breaches of regulations depending on the circumstances. Additionally, there are other regulators in the U.K. who may take enforcement action against us, including (i) the Health and Safety Executive (“HSE”) for violationsterms of the Health and Safety at Work Act in connection with patient incidents at our facilities; (ii) the Information Commissioners Office (“ICO”) for breaches of data protection legislation (and following the introduction of the General Data Protection Regulations (the “GDPR”) which come into force in May 2018, fines for material breaches may be as high as 4% of global turnover); and (iii) Her Majesty’s Revenue and Customs (“HMRC”) who in November 2017 established the Social Care Compliance Scheme (the “SCCS”) for social care providers in the U.K. with the aim of addressing the issue of potential underpayments of the National Minimum Wage (“NMW”) to workers who are paid a fixed allowance to undertake“sleep-in shifts” at care homes and other facilities at night. See “—Our operating costs are subject to increases, including due to statutorily mandated increases in the wages and salaries of our staff” for further details on U.K. staffing risks to which we are subject.
NHS Improvement.NHS Improvement now incorporates Monitor, the former economic regulator for the NHS in England. NHS Improvement is responsible for regulating the market for NHS funded services in England. It fulfills this role through licensing NHS Foundation Trusts and certain other healthcare providers and, together with the NHS England, sets the Tariff Rules for national and local pricing of NHS services. NHS Improvement’s role is to oversee the NHS healthcare market, at all times protecting and promoting patients’ interests, tackling abuses by commissioners and/or providers and dealing with unjustifiable restrictions on competition.
The CQC. The CQC is the independent regulator for health and adult social care in England. The CQC is distinct from NHS Improvement in that it focuses on quality and ensuring the maintenance of standards in health and social care practices. The CQC licenses NHS and adult social care service providers to enable it to keep a check on safety and quality standards. The CQC also carries out facility inspections. Care homes for young adults (including specialist college accommodation) are registered and inspected by the CQC. In addition, the CQC is responsible for monitoring the financial viability of corporate providers of social care.
HIWCIA”. HIW is the independent inspectorate and regulator of all health care in Wales. Certain independent healthcare services are required to register with HIW. HIW also inspects NHS and independent healthcare organizations in Wales to ensure compliance with its and the NHS’s standards, policies, guidance and regulations. The HIW Review Service for Mental Health monitors the use of the Mental Health Act 1983 to ensure that it is being used properly on behalf of Welsh Ministers.
CIW. Social care and social services in Wales are regulated by the CIW. CIW carries out unannounced inspections and measure against regulations. Children’s homes in Wales are inspected by CIW.
HIS. HIS is the independent regulator for healthcare services in Scotland. HIS inspects healthcare providers in Scotland to ensure compliance with its standards, policies, guidance and regulations.
SCSWIS. Care services in Scotland are regulated by the Care Inspectorate Scotland (also known as SCSWIS) and all care services in Scotland must be registered with them. As well as registration, SCSWIS inspects services against the National Care Standards and they can take action to force services to improve and can close services if necessary. Independent schools with boarding facilities must register their boarding provision with SCSWIS for the regulation of care as a school care accommodation service.
RQIA. In Northern Ireland, RQIA is Northern Ireland’s independent health and social care regulator. RQIA is responsible for registering, inspecting and encouraging improvement in a range of health and social care services in accordance with the Health and Personal Social Services (Quality, Improvement and Regulation) (Northern Ireland) Order 2003 and its supporting regulations. RQIA inspections are based on certain minimum care standards.
OFSTED. OFSTED was established under the Education (Schools) Act of 1992 and regulates and inspects services in England that care for children and young people, and services providing education and skills for learners of all ages. OFSTED carries out routine day school and further education college inspections to ensure compliance with inspection frameworks.
Estyn. In Wales, Estyn is led by Her Majesty’s Chief Inspector of Education and Training and inspects quality standards in all education provisions in Wales including children’s homes, independent and residential schools and colleges.
Education Scotland. In Scotland, the education provision for independent schools with boarding facilities is regulated by Education Scotland.
Risk Management and Insurance
The healthcare industry in general continues to experience an increase in the frequency and severity of litigation and claims. As is typical in the healthcare industry, we could beare subject to claims that our services have resulted in injury to our patients or clients or other adverse effects. In addition, resident, visitor and employee injuries could also subject us to the risk of litigation. While management believes that quality care is provided to patients and clients in our facilities and that we materiallysubstantially comply with all applicable regulatory requirements, an adverse settlement determination in a legal proceeding or government investigation could have a material adverse effect on our business, financial condition or results of operations.
Our statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. A portion of our professional liability risk isrisks are insured through a wholly-owned insurance subsidiary. Our wholly-owned insurance subsidiary insures usproviding coverage for professional liability losses up to $78.0$10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. We have obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. TheOur reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 millionpolicies in excess of a retention level of $3.0 million.place.
Environmental Matters
We are subject to various federal, state and local environmental laws that: (i) regulate certain activities and operations that may have environmental or health and safety effects, such as the handling, storage, transportation, treatment and disposal of medical waste
11
products generated at our facilities, the identification and warning of the presence of asbestos-containing materials in buildings, as well as the removal of such materials, the presence of other hazardous substances in the indoor environment and protection of the environment and natural resources in connection with the development or construction of our facilities; (ii) impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on andoff-site, or other releases of hazardous materials or regulated substances; and (iii) regulate workplace safety. Some of our facilities generate infectious or other hazardous medical waste due to the illness or physical condition of our patients. The management of infectious medical waste is subject to regulation under various federal, state and local environmental laws, which establish management requirements for such waste. These requirements include record-keeping, notice and reporting obligations. Each of our facilities has an agreement with a waste management company for the disposal of medical waste. The use of such companies, however, does not completely protect us from violations of medical waste laws or from related third-party claims forclean-up costs.
From time to time, our operations have resulted in, or may result in,non-compliance with, or liability pursuant to, environmental or health and safety laws or regulations. Management believes that our operations are generally in compliance with environmental and health and safety regulatory requirements, including legal requirements relating to climate change, or that anynon-compliance will not result in a material liability or cost to achieve compliance. Historically, the costs of achieving and maintaining compliance with environmental laws and regulations at our facilities have not been material. However, we cannot assure you that future costs and expenses required for us to comply with any new or changes in existing environmental and health and safety laws and regulations or new or discovered environmental conditions will not have a material adverse effect on our business, financial condition or results of operations. In addition, we could be affected by climate change to the extent that climate change results in severe weather conditions or other disruptions impacting the communities in which our facilities are located. For more information regarding climate change and its possible adverse impact on us, see “Item 1A. Risk Factors — Operational Risks — Our business and operations are subject to risks related to natural disasters and climate change”.
We have not been notified of and management is otherwise currently not aware of any contamination at our currently or formerly operated facilities that could result in material liability or cost to us under environmental laws or regulations for the investigation and remediation of such contamination, and we currently are not undertaking any remediation or investigation activities in connection with any such contamination conditions. There may, however, be environmental conditions currently unknown to us relating to our prior, existing or future sites or operations or those of predecessor companies whose liabilities we may have assumed or acquired which could have a material adverse effect on our business.
New laws, regulations or policies or changes in existing laws, regulations or policies or their enforcement, future spills or accidents or the discovery of currently unknown conditions ornon-compliances may give rise to investigation and remediation liabilities, compliance costs, fines and penalties, or liability and claims for alleged personal injury or property damage due to substances or materials used in our operations, any of which may have a material adverse effect on our business, financial condition or results of operations.
Competition
The healthcare industry is highly competitive. Our principal competitors include other behavioral healthcare service companies, including UHS, private equity firms,Universal Health Services, Inc. (NYSE: UHS) and the NHS in the U.K. We also compete againstother hospitals and general healthcare facilities that provide mental health services. An important part of our business strategy is to continue making targeted acquisitions of other behavioral health facilities. However, reduced capacity, the passage of mental health parity legislation and increased demand for mental health services are likely to attract other potential buyers, including diversified healthcare companies, and possibly other pure-play behavioral healthcare companies.
The mental health services sector in the U.K. comprises hospitals or establishments that provide psychiatric treatment for illness or mental disorder at all securitycompanies and treatment levels. We operate in several highly competitive markets in the U.K. with a variety offor-profit, the NHS and othernot-for-profit groups in each of our markets. Most competition is regional or local, based on relevant catchment areas and procurement initiatives. The NHS is often the dominant provider, although the trend has been towards increased outsourcing, whereby the NHS is both a provider and customer of mental healthcare services. NHSin-house beds accounts for approximately 71% of the total mental health hospital beds providing care in the U.K., with independent providers accounting for the remaining approximately 29% of beds.private equity firms.
In addition to the competition we face for acquisitions, we must also compete for patients. Patients are referred to our behavioral healthcare facilities through a number of different sources, including healthcare practitioners, public programs, other treatment facilities, managed care organizations, unions, emergency departments, judicial officials, social workers, police departments and word of mouth from previously treated patients and their families, among others. These referral sources may instead refer patients to hospitals that are able to provide a full suite of medical services or to other behavioral healthcare centers.
Human Capital
Employees
As ofAt December 31, 2017,2022, we had approximately 40,60023,000 employees, (approximately 20,000 in the U.S. and approximately 20,600 in the U.K), of which 27,50017,000 were employed full-time. As ofAt December 31, 2017,2022, labor unions represented approximately 460350 of our U.S. employees at fivetwo of our U.S. facilities through eightfour collective bargaining agreements. Organizing activities by labor unions and certain potential changes in federal labor laws and regulations could increase the likelihood of employee unionization in the future. The Royal College of Nursing is the trade union for full and part-time nurses, nursing cadets and healthcare assistants in the U.K.
Typically, our inpatient facilities are staffed by a chief executive officer, medical director, director of nursing, chief financial officer, clinical director and director of performance improvement. Psychiatrists and other physicians working in our facilities are
12
licensed medical professionals who are generally not employed by us and work in our facilities as independent contractors or medical staff members.
Diversity and Inclusion
We are committed to maintaining a welcoming and inclusive environment that treats everyone with dignity and respect. Approximately 74% of our employees are women and approximately 48% are people of color. We have policies that strictly prohibit any discrimination on the basis of race, color, national origin, age, religion, disability, gender, marital status, veteran status or any other basis prohibited by federal, state or local law.
We have also established a Diversity and Inclusion Council, a multidisciplinary group, to oversee and advance diversity and inclusion initiatives.
Talent Acquisition, Development and Retention
Our success is dependent on our ability to attract, develop and retain talented, dedicated employees. We are committed to being an employer of choice and offer a compelling total rewards program. In addition to base salaries, we offer our employees a full spectrum of benefits, including medical, dental, vision and disability plans, health savings and flexible spending accounts, a 401(k) retirement savings plan that includes a matching contribution, paid time off and employee assistance programs. We also conduct comprehensive employee satisfaction surveys to assess and ensure that we are responsive to the desires and concerns of our employees.
Like most healthcare providers, our facilities have experienced rising labor costs and turnover, and we have resorted to using more expensive contract labor at certain of our facilities. In some markets, the availability and retention of qualified medical personnel have become significant operating issues to healthcare providers, including at certain of our facilities. Shortages of nurses, qualified addiction counselors and other medical and care support personnel could result in a number of adverse impacts to our business, including capacity and growth constraints, reduced patient satisfaction, reduced employee satisfaction, impact on services offered, and increased costs, among others. For more information regarding risks of rising labor costs and its possible adverse impact on us, see “Item 1A. Risk Factors — Human Capital Risks — Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability”.
Health and Safety
We are committed to providing care to our patients in a safe, therapeutic environment. In furtherance of this commitment, we provide our employees with access to a variety of workplace safety training programs and continually evaluate our policies promoting patient safety and employee wellbeing. In response to the COVID-19 pandemic, we implemented numerous changes to our policies and procedures to ensure the health of our patients, employees, contractors and communities, including instituting social distancing practices and protective measures throughout our facilities, which included restricting or suspending visitor access, screening patients and staff who enter our facilities based on criteria established by the CDC and local health officials, and testing and isolating patients when warranted.
Seasonality of Demand for Services
Our residential recovery and other inpatient facilities typically experience lower patient volumes and revenue during the holidays, and our child and adolescent facilities typically experience lower patient volumes and revenue during the summer months, holidays and other periods when school is out of session.
Available Information
Our Internet website address is www.acadiahealthcare.com. We make available our annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form8-K and all amendments to those reports free of charge on our website on the Investors webpage under the caption “SEC Filings” as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (the “SEC”). The public may read and copy materials filed with the SEC at the Public Reference Room of the SEC at 100 F Street, NE, Washington, D. C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at1-800-732-0330.SEC. The SEC maintains a websitean internet site at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file or furnish information electronically with the SEC at www.sec.gov.we file. Our website and the information contained therein or linked thereto are not intended to be incorporated into this Annual Report on Form10-K.
13
Item 1A. Risk Factors
Risk Factors Summary
We are subject to a variety of risks and uncertainties, including financial risks, operational risks, human capital risks, legal proceedings and regulatory risks and certain general risks, which could have a material adverse effect on our business, financial condition, results of operations and cash flows. Risks that we deem material are described under “Risk Factors” below and include, but are not limited to, the following:
Financial Risks
• | Our revenue and results of operations are significantly affected by payments received from the government and third-party payors. |
• | Our debt could adversely affect our financial health and prevent us from fulfilling our obligations under our financing arrangements. |
• | Servicing our debt will require a significant amount of cash. Our ability to generate sufficient cash to service our debt depends on many factors beyond our control. |
• | We are subject to a number of restrictive covenants, which may restrict our business and financing activities. |
• | Despite our current debt level, we may incur significant additional amounts of debt, which could further exacerbate the risks associated with our debt. |
• | If we default on our obligations to pay our debt, we may not be able to make payments on our financing arrangements. |
• | We are subject to volatility in the global capital and credit markets as well as significant developments in macroeconomic and political conditions that are out of our control. |
• | Increases in inflation and rising interest rates may adversely impact our business, financial condition and results of operations. |
• | The industry trend on value-based purchasing may negatively impact our revenue. |
• | The COVID-19 global pandemic continues to impact our operations, business and financial condition, and our liquidity could be negatively impacted, particularly if the U.S. economy remains unstable for a significant amount of time or if patient volumes decline at our facilities. |
• | An increase in uninsured or underinsured patients or the deterioration in the collectability of patient accounts receivables could harm our results of operation. |
Operational Risks
• | An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock. |
• | Our business growth and acquisition strategies expose us to a variety of operational and financial risks. |
• | Joint ventures may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities. |
• | We care for a large number of vulnerable individuals with complex needs and any care quality deficiencies could adversely impact our brand, reputation and ability to market our services effectively. |
• | Our business could be disrupted if our information systems fail or if our databases are destroyed or damaged. |
• | A disruption to our information technology systems or a cyber security incident could have a material adverse impact on the Company, including substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to reputational harm and increased costs. |
• | Although we have facilities in 39 states and Puerto Rico, we have substantial operations in Pennsylvania, California, Arizona and Tennessee, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those locations. |
• | Our business and operations are subject to risks related to natural disasters and climate change. |
14
• | If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected. |
• | We operate in a highly competitive industry, and competition may lead to declines in patient volumes. |
Human Capital Risks
• | Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability. |
• | Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians. |
Legal Proceedings and Regulatory Risks
• | We are and in the future could become the subject of additional governmental investigations, regulatory actions and whistleblower lawsuits. |
• | We could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if we fail to comply with the terms of the CIA. |
• | We are and in the future may become involved in legal proceedings based on negligence or breach of a contractual or statutory duty from service users or their family members or from employees or former employees. |
• | If we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations. |
• | We could face risks associated with, or arising out of, environmental, health and safety laws and regulations. |
General Risk Factors
• | Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock. |
• | Future sales of common stock by our existing stockholders may cause our stock price to fall. |
• | If securities or industry analysts do not publish research or reports about our business, if they were to change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline. |
• | We incur substantial costs as a result of being a public company. |
Risk Factors
Any of the following risks could materially and adversely affect our business, financial condition or results of operations. These risks should be carefully considered before making an investment decision regarding us. The risks and uncertainties described below are not the only ones we face and there may be additional risks that we are not presently aware of or that we currently consider not likely to have a significant impact. If any of the following risks actually occurred,occur, our business, financial condition and operating results could suffer, and the trading price of our common stock could decline.
Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock.Financial Risks
The stock markets experience volatility, in some cases unrelated to operating performance. These broad market fluctuations may adversely affect the trading price of our common stock and, as a result, there may be significant volatility in the market price of our common stock. If we are unable to operate our facilities as profitably as we have in the past or as our investors expect us to in the future, the market price of our common stock will likely decline when it becomes apparent that the market expectations may not be realized. In addition to our operating results, many economic and seasonal factors outside of our control could have an adverse effect on the price of our common stock and increase fluctuations in our quarterly earnings. These factors include certain of the risks discussed herein, demographic changes, operating results of other healthcare companies, changes in our financial estimates or recommendations of securities analysts, speculation in the press or investment community, the possible effects of war, terrorist and other hostilities, adverse weather conditions, the level of seasonal illnesses, managed care contract negotiations and terminations, changes in general conditions in the economy or the financial markets or other developments affecting the healthcare industry.
An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock.
Because the patients we treat suffer from severe mental health and chemical dependency disorders, patient incidents, including deaths, assaults and elopements, occur from time to time. If one or more of our facilities experiences an adverse patient incident or is found to have failed to provide appropriate patient care, an admissions hold, loss of accreditation, license revocation or other adverse regulatory action could be taken against us. Any such patient incident or adverse regulatory action could result in governmental investigations, judgments or fines and have a material adverse effect on our business, financial condition and results of operations. In addition, we have been and could become the subject of negative publicity or unfavorable media attention, whether warranted or unwarranted, that could have a significant, adverse effect on the trading price of our common stock or adversely impact our reputation and how our referral sources and payors view us.
We have been and could become the subject of governmental investigations, regulatory actions and whistleblower lawsuits.
Healthcare companies in both the U.S. and the U.K. are subject to numerous investigations by various governmental agencies. Certain of our facilities have received, and other facilities may receive, government inquiries from, and may be subject to investigation by, governmental agencies. If we incur significant costs responding to or resolving these or future inquiries or investigations, our business, financial condition and results of operations could be adversely affected.
Further, under the False Claims Act, private parties are permitted to bring qui tam or “whistleblower” lawsuits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Because qui tam lawsuits are filed under seal, we could be named in one or more such lawsuits of which we are not aware. We may also be subject to substantial reputational harm as a result of the public announcement of any investigation into such claims.
Our revenue and results of operations are significantly affected by payments received from the government and third-party payors.
A significant portion of our revenue is derived from government healthcare programs. For the year ended December 31, 2017,2022, we derived approximately 38%66% of our continuing operations revenue from the Medicare and Medicaid programs and 32% of our revenue from public funded sources in the U.K. (including the NHS, CCGs and Local Authorities). See “— Structural shifts in the U.K. behavioral healthcare market may adversely affect us” for further details on U.K. funding risks to which we are subject.programs.
Government payors in the U.S., such as Medicaid, generally reimburse us on afee-for-service basis based on predetermined reimbursement rate schedules. As a result, we are limited in the amount we can record as revenue for our services from these government programs, and if we have a cost increase, we typically will not be able to recover this increase. In addition, the federal government and many state governments, are operating under significant budgetary pressures, and they may seek to reduce payments under their Medicaid programs for services such as those we provide. Government payors also tend to pay on a slower schedule. In addition to limiting the amounts they will pay for the services we provide their members, government payors may, among other things, impose prior authorization and concurrent utilization review programs that may further limit the services for which they will pay and shift patients to lower levels of care and reimbursement. Therefore, if governmental entities reduce the amounts they will pay
15
for our services, or if they elect not to continue paying for such services altogether, or if there is a total or partial repeal of PPACA results in significant contraction of the number of individuals covered by state Medicaid programs, our business, financial condition or results of operations could be adversely affected. In addition, if governmental entities slow their payment cycles further, our cash flow from operations could be negatively affected.
Commercial payors such as managed care organizations, private health insurance programs and labor unions generally reimburse us for the services rendered to insured patients based upon contractually determined rates. These commercial payors are under significant pressure to control healthcare costs. In addition to limiting the amounts they will pay for the services we provide their members, commercial payors may, among other things, impose prior authorization and concurrent utilization review programs that may further limit the services for which they will pay and shift patients to lower levels of care and reimbursement. These actions may reduce the amount of revenue we derive from commercial payors.
Changes in these government programs in recent years have resulted in limitations on reimbursement and, in some cases, reduced levels of reimbursement for healthcare services. Payments from federal and state government healthcare programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions, all of which could materially increase or decrease program payments, as well as affect the cost of providing service to patients and the timing of payments to facilities. We are unable to predict the effect of recent and future policy changes on our operations. In addition, since most states operate with balanced budgets and since the Medicaid program is often a state’s largest program, some states can be expected to enact or consider enacting legislation formulated to reduce their Medicaid expenditures. Furthermore, the potential repeal, replacement or modification of PPACA, may negatively affect the availability of taxpayer funds for Medicare and Medicaid programs. If the rates paid or the scope of services covered by government payors are reduced, there could be a material adverse effect on our business, financial condition and results of operations.
In addition to changes in government reimbursement programs, our ability to negotiate favorable contracts with private payors, including managed care providers, significantly affects the financial condition and operating results of our facilitiesfacilities. Further, we may not be able to negotiate or sustain rate increases we have experienced in the U.S.recent years, and may not be able to achieve consistent rate increases from year to year. Management expects third-party payors to aggressively manage reimbursement levels and cost controls. Reductions in reimbursement amounts received from third-party payors could have a material adverse effect on our business, financial condition and results of operations.
Our healthcare facilities are also subject to federal, state and commercial payor audits to validate the accuracy of claims submitted to government healthcare programs and commercial payors. If these audits identify overpayments, we could be required to make substantial repayments, subject to various appeal rights. Our facilities are routinely subjected to claims audits in the ordinary course of business. While no such audit has identified any material overpayment liability, should a potential material overpayment liability arise from a future audit, such overpayment liability may ultimately exceed established reserves, and any excess could potentially be substantial. Further, Medicare and Medicaid regulations, as well as commercial payor contracts, also provide for withholding or suspending payments in certain circumstances, which could adversely affect our cash flow.
Our substantial debt could adversely affect our financial health and prevent us from fulfilling our obligations under our financing arrangements.
As ofAt December 31, 2017,2022, we had approximately $3.2$1.4 billion of total debt (net of debt issuance costs, discounts and premiums of $50.4$12.6 million), which included approximately $1.8 billion of debt under our Amended and Restated Senior Credit Facility (including approximately $380.0 million of Senior Secured Term A Loans and approximately $1.4 billion of Senior Secured Term B Loans), $150.0$473.4 million of debt under our 6.125% Senior Notes (the “6.125% Senior Notes”), $300.0the New Credit Facility, $450.0 million of debt under our 5.125%the 5.500% Senior Notes (the “5.125% Senior Notes”), $650.0and $475.0 million of debt under our 5.625%the 5.000% Senior Notes, $390.0 million of debt under our 6.500% Senior Notes and $21.9 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5% (the “9.0% and 9.5% Revenue Bonds”).Notes. See “Item 1. Business—Financing Transactions” for additional details regarding our outstanding indebtedness.
Our substantial debt could have important consequences to our business. For example, it could:
• | increase our vulnerability to general adverse economic and industry conditions; |
• | make it more difficult for us to satisfy our other financial obligations; |
• | restrict us from making strategic acquisitions or cause us to make non-strategic divestitures; |
• | require us to dedicate a substantial portion of our cash flow from operations to payments on our debt (including scheduled repayments on our outstanding term loan borrowings under the New Credit Facility), thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes; |
• | expose us to interest rate fluctuations because the interest on the New Credit Facility is imposed at variable rates; |
• | make it more difficult for us to satisfy our obligations to our lenders, resulting in possible defaults on and acceleration of such debt; |
16
• | limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; |
• | place us at a competitive disadvantage compared to our competitors that have less debt; |
• | limit our ability to borrow additional funds; and |
• | limit our ability to pay dividends, redeem stock or make other distributions. |
In addition, the terms of our financing arrangements contain restrictive covenants that limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default which, if not cured or waived, could result in the acceleration of all of our debts, including the Amended and Restated SeniorNew Credit Facility and the Senior Notes.
Servicing our debt will require a significant amount of cash. Our ability to generate sufficient cash to service our debt depends on many factors beyond our control.
Our ability to make payments on and to refinance our debt, to fund planned capital expenditures and to maintain sufficient working capital will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control.
We cannot assure you that our business will generate sufficient cash flow from operations or that future borrowings will be available to us under the Amended and Restated SeniorNew Credit Facility or from other sources in an amount sufficient to enable us to service our debt or to fund our other liquidity needs. If our cash flow and capital resources are insufficient to allow us to make scheduled payments on our debt, we may need to reduce or delay capital expenditures, sell assets, seek additional capital or restructure or refinance all or a portion of our debt on or before the maturity thereof, any of which could have a material adverse effect on our business, financial condition or results of operations. We cannot assure you that we will be able to refinance any of our debt on commercially reasonable terms or at all, or that the terms of that debt will allow any of the above alternative measures or that these measures would satisfy our scheduled debt service obligations. If we are unable to generate sufficient cash flow to repay or refinance our debt on favorable terms, it could significantly adversely affect our financial condition and the value of our outstanding debt. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations.
We are subject to a number of restrictive covenants, which may restrict our business and financing activities.
Our financing arrangements impose, and the terms of any future debt may impose, operating and other restrictions on us. Such restrictions affect, and in many respects limit or prohibit, among other things, our and our subsidiaries’subsidiaries�� ability to:
• | incur or guarantee additional debt and issue certain preferred stock; |
• | pay dividends on our common stock or redeem, repurchase or retire our equity interests or subordinated debt; |
• | transfer or sell our assets; |
• | make certain payments or investments; |
• | make capital expenditures; |
• | create certain liens on assets; |
• | create restrictions on the ability of our subsidiaries to pay dividends or make other payments to us; |
• | engage in certain transactions with our affiliates; and |
• | merge or consolidate with other companies. |
The Amended and Restated SeniorNew Credit Facility also requires us to meet certain financial ratios, including a fixed charge coverage ratio and a consolidated leverage ratio. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources —Amended and Restated Senior—New Credit Facility”.
The restrictions may prevent us from taking actions that management believes would be in the best interests of our business, and may make it difficult for us to successfully execute our business strategy or effectively compete with companies that are not similarly restricted. We also may incur future debt obligations that might subject us to additional restrictive covenants that could affect our financial and operational flexibility. Our ability to comply with these covenants in future periods will largely depend on the pricing of
17
our products and services, our success at implementing cost reduction initiatives and our ability to successfully implement our overall business strategy. We cannot assure you that we will be granted waivers or amendments to our financing arrangements if for any reason we are unable to comply with our financial covenants. The breach of any of these covenants and restrictions could result in a default under the indentures governing the Senior Notes or under the Amended and Restated SeniorNew Credit Facility, which could result in an acceleration of our debt.
Despite our current debt level, we may incur significant additional amounts of debt, which could further exacerbate the risks associated with our substantial debt.
We may incur substantial additional debt, including additional notes and other debt, in the future. Although the indentures governing our outstanding Senior Notes and our Amended and Restated Seniorthe New Credit Facility contain restrictions on the incurrence of additional debt, these restrictions are subject to a number of significant qualifications and exceptions, and under certain circumstances, the amount of debt that could be incurred in compliance with these restrictions could be substantial. If new debt is added to our existing debt levels, the related risks that we now face would intensify and we may not be able to meet all our debt obligations.
If we default on our obligations to pay our debt, we may not be able to make payments on our financing arrangements.
Any default under the agreements governing our debt, including a default under the Amended and Restated SeniorNew Credit Facility or the indentures governing our Senior Notes, and the remedies sought by the holders of such debt, could adversely affect our ability to pay the principal, premium, if any, and interest on the Senior Notes and substantially decrease the market value of the Senior Notes. If we are unable to generate sufficient cash flows and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our debt, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our debt (including the Amended and Restated SeniorNew Credit Facility and the indentures governing the Senior Notes), we would be in default under the terms of the agreements governing such debt. In the event of such default, the holders of such debt could elect to declare all the funds borrowed thereunder to be due and payable, the lenders under the Amended and Restated SeniorNew Credit Facility could elect to terminate their commitments or cease making further loans and institute foreclosure proceedings against our assets, or we could be forced to apply all available cash flows to repay such debt, and, in any such case, we could ultimately be forced into bankruptcy or liquidation. Because the indentures governing the Senior Notes and the agreement governing the Amended and Restated SeniorNew Credit Facility have customary cross-default provisions, if the debt under the Senior Notes or the Amended and Restated SeniorNew Credit Facility is accelerated, we may be unable to repay or refinance the amounts due.
Expanding our international operations poses additional risks to our business.
Our business or financial performanceWe may be adversely affected duerequired to record additional charges to future earnings if our goodwill, intangible assets and property and equipment become impaired.
We are required under U.S. generally accepted accounting principles (“GAAP”) to review annually, or more frequently if events indicate the riskscarrying value of operating internationally, including buta reporting unit may not limited to the following: economicbe recoverable, our goodwill and political instability, failure to comply with foreign laws and regulations and adverse changes in the health care policy of the U.K. (including decreases in fundingindefinite-lived intangible assets for impairment. Although there were no impairment charges recorded for the services provided by our U.K. facilities), adverse changes2022 annual impairment review, we may be required to record charges to earnings during any period in law and regulations affecting our operations in the U.K., difficulties and costs of staffing and managing our operations in the U.K. If any of these events were to materialize, they could lead to disruptionwhich an impairment of our business, significant expenditures and/or damages to our reputation, which could have a material adverse effect on our results of operations, financial condition or prospects.
As a company based outside of the U.K., we need to take certain actions to be more easily accepted in the U.K. For example, we may need to engage in a public relations campaign to emphasize service qualitygoodwill, intangible assets and company philosophy, preserve local management continuityproperty and business practices and be transparent in our dealings with local governments and taxing authorities. Such efforts require significant time and effort on the part of our management team. Our results of operation could suffer if these efforts are not successful.
With significant operations in the U.K., our business and operations may be adversely affected by economic and political conditions in the U.K.
The global financial markets continue to experience significant volatility as a result of, among other things, economic and political instability in the wake of the referendum in the U.K. on June 23, 2016, in which the voters approved an exit from the European Union, or Brexit. Following the vote on Brexit, stock markets worldwide experienced significant declines and certain currency exchange rates fluctuated substantially, and the outlook for the global economy in 2018 and beyond remains uncertain as negotiations commence to determine the future terms of the U.K.’s relationship with the European Union. Such global market instability may hinder future economic growth,equipment is determined which could adversely affect our assets, business, cash flow, condition (financial or otherwise), liquidity, prospects and results of operations.
Our facilities face competitionevaluation of goodwill and the need for staffing that may increaseany further impairment in subsequent periods is sensitive to revisions to our labor costscurrent projections. See “Item 7. Management’s Discussion and reduce our profitability.Analysis of Financial Condition and Results of Operations— Critical Accounting Policies — Property and Equipment and other Long-Lived Assets” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies — Goodwill and Indefinite-Lived Intangible Assets” for additional information.
Our operations depend on the efforts, abilities, and experience of our management and medical support personnel, including our addiction counselors, therapists, nurses, pharmacists, licensed counselors, clinical technicians, and mental health technicians, as well as our psychiatrists and other professionals. We compete with other healthcare providers in recruiting and retaining qualified management, program directors, physicians (including psychiatrists) and support personnel responsible for the daily operations of our business, financial condition or results of operations.
With respect to our facilities in the U.K., we compete with various providers, including the NHS, staffing agencies and other employers, in attracting and retaining qualified management, medical, nursing, care and teaching personnel. Competition for such employees is growing and could leadoperating costs are subject to increases in the wages and salaries of our personnel and recruiting costs, which would in turn adversely impact our operating costs and margins. Competitors, in particular the NHS, may offer more attractive wages, pension plans or other benefits than us and we may not be able to provide similar offerings to our prospective employees as a result of cost or other reasons.staff.
A shortage of nurses, qualified addiction counselors, and other medical support personnel has been aThe most significant operating issue facing us and other healthcare providers, particularlyexpense for our facilities is wage costs, which represent the staff costs incurred in providing our services and running our facilities, and which are primarily driven by the U.K. Such shortages may requirenumber of employees and pay rates. The number of employees employed by us is primarily linked to enhance wagesthe number of facilities we operate and benefitsthe number of individuals cared for by us. While we can reduce the number of employees should occupancy rates decrease at our facilities, there is a limit on the extent to recruit and retain nurses, qualified addiction counselors, and other medical support personnel or require us to hire more expensive temporary or contract personnel. The use of temporary or contract personnel could also heighten the risk onewhich this can be done without impacting quality of our facilities experiences an adverse patient incident. Further, because we generally recruit our personnel from the local area where the relevant facility is located, the availability in certain areasservices.
We also have a number of suitably qualified personnelrecurring costs including insurance, utilities and rental costs, and may face increases to other recurring costs such as regulatory compliance costs. There can be limited, particularly care home management, qualified teaching personnel and nurses. In addition, certainno assurance that any of our facilities are required to maintain specified staffing levels. To the extent we cannot meet those levels, we may be required to limit the services provided by these facilities, which would haverecurring costs will not grow at a corresponding adverse effect onfaster rate than our netrevenue. As a result, any increase in our operating revenue. Certain of our treatment facilities are located in remote geographical areas, far from population centers, which increases this risk.
We cannot predict the degree to which we will be affected by the future availability or cost of attracting and retaining talented medical support staff. If our general labor and related expenses increase, we may not be able to raise our rates correspondingly. Our failure either to recruit and retain qualified management, psychiatrists, therapists, counselors, nurses and other medical support personnel or control our labor costs could have a material adverse effect on our business, results of operations and financial condition.
18
We are subject to volatility in the global capital and credit markets as well as significant developments in macroeconomic and political conditions that are out of our control.
Our business can be affected by a number of factors that are beyond our control, such as general macroeconomic conditions, conditions in the financial services markets, geopolitical conditions and other general political and economic developments. In particular, we have historically financed acquisitions, the development of de novo and joint venture facilities and the modification of our existing facilities through a variety of sources, including our own cash reserves and debt financing. While we intend to seek to finance acquisitions and new and existing developments from similar sources in the future, there may be insufficient cash reserves to fund the budgeted capital expenditure and market conditions and other factors may prevent us from obtaining debt financing on appropriate terms or at all. In addition, market conditions may limit the number of financial institutions that are willing to provide financing to landlords with whom we wish to contract to build new healthcare facilities which can then be made available to us under a long-term operating lease. If conditions in the global economy remain uncertain or weaken further, this could materially adversely impact our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.
A worsening of the economic and employment conditions in the geographies in which we operate could materially affect our business and future results of operations.
During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at the federal, state and local levels have decreased, and may continue to decrease, spending for health and human service programs, including Medicare and Medicaid, which are significant payor sources for our facilities. In periods of high unemployment, we also face the risk of potential declines in the population covered under private insurance, patient decisions to postpone or decide against receiving behavioral healthcare services, potential increases in the uninsured and underinsured populations we serve and further difficulties in collecting patient co-payment and deductible receivables.
A sizable portion of our revenue from certain residential recovery, eating disorder facilities, CTCs and youth programs is from self-payors. Accordingly, a sustained downturn in the U.S. economy could restrain the ability of our patients and the families of our students to pay for services.
Furthermore, the availability of liquidity and capital resources to fund the continuation and expansion of many business operations worldwide has been limited in recent years. Our ability to access the capital markets on acceptable terms may be severely restricted at a time when we would like, or need, access to those markets, which could have a negative impact on our growth plans, our flexibility to react to changing economic and business conditions and our ability to refinance existing debt (including debt under the New Credit Facility and the Senior Notes). A sustained economic downturn or other economic conditions could also adversely affect the counterparties to our agreements, including the lenders under the New Credit Facility, causing them to fail to meet their obligations to us.
Increases in inflation and rising interest rates may adversely impact our business, financial condition and results of operations.
Inflation in the U.S. has recently accelerated and is currently expected to continue at an elevated level in the near-term. Current and future inflationary effects may be driven by, among other things, supply chain disruptions and governmental stimulus or fiscal policies, and geopolitical instability, including the ongoing conflict between the Ukraine and Russia. Continuing increases in inflation, have in the past, and could in the future, impact our costs of labor and services and the margins we are able to realize on the operation of our facilities and services, all of which could have an adverse impact on our business, financial position, results of operations and cash flows. Inflation has also resulted in higher interest rates, which in turn will result in higher costs of debt borrowing and could limit our growth strategy.
The industry trend on value-based purchasing may negatively impact our revenue.
There is a trend in the healthcare industry toward value-based purchasing of healthcare services, rather than per diem charges. These value-based purchasing programs include both public reporting of quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for care related to certain preventable adverse events. Many large commercial payors currently require hospitals to report quality data, and several commercial payors do not reimburse hospitals for certain preventable adverse events.
We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. We are unable at this time to predict how this trend will affect our results of operations, but it could negatively impact our revenue if we are unable to meet quality standards established by both governmental and private payers.
19
The trend by insurance companies and managed care organizations to enter into sole-source contracts may limit our ability to obtain patients.
Insurance companies and managed care organizations are entering into sole-source contracts with healthcare providers, which could limit our ability to obtain patients since we do not offer the range of services required for these contracts. Moreover, private insurers, managed care organizations and, to a lesser extent, Medicaid and Medicare, are beginning to carve-out specific services, including mental health and substance abuse services, and establish small, specialized networks of providers for such services at fixed reimbursement rates. Continued growth in the use of carve-out arrangements could materially adversely affect our business to the extent we are not selected to participate in such networks or if the reimbursement rate in such networks is not adequate to cover the cost of providing the service.
The COVID-19 global pandemic continues to impact our operations, business and financial condition, and our liquidity could be negatively impacted, particularly if the U.S. economy remains unstable for a significant amount of time or if patient volumes decline at our facilities.
The global pandemic of COVID-19 is affecting our facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. economy and financial markets. During 2020, 2021 and 2022 COVID-19 resulted in fewer referrals to our facilities and lower voluntary admissions as individuals were less inclined to leave their homes and seek treatment. When employees and/or patients at a facility are infected with COVID-19, there is a risk that the virus will spread to others at the facility and impact the operations of such facility. COVID-19 is continuing to evolve and its full impact remains unknown and difficult to predict; however, it has adversely affected our business operations in 2020, 2021 and 2022 and could negatively impact our financial performance for 2023 or longer.
We could experience supply chain disruptions and significant price increases in equipment, pharmaceuticals and medical supplies, which could cause delays in our ability to develop a de novo or joint venture facility or modify an existing facility. Pandemic-related staffing difficulties and equipment, pharmaceutical and medical supplies shortages may impact our ability to treat patients at our facilities. Such shortages could lead to us paying higher prices for supplies, equipment and labor and an increase in overtime hours paid to our employees.
The steps we have taken to mitigate the financial impact of COVID-19, see “Item 1. Business — COVID-19 Impact,” may not be successful, and we could experience material decreases in Adjusted EBITDA in 2023 or longer. In addition, we may need to take further steps to mitigate the financial impact of COVID-19, which actions could adversely affect our financial condition and results of operations.
Broad economic factors resulting from COVID-19, including reduced consumer spending, could also negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Business closings and layoffs in the areas in which we operate may lead to increases in the uninsured and underinsured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services as rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions continue to deteriorate or remain uncertain for an extended period of time, our liquidity and ability to repay our outstanding debt may be adversely affected.
In addition, our results and financial condition may be further adversely affected by future federal or state laws, regulations, orders, or other governmental or regulatory actions addressing the current COVID-19 pandemic or the U.S. healthcare system, which, if adopted, could result in direct or indirect restrictions to our business. We may also be subject to negative press and/or lawsuits from patients, employees and others exposed to COVID-19 at our facilities. Such actions may involve large demands, as well as substantial costs to resolve. Our professional and general liability insurance may not cover all claims against us.
The foregoing and other continued disruptions to our business as a result of the COVID-19 pandemic have impacted our business and may have a material adverse effect on our business, results of operations, financial condition, cash flows and our ability to service our indebtedness. Additionally, the COVID-19 pandemic (including governmental responses, broad economic impacts and market disruptions) has heightened the materiality of certain other risk factors described herein.
An increase in uninsured or underinsured patients or the deterioration in the collectability of patient accounts receivables could harm our results of operation.
Collection of receivables from third-party payors and patients is critical to our operating performance. Our primary collection risks relate to uninsured patients and the portion of the bill that is the patient’s responsibility, which primarily includes co-payments and deductibles. We determine the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical
20
collection experience. At December 31, 2022, our estimated implicit price concessions represented approximately 15% of our accounts receivable balance as of such date.
Significant changes in business office operations, payor mix, economic conditions or trends in federal and state governmental health coverage could affect our collection of accounts receivable, cash flow and results of operations. If we experience unexpected increases in the growth of uninsured and underinsured patients or in bad debt expenses, our results of operations will be harmed.
Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), could have a material adverse effect on our business.
We are required to maintain internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act. If we are unable to maintain adequate internal control over financial reporting, we may be unable to report our financial information on a timely basis, may suffer adverse regulatory consequences or violations of NASDAQ listing rules and may breach the covenants under our financing arrangements. There could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements. If we or our independent registered public accounting firm identify any material weakness in our internal control over financial reporting in the future (including any material weakness in the controls of businesses we have acquired), their correction could require additional remedial measures which could be costly, time-consuming and could have a material adverse effect on our business.
We do not anticipate paying any cash dividends in the foreseeable future.
We intend to retain our future earnings, if any, for use in our business or for other corporate purposes and do not anticipate that cash dividends with respect to common stock will be paid in the foreseeable future. Any decision as to the future payment of dividends will depend on our results of operations, financial position and such other factors as our board of directors, in its discretion, deems relevant. In addition, the terms of our debt substantially limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain for the foreseeable future.
Operational Risks
An incident involving one or more of our patients or the failure by one or more of our facilities to provide appropriate care could result in increased regulatory burdens, governmental investigations, negative publicity and adversely affect the trading price of our common stock.
Because many of the patients we treat suffer from severe mental health and chemical dependency disorders, patient incidents, including deaths, sexual abuse, assaults and elopements, occur from time to time. If one or more of our facilities experiences an adverse patient incident or is found to have failed to provide appropriate patient care, an admissions hold, loss of accreditation, license revocation or other adverse regulatory action could be taken against us. Any such patient incident or adverse regulatory action could result in governmental investigations, judgments or fines and have a material adverse effect on our business, financial condition and results of operations. In addition, we have been and could become the subject of negative publicity or unfavorable media attention, whether warranted or unwarranted, that could have a significant, adverse effect on the trading price of our common stock or adversely impact our reputation and how our referral sources and payors view us.
Our business growth and acquisition strategy exposesstrategies expose us to a variety of operational and financial risks.
A principal element of our business strategy is to grow by acquiring other companies and assets in the behavioral healthcare industry. Growth especially rapid growth, through acquisitions exposes us to a variety of operational and financial risks. We summarize the most significant of these risks below.
Integration risks
We must integrate our acquisitions with our existing operations. This process includes the integration of the various components of our business and of the businesses we have acquired or may acquire in the future, including the following:
• | additional psychiatrists, other physicians and employees who are not familiar with our operations; |
• | patients who may elect to switch to another behavioral healthcare provider; |
• | regulatory compliance programs; and |
• | disparate operating, information and record keeping systems and technology platforms. |
21
Integrating a newnewly acquired facility could be expensive and time consuming and could disrupt our ongoing business, negatively affect cash flow and distract management and other key personnel fromday-to-day operations.
We may not be able to successfully combine the operations of acquired facilities with our operations, and even if such integration is accomplished, we may never realize the potential benefits of the acquisition. The integration of acquisitions with our operations requires significant attention from management, may impose substantial demands on our operations or other projects and may impose challenges on the combined business including, but not limited to, consistencies in business standards, procedures, policies, business cultures and internal controls and compliance. Certain acquisitions involve a capital outlay, and the return that we achieve on any capital invested may be less than the return that we would achieve on our other projects or investments. If we fail to complete the integration of acquired facilities, we may never fully realize the potential benefits of the related acquisitions.
Successful integration depends on the ability to effect any required changes in operations or personnel, which may entail unforeseen liabilities. The integration of acquired businesses may expose us to certain risks, including the following: difficulty in integrating these businesses in a cost-effective manner, including the establishment of effective management information and financial control systems; unforeseen legal, regulatory, contractual, employment or other issues arising out of the combination; combining corporate cultures; maintaining employee morale and retaining key employees; potential disruptions to ouron-going business caused by our senior management’s focus on integrating these businesses; and performance of the combined assets not meeting our expectations or plans. A failure to properly integrate these businesses could have a corresponding material adverse effect on our business, results of operations, financial condition or prospects.
Benefits may not materialize
When evaluating potential acquisition targets, we identify potential synergies and cost savings that we expect to realize upon the successful completion of the acquisition and the integration of the related operations. We may, however, be unable to achieve or may otherwise never realize the expected benefits. Our ability to realize the expected benefits from potential cost savings and revenue improvement opportunities is subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control, such as changes to government regulation governing or otherwise impacting the behavioral healthcare industry, reductions in reimbursement rates from third-party payors, reductions in service levels under our contracts, operating difficulties, client preferences, changes in competition and general economic or industry conditions. If we are unsuccessful in implementing these improvements or if we do not achieve our expected results, it may adversely impact our business, financial condition or results of operations.
Assumptions of unknown liabilities
Facilities that we acquire may have unknown or contingent liabilities, including, but not limited to, liabilities for uncertain tax positions, liabilities for failure to comply with healthcare laws and regulations and liabilities for unresolved litigation or regulatory reviews. Although we typically attempt to exclude significant liabilities from our acquisition transactions and seek indemnification from the sellers of such facilities, the purchase agreement with Priory containedfor some of our significant acquisitions contain minimal representations and warranties about the entities and business that we acquired. In addition, we have no indemnification rights against the sellers under the Priorysome purchase agreementagreements and all of the purchase price consideration was paid at closing of the Priory acquisition.closing. Therefore, we may incur material liabilities for the past activities of acquired entities and facilities. Even in those acquisitions in which we have such rights, we may experience difficulty enforcing the sellers’ obligations, or we may incur material liabilities for the past activities of acquired facilities. Such liabilities and related legal or other costs and/or resulting damage to a facility’s reputation could negatively impact our business, financial condition or results of operations.
Competing for acquisitions
We face competition for acquisition candidates primarily from otherfor-profit healthcare companies, as well as fromnot-for-profit entities. Some of our competitors may have greater resources than we do. As a result, we may pay more to acquire a target business or may agree to less favorable deal terms than we would have otherwise. Our principal competitors for acquisitions have included Universal Health ServicesUHS and private equity firms. Also, suitable acquisitions may not be accomplished due to unfavorable terms. Further, the cost of an acquisition could result in a dilutive effect on our results of operations, depending on various factors, including the amount paid for an acquired facility, the acquired facility’s results of operations, the fair value of assets acquired and liabilities assumed, effects of subsequent legislation and limits on rate increases. In addition, we may have to pay cash, incur debt, or issue equity securities to pay for any such acquisition, which could adversely affect our financial results, result in dilution to our stockholders, result in increased fixed obligations or impede our ability to manage our operations. There can be no assurances that we will be able to acquire facilities at historical or expected rates or on favorable terms.
22
Antitrust and other legal challenges
We may face antitrust and other legal challenges when acquiring facilities or other businesses, which could negatively impact our ability to close acquisition transactions. Antitrust enforcement in the healthcare industry is currently a priority of the Federal Trade Commission, the Department of Justice and many state agencies, including with respect to hospital acquisitions. Additionally, many states require CONs in order to acquire a hospital or other healthcare facility. The acquisition of hospitals and other healthcare facilities also often requires licensure approvals or reviews and complex change of ownership processes for Medicare and other payers. The increasingly challenging antitrust enforcement environment and other regulatory review or approval processes could significantly delay or even prevent our ability to acquire facilities and other businesses and increase our acquisition costs, which could adversely affect our overall growth strategy.
Managing growth
Some of the facilities we have acquired or may acquire in the future may have had significantly lower operating margins prior to the time of our acquisition or may have had operating losses prior to such acquisition. If we fail to improve the operating margins of the facilities we acquire, operate such facilities profitably or effectively integrate the operations of the acquired facilities, our results of operations could be negatively impacted.
Joint ventures may use significant resources, may be unsuccessful and could expose us to unforeseen liabilities.
As part of our growth strategy, we have completed, orand have announced plans to complete, a number of joint ventures and strategic alliances. These joint ventures may involve significant cash expenditures, debt incurrence, additional operating losses and expenses, and compliance risks that could negatively impact our business, financial condition or results of operations. Further, there is often a significant delay between our formation of a joint venture and the time that a de novo facility can be constructed and have a positive financial impact on our results of operations.
The nature of a joint venture requires us to consult with and share certain decision-making powers with unaffiliated third parties, some of which may benot-for-profit healthcare systems. If our joint venture partners do not fulfill their obligations, the affected joint venture may not be able to operate according to its business or strategic plans. In that case, our financial condition and results of operations may be materially adversely affected or we may be required to increase our level of financial commitment to the joint venture. Moreover, differences in economic or business interests or goals among joint venture participants could result in delayed decisions, failures to agree on major issues and even litigation. If these differences cause the joint ventures to deviate from their business or strategic plans, or if our joint venture partners take actions contrary to our policies, objectives or the best interests of the joint venture, our business, financial condition and results of operationoperations could be negatively impacted. In addition, our relationships withnot-for-profit healthcare systems and the joint venture agreements that govern these relationships are intended to be structured to comply with current revenue rulings published by the Internal Revenue Service (“IRS”), as well as case law relevant to joint ventures betweenfor-profit andnot-for-profit healthcare entities. Material changes in these authorities could adversely affect our relationships withnot-for-profit healthcare systems and related joint venture arrangements.
The majority of our revenue from our operationsWe incur significant transaction-related costs in the U.K. is not guaranteedconnection with acquisitions and is being generated either from spot purchasing or under framework agreements where no volume commitments are given.other strategic transactions.
We incur substantial costs in connection with acquisitions and other strategic transactions, including transaction-related expenses. In addition, there can be no assurancewe may incur additional costs to maintain employee morale, retain key employees, and to formulate and execute integration plans. Although we expect that we can achieve any fee rate increases in the future or will not suffer any fee rate decreases.
Any decline in demand for our services inelimination of duplicative costs, as well as the U.K. from publicly funded entities or private payers or any failure by us to extend current agreements or enter into alternative agreements on comparable terms with such entities could have an adverse effect on our average daily census (“ADC”), which would have a corresponding negative impact on our business, resultsrealization of operations and financial condition. Further, there can be no assurances that we will be able to implement fee rate increases, which are a driver of our revenue from our operations, or not suffer from any decline in fee rates in the future. Should the effect of any increase in annual wages or other operating costs of the business exceed the effect of any increase in our fee rates or should our fee rates suffer a decline, we would have to absorb any costs that cannot be offset by our fees, which could have a negative impact on our business, results of operations and financial condition.
Publicly funded entities
A significant portion of our services funded by U.K. publicly funded entities are commissioned on a spot-purchase basis at prices determined by prevailing market conditions. It is generally a matter for the relevant commissioner to determine whether to use our services, and there is no guarantee that previous spot market purchasing activity by a commissioner will continue in the future or at all. We also have a number of fixed-term framework agreements which grant us preferred provider status with Local Authorities or the NHS typically lasting between one to three years. While we and the commissioners typically agree on pricing for 12 months, at times with discountsefficiencies related to the numberintegration of beds purchased, the commissioners do not make minimum purchasing commitments under such agreements. As such, commissioners may decideacquired businesses, should allow us to place existingmore than offset incremental transaction and new service users with our competitors, including their ownin-house service providers, on short notice. We also have a small number of fixed-period block contracts, where a set number of beds are paid for at a discount to spot prices regardless of occupancy. While we may have flexibility to increase spot rates for new admissions, any fee increases under our block contracts are restricted by the terms and conditions of those block contracts.
The rates that we charge publicly-funded entities for our services are negotiated individually with commissioners and historically have been subject to annual review on April 1 of each year, with customary adjustments based on the Retail Prices Index (“RPI”), Consumer Price Index (“CPI”) or sector specificacquisition-related costs indices. However, the current economic climate and the U.K. government’s overriding economic policy to reduce the budget deficit means that, in the short term at least, commissioners are resistant to fee increases, often expecting that efficiency savings be made to offset inflationary cost increases in accordance with national policy. As a result, there can be no assurance that we can maintain the payment terms of our arrangements with publicly funded entities, including with respect to the timing of payments.
Further, following expiration of contracts there can be no assurance that negotiations with commissioners will result in the extension or renewal of existing arrangements or the entering into of alternative arrangements for those services. Commissioners may also require that following the expiration date of current agreements with us, they contract with us on a spot basis rather than through a block arrangement or reduce the number of beds subject to block arrangements. Even if we are successful in extending current agreements or in entering into alternative arrangements, the duration of such extensions or arrangements is uncertain, and we may be unsuccessful in implementing rate increases under such agreements.
In addition, changing commissioning structures and practices, such as those under the Health and Social Care Act 2012, involve tendering processes that could result in failing to remain or become an approved provider. There are currently a number of commissioning initiatives involving public and independent providers that could change the distribution ofin-patient beds in the U.K. Certain services that were historically commissioned centrally by NHS England are moving towards more local commissioning to better meet patient needs and to enhance local care pathways. These initiatives could cause our ADC to decrease in areas where there is surplus capacity or more focus on community-based treatment. Further, if we are not invited to participate in initiatives or do not meet the local commissioning standards, our ADC could be adversely affected.
Private payers
Although we have agreements in place with a number of private medical insurance (“PMI”) plans where pricing is generally agreed annually, there is no obligation on the PMI plans to refer its members to us or to pay for its members to use our services. Further, weover time, this net benefit may not be able to renew our existing arrangements with PMI plans on terms comparable to what it has achieved in the past. Fee rates for self-paying individuals are adjusted on January 1 of each year depending on capacity and demand in the relevant service markets. Fees paidnear term, or reimbursed by PMI plans are typically adjusted in line with specific contract terms and are generally based on RPI and specific wage indices. Demand in both the PMI market and theself-pay is dependent on economic conditions, which impacts the number of people with sufficient income or capital to pay for insurance coverage or treatment themselves.at all.
Structural shifts in the U.K. behavioral healthcare market may adversely affect us.
Publicly funded entities
Payments for our services by publicly funded entities in the U.K., particularly the NHS and Local Authorities, account for the vast majority of our U.K. revenue. We expect publicly funded entities in the U.K. to continue to generate the significant majority of our revenue from our operations in the U.K. Budget constraints, public spending cuts or other financial pressures could cause such publicly funded entities to spend less money on the type of services that we provide, or political or U.K. government policy changes could mean that fewer of such services are purchased by publicly funded entities from independent sector providers in favor of protecting NHS and Local Authorityin-house services.
While the outsourcing by the NHS in England of healthcare services has been increasing in recent years, the need of the NHS in England to achieve substantial efficiency savings is likely to result in continued funding pressure in the pricing of such services. For instance, Monitor (now part of NHS Improvement), the NHS economic regulator, has, under NHS Tariff Rules, determined national prices across a range of NHS services and has issued extensive guidance on how they are to be applied, including provision for local variations to national tariffs, subject to approval by Monitor. While none of our services are currently subject to national prices, the future application of any national prices regime upon our services could have a material adverse impact on our revenue.
In addition, the allocation of funding responsibility for adult social care may be subject to change at some time in the future under the provisions of the Care Act 2014 under which individuals identified as being required to pay for their own care under the relevant means test will be required to take funding responsibility up to a specified lifetime monetary cap, with Local Authorities responsible for the remainder of expenses for personal care, excluding “daily living” expenses. This would potentially place greater funding responsibility with public sector bodies over the longer term, which would potentially exacerbate the current funding challenges faced by such bodies.
Private payers
Payments for our services in the U.K. by PMI plans account for a small portion of our U.K. revenue. In addition, payments for our services in the U.K. byself-pay patients, who purchase treatment on a spot basis account for a small portion of our U.K. revenue. Many of the patients who use our acute healthcare services in the U.K. do so because their PMI plan recognizes our facilities as being an appropriate provider of the psychiatric treatment services required by the patient. Our ability to attract patients who are funded by PMI plans could be adversely impacted if one or more PMI plans withdraws recognition status from our facilities, for example, as a result of a change in a PMI plan’s recognition status standards. In addition, many PMI plans have been changing the terms of their policies and shortening the length of time they will cover a stay at one of our U.K. facilities.
There can be no assurance that the entities or individuals who fund our services will not reduce or cease spending on the types of services that we provide or that alternative service or funding models for mental healthcare, learning disabilities care, specialist education or elderly care will not emerge. Any such funding or structural change in the markets where we operate could have a material adverse effect on our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.
We are reliant upon maintaining strong relationships with commissioners employed by publicly funded entities, psychiatric and other medical consultants, and any reorganization of such publicly funded entities may result in the loss of those relationships.
The relationships that we have with commissioners is a key driver of referrals for our facilities in the U.K. Referrals to our U.K. business by the NHS accounted for a significant percentage of our revenue for the year ended December 31, 2017. Should there be a major reorganization of publicly funded entities, such as the NHS reorganization announced in 2010 and implemented between 2012 and 2013, we may need to rebuild such relationships which could result in a decrease in the number of referrals made to our facilities, which could have a corresponding material adverse effect on our business, results of operations, financial condition or prospects. Any actual or perceived deterioration in service quality, any serious incidents at our facilities or any other event that could cause commissioners to prefer other service providers over us could also adversely impact referrals from commissioners. Further, our business also depends, in part, on psychiatric and other medical consultants referring their patients to us for treatment either asin-patients or day patients. From time to time, consultants may decide to relocate or reposition their practices, retire or refer patients elsewhere with the result that there is a decrease in the number of referrals made to our facilities. A deterioration in relationships with commissioners or consultants or the decision by one or more commissioners or consultants to refer patients to our competitors or to stop all referrals would have an adverse effect on the ADC at our facilities in the U.K., which would have a corresponding negative impact on our business, results of operations and financial condition.
Our operating costs are subject to increases, including due to statutorily mandated increases in the wages and salaries of our staff.
The most significant operating expense for our facilities is wage costs, which represent the staff costs incurred in providing our services and running our facilities, and which are primarily driven by the number of employees and pay rates. The number of employees employed by us is primarily linked to the number of facilities we operate and the number of individuals cared for by us. While we can reduce the number of employees should occupancy rates decrease at our facilities, there is a limit on the extent to which this can be done without impacting quality of our services.
Furthermore, in April 2016, a new “National Living Wage” was introduced across the U.K. which was increased in April 2017 and is scheduled to increase again in April 2018 with further annual increases expected until at least 2020. These changes to the National Living Wage have and will increase our operating costs and, unless we can increase revenue or reduce other costs, will reduce our margins.
In the U.K., there has been an increase in enforcement action by HMRC against employers who do not pay the NMW, particularly for fixed allowance payments forsleep-in shifts in the care sector. The industry standard practice has been to pay a fixed allowance to employees who sleep at sites at night with a“top-up” if an employee is woken and provides care to residents during the
night. Our U.K. facilities have elected to join the SCCS established by HMRC to mitigate our exposure to potentialback-pay liability. Nevertheless, we may be subject to (i) increased payments to employees forsleep-in shifts on anon-going basis; (ii) payments of up to 6 years of arrears to employees or former employees who have carried outsleep-in shifts at our U.K. facilities; and (iii) payments of interest and penalties to HMRC, all of which would have a corresponding negative impact on our business, results of operations and financial condition.
We also have a number of recurring costs including insurance, utilities and rental costs, and may face increases to other recurring costs such as regulatory compliance costs. There can be no assurance that any of our recurring costs will not grow at a faster rate than our revenue. As a result, any increase in our operating costs could have a material adverse effect on our business, results of operations and financial condition.
We care for a large number of vulnerable individuals with complex needs and any care quality deficiencies could adversely impact our brand, reputation and ability to market our services effectively.
Our future growth will partly depend on our ability to maintain our reputation for providing quality patient care and, through successful salesnew programs and marketing activities, increased demand for our services. Factors such as increased acuity of our patients, health and safety incidents problems at our facilities, regulatory enforcement actions, negative press or general customer dissatisfaction could lead to deterioration in the level of our quality ratings or the public perception of the quality of our services (including as a result of negative publicity about our industry generally), which in turn could lead to a loss of patient placements, referrals andself-pay patients or service users. Any impairment of our reputation, loss of goodwill or damage to the value of our brand name could have a material
23
adverse effect on our business, results of operations and financial condition.
Many of our service users have complex medical conditions or special needs, are vulnerable and often require a substantial level of care and supervision. There is a risk that one or more service users could be harmed by one or more of our employees, either intentionally, through negligence or by accident. Further, individuals cared for by us have in the past engaged, and may in the future engage, in behavior that results in harm to themselves, our employees or to one or more other individuals, including members of the public. A serious incident involving harm to one or more service users or other individuals could result in negative publicity. Such negative publicity could have a material adverse effect on our brand, reputation and ADC, which would have a corresponding negative impact on our business, results of operations and financial condition. Furthermore, the damage to our reputation or to the reputation of the relevant facility from any such incident could be exacerbated by any failure on our part to respond effectively to such incident.
We are and in the future may become involved in legal proceedings based on negligence or breach of a contractual or statutory duty from service users or their family members or from employees or former employees.
From time to time, we are subject to complaints and claims from service users and their family members alleging professional negligence, medical malpractice or mistreatment. We are also subject to claims for unlawful detention from time to time when patients allege they should not have been detained under the Mental Health Act or where the appropriate procedures were not correctly followed.
Similarly, there may be substantial claims from employees in respect of personal injuries sustained in the performance of their duties, particularly in respect of incidents involving patients detained under the Mental Health Act and where future employment prospects are impaired. Current or former employees may also make claims against us in relation to breaches of employment legislation.
We may also be involved in coroner’s inquests (or the Scottish equivalent) where there is a fatality at one of our facilities in the U.K. resulting in an adverse coroner’s verdict or civil claims by individuals or criminal prosecutions by regulatory authorities. Any fines imposed by the courts are likely to be substantial in view of the Sentencing Council guidelines published in November 2015, which materially increase fines for corporate manslaughter and certain health and safety offenses. There may also be safeguarding incidents at our facilities which, depending on the circumstances, may result in custodial sentences or other criminal sanctions for the member of staff involved.
The incurrence of any legal fees, damage awards or other fines as summarized above as well as any impact on our brand or reputation as a result of being involved in any legal proceedings are likely to have a material adverse impact on our business, results of operations and financial condition.
We handle sensitive personal data which are protected by numerous U.S. and U.K. laws in the ordinary course of business and any failure to maintain the confidentiality of such data could result in legal liability and reputational harm.
We process and store sensitive personal data as part of our business. In the event of a security breach, sensitive personal data could become public. We are currently not aware of any material incidences of potential data breach; however, there can be no assurance that such breaches will not arise in future. Although we have in place policies and procedures to prevent such breaches, breaches could occur either as a result of a breach by us or as a result of a breach by a third party to whom we have provided sensitive personal data, and as a result, we could face liability under data protection laws.
In addition to U.S. data protection laws, we are subject to similar, and in some cases more restrictive, U.K. data protection laws. For example, the GDPR will provide heightened data protection requirements once effective in May 2018, including more stringent consent requirements, data protection and security measures and requirements to appoint a data protection officer. While we are taking appropriate steps to ensure compliance with U.K. data protection laws and regulations, we cannot guarantee that our facilities will not be subject to data breaches which could have a material adverse effect on our business, financial condition, or results of operations.
Liability under data protection laws may result in sanctions, including substantial fines and/or may cause us to suffer damage to our brand and reputation, which could have a material adverse effect on our business, results of operations and financial condition.
We may be subject to liabilities from claims brought against us or our facilities.
We are subject to medical malpractice lawsuits and other legal actions in the ordinary course of business. Some of these actions may involve large claims, as well as significant defense costs. We cannot predict the outcome of these lawsuits or the effect that findings in such lawsuits may have on us. All professional and general liability insurance we purchase is subject to policy limitations and in some cases, an insurance company may defend us subject to a reservation of rights. Management believes that, based on our past experience and actuarial estimates, our insurance coverage is adequate considering the claims arising from the operations of our facilities. While we continuously monitor our coverage, our ultimate liability for professional and general liability claims could change materially from our current estimates. If such policy limitations should be partially or fully exhausted in the future, or payments of claims exceed our estimates or are not covered by our insurance, it could have a material adverse effect on our business, financial condition or results of operations. Further, insurance premiums have increased year over year and insurance coverage may not be available at a reasonable cost, especially given the significant increase in insurance premiums generally experienced in the healthcare industry.
We carry a large self-insured retention and may be responsible for significant amounts not covered by insurance. In addition, our insurance may be inadequate, premiums may increase and, if there is a significant deterioration in our claims experience, insurance may not be available on acceptable terms.
We maintain liability insurance intended to cover service user, third-party and employee personal injury claims. Due to the structure of our insurance program under which we carry a large self-insured retention, there may be substantial claims in respect of which the liability for damages and costs falls to us before being met by any insurance underwriter. There may also be claims in excess of our insurance coverage or claims which are not covered by our insurance due to other policy limitations or exclusions or where we have failed to comply with the terms of the policy. Furthermore, there can be no assurance that we will be able to obtain liability insurance coverage in the future on acceptable terms, or without substantial premium increases or at all, particularly if there is a deterioration in our claim experience history. A successful claim against us not covered by or in excess of our insurance coverage could have a material adverse effect on our business, results of operations and financial condition.
Foreign currency exchange rate fluctuations could materially impact our consolidated financial position and results of operations.
We have significant U.K. operations. Accordingly, we translate revenue and other results denominated in a foreign currency into U.S. dollars (“USD”) for our consolidated financial statements. During periods of a strengthening USD or weakening British pound (“GBP”), our reported international revenue and expenses could be reduced because foreign currencies may translate into fewer USD. Following the Brexit vote and subsequent developments, the GBP dropped to its lowest level against the USD in more than 30 years. If the exchange rate further declines, our results of operations will be negatively impacted in future periods.
In all jurisdictions in which we operate, we are also subject to laws and regulations that govern foreign investment, foreign trade and currency exchange transactions. These laws and regulations may limit our ability to repatriate cash as dividends or otherwise to the U.S. and may limit our ability to convert foreign currency cash flows into USD.
We incur significant transaction related costs in connection with acquisitions.
We incur substantial costs in connection with acquisitions, including transaction-related expenses. In addition, we may incur additional costs to maintain employee morale, retain key employees, and to formulate and execute integration plans. Although we expect that the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of acquired businesses, should allow us to more than offset incremental transaction and acquisition-related costs over time, this net benefit may not be achieved in the near term, or at all.
Our ability to grow our business through organic expansion either by developing newde novo or joint venture facilities or by modifying existing facilities is dependent upon many factors.
Our ability to grow our business through organic expansion is dependent on capacity and occupancy at our facilities. Should our facilities reach maximum occupancy, we may need to implement other growth strategies either by developing newde novo or joint venture facilities or by modifying existing facilities.
Our facilities typically need to be purpose-designed in order to enable the type and quality of service that we provide. Consequently, we must either develop sites to create facilities or purchase or lease existing facilities, which may require substantial modification. We must be able to identify suitable sites and there is no guarantee that such sites will be available at all, or at an economically viable cost or in areas of sufficient demand for our services. The subsequent successful development and construction of a newde novo or joint venture facility is contingent upon, among other things, negotiation of construction contracts, regulatory permits and planning consents and satisfactory completion of construction. Similarly, our ability to expand existing facilities is also dependent upon various factors, including identification of appropriate expansion projects, permitting, licensure, financing, integration into our relationships with payors and referral sources, and margin pressure as newde novo and joint venture facilities are filled with patients.
Delays caused by difficulties in respect of any of the above factors may lead to cost overruns and longer periods before a return is generated on an investment, if at all. We may incur significant capital expenditure but due to a regulatory, planning or other reason, may find that we are prevented from opening a newde novo or joint venture facility or modifying an existing facility. Moreover, even when incurring such development capital expenditure, there is no guarantee that we can fill beds when they become available. Upon operational commencement of a newde novo or joint venture facility, we typically expect that it will take approximately12-1810 to 12 months, on average, to reach our targeted occupancy level.break-even results. Any delays or stoppages in our projects, the unsatisfactory completion or construction of such projects or the failure of such projects to increase our occupancy levels could have a material adverse effect on our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.
The cost of construction materials and labor has significantly increased, and we continue to grow our business through expansion of existing facilities and development of de novo and joint venture facilities.
Although we evaluate the financial feasibility of construction projects by determining whether the projected cash flow return on investment exceeds our cost of capital and have implemented efforts to realize efficiencies in our design and construction processes, such returns may not be achieved if the cost of construction continues to rise significantly or the expected patient volumes are not attained.
Our business could be disrupted if our information systems fail or if our databases are destroyed or damaged.
Our information technology (“IT”) platforms support, among other things, management control of patient administration, billing and financial information and reporting processes. For example, patients in some of our facilities have an electronic patient record that allows our caregivers and nurses to see information about a patient’s care and treatment. Our IT systems are subject to damage or interruption from power outages, facility damage, computer and telecommunications failures, computer viruses, security breaches including credit card or personally identifiable information breaches, vandalism, theft, natural disasters, catastrophic events, human error and potential cyber threats, including malicious codes, worms, phishing attacks, denial of service attacks, ransomware and other sophisticated cyber-attacks, and our disaster recovery planning cannot account for all eventualities. Any failure in or breach of our IT systems could adversely impact our business, results of operations and financial condition.
24
If we do not continually enhance our facilities with the most recent technological advances, our ability to maintain and expand our markets will be adversely affected.
As healthcare technology continues to advance, we expect information technology to play a greater role in our marketing and admissions processes and the operation of our facilities. To compete effectively, we must continually assess our automation needs and upgrade when significant technological advances occur. If our facilities do not stay current with technological advances in the healthcare industry, patients may seek treatment from other providers and/or physicians may refer their patients to alternate sources, which could adversely affect our results of operations and harm our business.
A cyber security incident could have a material adverse impact on the Company, including substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to reputational harm and increased costs.
We have experienced adverse IT events in the past including a criminal ransomware attack on our computer network which resulted in a temporary systems outage, as well as attempts of computer hacking, vandalism and theft, malware, computer viruses, malicious codes, worms, phishing and other cyber-attacks. To date, we have seen no material impact on our business or operations from these attacks or events. However, it is widely reported that healthcare companies are increasingly prime targets for cyber-attacks and we expect our systems to continue to be subject to attack on a regular basis.
The proliferation of ever-evolving cyber threats mean that we and our third-party service providers and vendors must continually evaluate and adapt our respective systems and processes and overall security environment, as well as those of any operations we acquire. As cyber criminals continue to become more sophisticated through evolution of their tactics, techniques and procedures, we have taken, and will continue to take, additional preventive measures to strengthen the cyber defenses of our networks and data. There is no guarantee that these measures will be adequate to safeguard against all data security breaches, system compromises, or misuses of data.
We may be required to expend significant capital and other resources to protect against the threat of security breaches or to alleviate problems caused by breaches, including unauthorized access to patient data and personally identifiable information stored in our IT systems, and the introduction of computer viruses or other malicious software programs to our systems, and cyber-attacks, email phishing schemes, malware, and ransomware. Moreover, a security breach, or threat thereof, could require that we expend significant resources to repair or improve our information systems and infrastructure and could distract management and other key personnel from performing their primary operational duties. In the event of a material breach or cyber-attack, the associated expenses and losses may exceed our current insurance coverage for such events. In addition, some adverse consequences are not insurable, such as reputational harm and third-party business interruption.
A cyber-attack that bypasses our IT security systems, or other adverse IT event, resulting in an IT security breach, loss of PHI or other data subject to privacy laws, loss of proprietary business information, or a material disruption of our IT business systems, could have a material adverse impact on our business, financial condition or results of operations. Any successful cybersecurity attack or other unauthorized attempt to access our systems or facilities could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors, or other third parties and could subject us to substantial sanctions, fines, and damages and civil and criminal penalties under federal and state privacy laws, in addition to litigation with those affected.
We may fail to deal with clinical waste in accordance with applicable regulations or otherwise be in breach of relevant medical, health and safety or environmental laws and regulations.
As part of our normal business activities, we produce and store clinical waste which may produce effects harmful to the environment or human health. The storage and transportation of such waste is strictly regulated. Our waste disposal services are outsourced and should the relevant service provider fail to comply with relevant regulations, we could face sanctions or fines which could adversely affect our brand, reputation, business or financial condition. Health and safety risks are inherent in the services that we provide and are constantly present in our facilities, primarily in respect of food and water quality, as well as fire safety and the risk that service users may cause harm to themselves, other service users or employees. From time to time, we have experienced, like other providers of similar services, undesirable health and safety incidents. Some of our activities are particularly exposed to significant medical risks relating to the transmission of infections or the prescription and administration of drugs for residents and patients. If any of the above medical or health and safety risks were to materialize, we may be held liable, fined and any registration certificate could be suspended or withdrawn for failure to comply with applicable regulations, which may have a material adverse impact on our business, results of operations and financial condition.
The value25
Although we have facilities in 39 states and Puerto Rico, we have substantial operations in Pennsylvania, California, Arizona and Tennessee, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those states.
Revenue from Pennsylvania, California, Arizona and Tennessee represented approximately 13%, 8%, 6% and 6% of our real estate assets willtotal revenue for the year ended December 31, 2022, respectively. This concentration makes us particularly sensitive to legislative, regulatory, economic, environmental and competition changes in those states. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these locations could have a disproportionate effect on our overall business results. If our facilities in these locations are adversely affected by changes in regulatory and economic conditions, our business, financial condition or results of operations could be adversely affected.
Our business and operations are subject to fluctuationsrisks related to natural disasters and climate change.
Some of our facilities are located in areas prone to hurricanes or wildfires. Natural disasters have historically had a disruptive effect on the operations of facilities and the patient populations in such areas. Our business activities could be significantly disrupted by wildfires, hurricanes or other natural disasters, and our property insurance may not be adequate to cover losses from such wildfires, storms or other natural disasters. Even if our facilities are not directly damaged, we may experience considerable disruptions in our operations due to property damage or electrical outages experienced in storm-affected areas by our personnel, payors, vendors and others. Additionally, long-term adverse weather conditions, whether caused by global climate change or otherwise, could cause an outmigration of people from the communities where our facilities are located. If any of the circumstances described above occur, our business, financial condition or results of operations could be adversely affected.
A pandemic, epidemic or outbreak of an infectious disease in the U.K. real estate market.markets in which we operate or that otherwise impacts our facilities could adversely impact our business.
If a pandemic, epidemic, outbreak of an infectious disease, such as COVID-19, or other public health crisis were to occur in an area in which we operate, our operations could be adversely affected. Such a crisis could diminish the public trust in healthcare facilities, especially facilities with patients affected by infectious diseases. If any of our facilities were involved, or perceived as being involved, in treating such patients, other patients might fail to seek care at our facilities, and our reputation may be negatively affected. Further, a pandemic, epidemic or outbreak might adversely impact our business by causing a temporary shutdown or diversion of patients, by disrupting or delaying production and delivery of pharmaceuticals and other medical supplies or by causing staffing shortages in our facilities. Although we have disaster plans in place and operate pursuant to infectious disease protocols, the potential impact of a pandemic, epidemic or outbreak of an infectious disease with respect to our markets or our facilities is difficult to predict and could adversely impact our business, financial condition or results of operations.
If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected.
Our ability to grow or even to maintain our existing level of business depends significantly on our ability to establish and maintain close working relationships with physicians, managed care companies, insurance companies, educational consultants and other referral sources. We may not be able to maintain our existing referral source relationships or develop and maintain new relationships in existing or new markets. If we lose existing relationships with our referral sources, the number of people to whom we provide services may decline, which may adversely affect our revenue. If we fail to develop new referral relationships, our growth may be restrained.
We holdoperate in a highly competitive industry, and competition may lead to declines in patient volumes.
The healthcare industry is highly competitive, and competition among healthcare providers (including hospitals) for patients, physicians and other healthcare professionals has intensified in recent years. There are other healthcare facilities that provide behavioral and other mental health services comparable to those offered by our facilities in each of the geographical areas in which we operate. Some of our competitors are owned by tax-supported governmental agencies or by non-profit corporations and may have certain financial advantages not available to us, including endowments, charitable contributions, tax-exempt financing and exemptions from sales, property and income taxes. Some of our for-profit competitors are local, independent operators or physician groups with strong established reputations within the surrounding communities, which may adversely affect our ability to attract a sufficiently large portfolionumber of patients in markets where we compete with such providers. We also face competition from other for-profit entities, who may possess greater financial, marketing or research and development resources than us or may invest more funds in renovating their facilities or developing technology.
If our competitors are better able to attract patients, recruit and retain physicians and other healthcare professionals, expand services or obtain favorable managed care contracts at their facilities, we may experience a decline in patient volume and our results of operations may be adversely affected.
26
We may be unable to extend leases at expiration, which could harm our business, financial condition or results of operations.
We lease the real estate assets, including significantproperty on which a number of our facilities are located. Our lease agreements generally give us the right to renew or extend the term of the leases and, in certain cases, purchase the real estate assetsproperty. These renewal and purchase rights generally are based upon either prescribed formulas or fair market value. Management expects to renew, extend or exercise purchase options with respect to our leases in the U.K. The valuenormal course of our U.K. property portfolio is subject to, among other things, the conditions of the real estate market in the U.K. The average values of real estate in the U.K., as in other European countries, experienced sharp declines from 2007 as a result of the credit crisis, economic recession and reduced confidence in global financial markets. Although real estate asset values have recovered and stabilized in recent years in the U.K.,business; however, there can be no assurance that this improvementthese rights will continuebe exercised in the future or that we will be sustainable. Real estate asset valuesable to satisfy the conditions precedent to exercising any such renewal, extension or purchase options. Furthermore, the terms of any such options that are based on fair market value are inherently uncertain and could decline substantially, particularlybe unacceptable or unfavorable to us depending on the circumstances at the time of exercise. If we are not able to renew or extend our existing leases, or purchase the real property subject to such leases, at or prior to the end of the existing lease terms, or if the U.K. economyterms of such options are unfavorable or unacceptable to us, our business, financial condition or results of operations could be adversely affected.
Controls designed to reduce inpatient services may reduce our revenue.
Controls imposed by Medicare, Medicaid and commercial third-party payors designed to reduce admissions and lengths of stay, commonly referred to as “utilization review,” have affected and are expected to continue to affect our facilities. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required preadmission authorization and utilization review and by payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Efforts to impose more stringent cost controls are expected to continue. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, expanded the potential use of prepayment review by Medicare contractors by eliminating certain statutory restrictions on its use. Utilization review is also a requirement of most non-governmental managed-care organizations and other third-party payors. Although we are unable to predict the effect these controls and changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on our financial condition and results of operations.
Human Capital Risks
Our facilities face competition for staffing, labor shortages and higher turnover rates that may increase our labor costs and reduce our profitability.
Our operations depend on the efforts, abilities and experience of our management and medical support personnel, including our addiction counselors, therapists, nurses, pharmacists, licensed counselors, clinical technicians, and mental health technicians, as well as our psychiatrists and other professionals. We compete with other healthcare providers in recruiting and retaining qualified management, program directors, physicians (including psychiatrists) and support personnel responsible for the daily operations of our business, financial condition or results of operations.
A shortage of nurses, qualified addiction counselors and other medical and care support personnel, combined with low unemployment rates for such personnel and intense competition from other healthcare facilities, has been a significant operating issue facing us and other healthcare providers. We may be required to enhance wages and benefits to hire nurses, qualified addiction counselors and other medical and care support personnel, hire more expensive temporary personnel or increase our recruiting and marketing costs relating to labor. We have resorted to using more expensive contract labor at certain of our facilities, and the use of temporary or agency staff could heighten the risk one of our facilities experiences an adverse patient incident. Further, because we generally recruit our personnel from the local area where the relevant facility is located, the availability in certain areas of suitably qualified personnel can be limited, particularly care home management, qualified teaching personnel and nurses. In addition, certain of our facilities are required to maintain specified staffing levels. To the extent we cannot meet those levels, we may be required to limit the services provided by these facilities, which would have a corresponding adverse effect on our net operating revenue. Certain of our treatment facilities are located in remote geographical areas, far from population centers, which increases this risk.
We cannot predict the degree to which we will be affected by the future availability or cost of attracting and retaining talented medical support staff. If our general labor and related expenses increase, we may not be able to raise our rates correspondingly. Increased turnover rates within our employee base can lead to decreased efficiency and increased costs, such as increased overtime and use of contract labor to meet demand and increased wage rates to attract and retain employees. Our failure either to recruit and retain qualified management, psychiatrists, therapists, counselors, nurses and other medical support personnel or control our labor costs could have a material adverse effect on our results of operations.
Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians.
The success and competitive advantage of our facilities depends, in part, on the number and quality of the psychiatrists and other physicians on the medical staffs of our facilities and our maintenance of good relations with those medical professionals. Although we
27
employ psychiatrists and other physicians at many of our facilities, psychiatrists and other physicians generally are not employees of our facilities, and, in a number of our markets, they have admitting privileges at competing hospitals providing acute or inpatient behavioral healthcare services. Such physicians (including psychiatrists) may terminate their affiliation with us at any time or admit their patients to competing healthcare facilities or hospitals. If we are unable to attract and retain sufficient numbers of quality psychiatrists and other physicians by providing adequate support personnel and facilities that meet the needs of those psychiatrists and other physicians, they may stop referring patients to our facilities and our results of operations may decline.
It may become difficult for us to attract and retain an adequate number of psychiatrists and other physicians to practice in certain of the communities in which our facilities are located. Our failure to recruit psychiatrists and other physicians to these communities or the Eurozone economyloss of such medical professionals in these communities could make it more difficult to attract patients to our facilities and thereby may have a material adverse effect on our business, financial condition or results of operations. Additionally, our ability to recruit psychiatrists and other physicians is closely regulated. The form, amount and duration of assistance we can provide to recruited psychiatrists and other physicians is limited by the Stark Law, the Anti-Kickback Statute, state anti-kickback statutes, and related regulations.
Some of our employees are represented by labor unions and any work stoppage could adversely affect our business.
Increased labor union activity could adversely affect our labor costs. At December 31, 2022, labor unions represented approximately 350 of our employees at two of our facilities through four collective bargaining agreements. We cannot assure you that employee relations will remain stable. Furthermore, there is a possibility that work stoppages could occur as a whole were to sufferresult of union activity, which could increase our labor costs and adversely affect our business, financial condition or results of operations. To the extent that a further recession or debt crisis, and could result in declines in the carrying valuesgreater portion of our real estate assets (andemployee base unionizes and the value at which weterms of any collective bargaining agreements are significantly different from our current compensation arrangements, it is possible that our labor costs could disposeincrease materially and our business, financial condition or results of such assets). Anyoperations could be adversely affected.
We depend on key management personnel, and the departure of one or more of our key executives or a significant portion of our local facility management personnel could harm our business.
The expertise and efforts of our senior executives and the chief executive officer, chief financial officer, medical directors, physicians and other key members of our facility management personnel are important to the success of our business. The loss of the above mayservices of one or more of our senior executives or our facility management personnel could significantly undermine our management expertise and our ability to provide efficient, quality healthcare services at our facilities, which could have a material adverse effect on our business, results of operations and financial condition.
OurLegal Proceedings and Regulatory Risks
We are and in the future could become the subject of additional governmental investigations, regulatory actions and whistleblower lawsuits.
Healthcare companies in the U.S. may be subject to investigations by various governmental agencies. Certain of our individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit reports and other inquiries from, and may be subject to investigation by, federal and state agencies. See Note 20— Commitments and Contingencies in the accompanying notes to our consolidated financial statements beginning on Page F-1 of this Annual Report on Form 10-K for additional information about pending investigations. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. If we incur significant costs responding to or resolving these or future inquiries or investigations, our business, financial condition and results of operations could be disruptedmaterially adversely affected.
Further, under the False Claims Act, private parties are permitted to bring qui tam or “whistleblower” lawsuits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Because qui tam lawsuits are filed under seal, we could be named in one or more such lawsuits of which we are not aware. We may also be subject to substantial reputational harm as a result of the public announcement of any investigation into such claims.
We could be subject to monetary penalties and other sanctions, including exclusion from federal healthcare programs, if our information systemswe fail or if our databases are destroyed or damaged.to comply with the terms of the CIA.
Our information technology platform supports, among other things, management controlDuring the second quarter of patient administration, billing and financial information and reporting processes. For example, patients2019, we reached a settlement with the U.S. Attorney’s Office for the Southern District of West Virginia relating to the manner in our U.K. facilities and somewhich seven of our U.S. facilities have an Electronic Patient Record that allowsCTCs in West Virginia had historically billed lab claims to the West Virginia
28
Medicaid Program. During the three months ended June 30, 2019, we entered into the CIA with the OIG imposing certain compliance obligations on us and our caregiverssubsidiary, CRC Health, in connection with such settlement. Material, uncorrected violations of the CIA could lead to our suspension or exclusion from participation in Medicare, Medicaid and nursesother federal and state healthcare programs and repayment obligations. In addition, we are subject to see all information aboutpossible civil penalties for failure to substantially comply with the terms of the CIA, including stipulated penalties ranging between $1,000 to $2,500 per day. We are also subject to a patient’s care and treatment. Although
we have taken measuresstipulated penalty of $50,000 for each false certification made by us or on our behalf, pursuant to mitigate potential information technology security risks and have information technology continuity plans across our business intended to minimize the impactreporting provisions of the CIA. The CIA increases the amount of information technology failures, there can be no assurance that such measureswe must provide to the federal government regarding our healthcare practices and plans will be effective. Any failureour compliance with federal regulations. The reports we provide in connection with the CIA could result in greater scrutiny by regulatory authorities.
We are and in the future may become involved in legal proceedings based on negligence or breach of our information technology systems could adversely impact our business, results of operations and financial condition.a contractual or statutory duty from service users or their family members or from employees or former employees.
WeFrom time to time, we are subject to volatilitycomplaints and claims from service users and their family members alleging professional negligence, medical malpractice or mistreatment. We are also subject to claims for unlawful detention from time to time when patients allege they should not have been detained under applicable laws and regulations or where the appropriate procedures were not correctly followed.
Similarly, there may be substantial claims from employees in respect of personal injuries sustained in the global capital and credit marketsperformance of their duties. Current or former employees may also make claims against us in relation to breaches of employment laws.There may also be safeguarding incidents at our facilities which, depending on the circumstances, may result in custodial sentences or other criminal sanctions for the member of staff involved.
The incurrence of substantial legal fees, damage awards or other fines as well as significant developmentsthe potential impact on our brand or reputation as a result of being involved in macroeconomic and political conditions that are out of our control.
Our business can be affected by a number of factors that are beyond our control, such as general macroeconomic conditions, conditions in the financial services markets, geopolitical conditions and other general political and economic developments. These conditions and developments may continue to put pressure on the economy in the U.K., whichany legal proceedings could have a negative effect on our business. There may be a shortage of liquidity and credit in the U.K. or worldwide and this can be exacerbated bymaterial adverse developments in global or national political and/or macroeconomic conditions. In particular, we have historically financed the development of new facilities and the modification of our existing facilities through a variety of sources, including our own cash reserves and debt financing. While we intend to seek to finance new and existing developments from similar sources in the future, there may be insufficient cash reserves to fund the budgeted capital expenditure and market conditions and other factors may prevent us from obtaining debt financing on appropriate terms or at all. In addition, market conditions may limit the number of financial institutions that are willing to provide financing to landlords with whom we wish to contract to build homes for learning disability services, new schools or new mental health facilities which can then be made available to us under a long-term operating lease. If conditions in the U.K. or the global economy remain uncertain or weaken further, this could materially adversely impact our ADC, which would have a corresponding negative impact on our business, results of operations and financial condition.
Failure to comply with the international andWe handle sensitive personal data which are protected by numerous U.S. laws in the ordinary course of business and regulations applicable to our international operations could subject us to penalties and other adverse consequences.
We face several risks inherent in conducting business internationally, including compliance with international and U.S. laws and regulations that apply to our international operations. These laws and regulations include U.S. laws such as the Foreign Corrupt Practices Act and other U.S. federal laws and regulations established by the Office of Foreign Asset Control, local laws such as the U.K. Bribery Act 2010 or other local laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. Given the high level of complexity of these laws, however, there is a risk that some provisions may be inadvertently breached by us, for example through fraudulent or negligent behavior of individual employees, ourany failure to comply with certain formal documentation requirements, or otherwise. Violationsmaintain the confidentiality of these laws and regulationssuch data could result in fines, criminal sanctions against us, our officers or our employees, implementation of compliance programs,legal liability and prohibitions on the conductreputational harm.
We collect, process and store sensitive personal data as part of our business. AnyIn the event of a security breach, sensitive personal data could become public. We are currently not aware of any material incidences of potential data breach; however, there can be no assurance that such violationsbreaches will not arise in future. Although we have in place policies and procedures to prevent such breaches, breaches could include prohibitions onoccur either as a result of a breach by our abilityemployees or as a result of a breach by a third party to conduct businesswhom we have provided sensitive personal data, and we could face liability under data protection laws.
Liability under data protection laws may result in the U.K. and could materiallysanctions, including substantial fines and/or compensation to those affected. Additionally, liability may cause us to suffer damage our reputation,to our brand our international expansion efforts, our ability to attract and retain employees, our business and our operating results. Our success depends, in part, on our ability to anticipate these risks and manage these challenges.
We are subject to taxation in the U.S. and certain foreign jurisdictions. Any adverse development in the tax laws of such jurisdictions or any disagreement with our tax positionsreputation, which could have a material adverse effect on our business, financial condition or results of operations.operations and financial condition.
We carry a large self-insured retention and may be responsible for significant amounts not covered by insurance. In addition, our effective tax rate could change materially asinsurance may be inadequate, premiums may increase and, if there is a result of certain changessignificant deterioration in our mix of U.S. and foreign earnings and other factors, including changes in tax laws.claims experience, insurance may not be available on acceptable terms.
We are subject to taxationmedical malpractice lawsuits and other legal actions in the ordinary course of business. Some of these actions may involve large claims, as well as significant defense costs. We cannot predict the outcome of these lawsuits or the effect that findings in such lawsuits may have on us. We maintain liability insurance intended to cover service user, third-party and employee personal injury claims. Due to the tax lawsstructure of our insurance program under which we carry a large self-insured retention, there may be substantial claims in respect of which the liability for damages and regulationscosts falls to us before being met by any insurance underwriter. There may also be claims in excess of our insurance coverage or claims which are not covered by our insurance due to other policy limitations or exclusions or where we have failed to comply with the terms of the U.S. and certain foreign jurisdictions aspolicy. Furthermore, there can be no assurance that we will be able to obtain liability insurance coverage in the future on acceptable terms, or without substantial premium increases or at all, particularly if there is a resultdeterioration in our claim experience history. A successful claim against us not covered by or in excess of our operations and our corporate and financing structure. Adverse developments in these tax laws or regulations, or any change in position regarding the application, administration or interpretation thereof, in any applicable jurisdiction,insurance coverage could have a material adverse effect on our business, financial condition or results of operations. In addition, the tax authorities in any applicable jurisdiction may disagree with the tax treatment or characterization of any of our transactions, which, if successfully challenged by such tax authorities, could have a material adverse effect on our business, financial condition or results of operations. Certain changes in the mix of our earnings between jurisdictions and assumptions used in the calculation of income taxes, among other factors, could have a material adverse effect on our overall effective tax rate. In addition, the Tax Act makes significant changes to the rules applicable to the taxation of corporations. The Company is currently in the process of analyzing the effects of the Tax Act on the Company. It is uncertain at this time whether the application of these new rules will have any material and adverse impact on our operating results, cash flowsoperations and financial condition.
A worsening of the economic and employment conditions in the geographies in which we operate could materially affect our business and future results of operations.
During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at the federal, state and local levels have decreased, and may continue to decrease, spending for health and human service programs, including Medicare and Medicaid in the U.S., which are significant payor sources for our facilities. In periods of high unemployment, we also face the risk of potential declines in the population covered under private insurance, patient decisions to postpone or decide against receiving behavioral healthcare services, potential increases in the uninsured and underinsured populations we serve and further difficulties in collecting patientco-payment and deductible receivables.
A sizable portion of our revenue from certain residential recovery, eating disorder facilities, comprehensive treatment centers and youth programs is from self-payors. Accordingly, a sustained downturn in the U.S. economy could restrain the ability of our patients and the families of our students to pay for services.
Furthermore, the availability of liquidity and capital resources to fund the continuation and expansion of many business operations worldwide has been limited in recent years. Our ability to access the capital markets on acceptable terms may be severely restricted at a time when we would like, or need, access to those markets, which could have a negative impact on our growth plans, our flexibility to react to changing economic and business conditions and our ability to refinance existing debt (including debt under our Amended and Restated Senior Credit Facility and the Senior Notes). A sustained economic downturn or other economic conditions could also adversely affect the counterparties to our agreements, including the lenders under the Amended and Restated Senior Credit Facility, causing them to fail to meet their obligations to us.
Our reimbursement may be adversely affected by the repeal, replacement or modification of PPACA.
On January 20, 2017, Donald Trump became President of the United States. During the 2016 election cycle, Republicans also assumed control of both the United States Senate and House of Representatives. Shortly after his inauguration, President Trump issued an executive order that, among other things, stated that it was the intent of his administration to repeal PPACA. Several bills have been introduced and voted upon in the House of Representatives and United States Senate that would either repeal and replace or simply repeal PPACA, although no such comprehensive legislation has been enactedto-date. The Tax Act does, however, effectively repeal the individual mandate to obtain and maintain health insurance by eliminating the tax penalty associated with failing to do so.
If PPACA is repealed, with or without a replacement, we may experience a significant decrease in reimbursement from state Medicaid programs. We may also experience a significant increase in uncompensated care if many of our patients who currently obtain private health insurance coverage or Medicaid coverage under the provisions of PPACA are no longer able to maintain that coverage. Finally, PPACA currently works in conjunction with MHPAEA to require that third-party payors reimburse providers of certain mental health and substance abuse treatment services on anout-of-network basis. If PPACA or this particular provision thereof is repealed, we may experience a significant decrease inout-of-network reimbursement at certain of our facilities.
If we fail to comply with extensive laws and government regulations, we could suffer penalties or be required to make significant changes to our operations.
Companies operating in the behavioral healthcare industry in the U.S. are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things: billing practices and prices for services; relationships with physicians and other referral sources; necessity and quality of medical care; condition and adequacy of facilities; qualifications of medical and support personnel; confidentiality, privacy and security issues associated with health-related
29
information and PHI; EMTALA compliance; handling of controlled substances; certification, licensure and accreditation of our facilities; operating policies and procedures; activities regarding competitors; state and local land use and zoning requirements; and addition or expansion of facilities and services.
Among the laws applicable to our operations are the federal Anti-Kickback Statute, the Stark Law, the federal False Claims Act, the EKRA, and similar state laws. These laws impact the relationships that we may have with physicians and other potential referral sources. We have a variety of financial relationships with physicians and other professionals who refer patients to our facilities, including employment contracts, leases and professional service agreements. The OIG has issued certain safe harbor regulations that outline practices that are deemed acceptable under the Anti-Kickback Statute, and similar regulatory exceptions have been promulgated by CMS under the Stark Law. While we endeavor to ensure that our arrangements with referral sources comply with an applicable safe harbor to the Anti-Kickback Statute where possible, certain of our current arrangements with physicians and other potential referral sources may not qualify for such protection. Failure to meet a safe harbor does not mean that the arrangement automatically violates the Anti-Kickback Statute, but may subject the arrangement to greater scrutiny. Even if our arrangements are found to be in compliance with the Anti-Kickback Statute, they may still face scrutiny under the newly enacted EKRA law. Moreover, while we believe that our arrangements with physicians comply with applicable Stark Law exceptions, the Stark Law is a strict liability statute for which no intent to violate the law is required.
Effective January 1, 2022, the No Surprises Act, enacted as part of the Consolidated Appropriations Act (the “CAA”), creates price transparency requirements, including (i) requiring providers to send to patients or their health plan a good faith estimate of the expected charges and diagnostic codes prior to furnishing scheduled items or services and (ii) prohibiting providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to limited exceptions. Price transparency initiatives like the No Surprises Act may impact our ability to obtain or maintain favorable contract terms, and may impact our competitive position and our relationships with patients and insurers.
These laws and regulations are extremely complex, and, in many cases, we do not have the benefit of regulatory or judicial interpretation. In the future, it is possible that different interpretations of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our arrangements for facilities, equipment,
personnel, services, capital expenditure programs and operating expenses. A determination that we have violated one or more of these laws could subject us to liabilities, including civil penalties, exclusion of one or more facilities from participation in the government healthcare programs and, for violations of certain laws and regulations, criminal penalties. Even the public announcement that we are being investigated for possible violations of these laws could cause our reputation to suffer and have a material adverse effect on our business, financial condition or results of operations. In addition, we cannot predict whether other similar legislation or regulations at the federal or state level will be adopted, what form such legislation or regulations may take or what their impact on us may be.
The construction and operation of healthcare facilities in the U.S. are subject to extensive federal, state and local regulation relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, fire prevention, rate-setting, compliance with building codes and environmental protection. Additionally, such facilities are subject to periodic inspection by government authorities to assure their continued compliance with these various standards. If we fail to adhere to these standards, we could be subject to monetary penalties or restrictions on our ability to operate.
All of our facilities that handle and dispense controlled substances must comply with strict federal and state regulations regarding the purchase, storage, distribution and disposal of such controlled substances. The potential for theft or diversion of such controlled substances for illegal uses has led the federal government as well as a number of states and localities to adopt stringent regulations not applicable to many other types of healthcare providers. Compliance with these regulations is expensive and these costs may increase in the future.
Property owners and local authorities have attempted, and may in the future attempt, to use or enact zoning ordinances to eliminate our ability to operate a given treatment facility or program. Local governmental authorities in some cases also have attempted to use litigation and the threat of prosecution to force the closure of certain comprehensive treatment facilities. If any of these attempts were to succeed or if their frequency were to increase, our revenue would be adversely affected and our operating results might be harmed. In addition, such actions may require us to litigate which would increase our costs.
Many of our U.S. facilities are also accredited by third-party accreditation agencies such as The Joint Commission or CARF. If any of our existing healthcare facilities lose their accreditation or any of our newde novo or joint venture facilities fail to receive accreditation, such facilities could become ineligible to receive reimbursement under Medicare or Medicaid.
Federal, state and local regulations determine the capacity at which many of our U.S. facilities may be operated. State licensing standards require many of our U.S. facilities to have minimum staffing levels; minimum amounts of residential space per student or patient
30
and adhere to other minimum standards. Local regulations require us to follow land use guidelines at many of our U.S. facilities, including those pertaining to fire safety, sewer capacity and other physical plant matters.
Similarly, providers of behavioral healthcare services in the U.K. are also subject to a highly regulated business environment. Failure to comply with regulations, lapses in the standards of care, the receipt of poor ratings or lower ratings, the receipt of a negative report that leads to a determination of regulatory noncompliance, or the failure to cure any defect noted in an inspection report could lead to substantial penalties, including the loss of registration or closure of one or more facilities as well as damage to reputation.
Our operations in the U.K. are subject to a high level of regulation and supervision, ranging from the initial establishment of new facilities, which are subject to registration and licensing requirements, to the recruitment and appointment of staff, occupational health and safety, duty of care to service users, clinical and educational standards, conduct of our professional and support staff, the environment, public health and other areas. The regulatory requirements differ across our divisions, though almost all of our activity in England in relation to mental healthcare, elderly care and learning disability care are regulated by the CQC and in Scotland, Wales and Northern Ireland, its local equivalent. In addition, our children’s homes, residential schools and colleges in England are regulated by OFSTED, and in Scotland and Wales by their local equivalent, and all of our schools must be licensed by the Department for Education. See “Item 1. Business—Regulation—U.K. Overview” for further details on the key U.K. regulations to which we are subject.
Inspections by CQC, OFSTED, and other regulators can be carried out on both an announced and unannounced basis depending on the specific regulatory provisions relating to the different healthcare, social care and specialist education services we provide.
A failure to comply with regulations, the receipt of a poor rating or a lower rating, or the receipt of a negative report that leads to a determination of regulatorynon-compliance or our failure to cure any defect noted in an inspection report could result in reputational damage, fines, the revocation or suspension of the registration of any facility or service or a decrease in, or cessation of, the services provided by us at any given facility. Additionally, where placements are funded by Local Authorities, most Local Authorities monitor performance and where there are shortcomings may impose punitive measures. These can, for example, include the suspension of new placements (known in the industry as “embargoes”) and, in extreme cases, removal of all residents placed by that authority, which in turn may affect the level of referrals from other publicly funded entities and our occupancy levels.
Furthermore, new regulations or regulatory bodies may be introduced in the future or existing regulations and regulatory bodies may be amended or replaced and we may not adapt to such changes quickly enough, or in a cost-efficient manner. For example, the U.K. government appointed Monitor (now part of NHS Improvement) as the market regulator for healthcare providers in 2012 by way of a licensing regime. Any failure by us to comply with the licensing regime could result in Monitor revoking our license, which would mean we would be unable to operate. In addition, such regulatory changes may preclude management from executing its business plan as intended, including the timing for new developments and openings.
We cannot guarantee that current laws, regulations and regulatory assessment methodologies will not be modified or replaced in the future. There can be no assurance that our business, results of operations and financial condition will not be adversely affected by any future regulatory developments or that the cost of compliance with new regulations will not be material.
If we fail to cultivate new or maintain established relationships with referral sources, our business, financial condition or results of operations could be adversely affected.
Our ability to grow or even to maintain our existing level of business depends significantly on our ability to establish and maintain close working relationships with physicians, managed care companies, insurance companies, educational consultants and other referral sources. We may not be able to maintain our existing referral source relationships or develop and maintain new relationships in existing or new markets. If we lose existing relationships with our referral sources, the number of people to whom we provide services may decline, which may adversely affect our revenue. If we fail to develop new referral relationships, our growth may be restrained.
We may be required to spend substantial amounts to comply with statutes and regulations relating to privacy and security of PHI.
There are currently numerous legislative and regulatory initiatives in both the U.S. and the U.K. addressing patient privacy and information security concerns. In particular, federal regulations issued under HIPAA require our U.S. facilities to comply with standards to protect the privacy, security and integrity of PHI. These requirements include the adoption of certain administrative, physical, and technical safeguards; development of adequate policies and procedures, training programs and other initiatives to ensure the privacy of PHI is maintained; entry into appropriate agreements withso-called business associates; and affording patients certain rights with respect to their PHI, including notification of any breaches. Compliance with these regulations requires substantial expenditures, which could negatively impact our business, financial condition or results of operations. In addition, our management has spent, and may spend in the future, substantial time and effort on compliance measures.
In addition to HIPAA, we are subject to similar, and in some cases more restrictive, state and federal privacy regulations. For example, the federal government and some states impose laws governing the use and disclosure of health information pertaining to mental health and/or substance abuse treatment that are more stringent than the rules that apply to healthcare information generally. As public attention is drawn to the issues of the privacy and security of medical information, states may revise or expand their laws concerning the use and disclosure of health information, or may adopt new laws addressing these subjects.
Violations of the privacy and security regulations could subject our operations to substantial civil monetary penalties and substantial other costs and penalties associated with a breach of data security, including criminal penalties. We may also be subject to substantial reputational harm if we experience a substantial security breach involving PHI.
We are subject to uncertainties regarding recent health reform and budget legislation.
Recent developments with respect to the implementation of PPACA have created uncertainty for many healthcare providers. For example, the Tax Act will effectively repeal the individual health insurance mandate imposed under PPACA by eliminating the tax penalty associated with failure to obtain and maintain coverage. Additionally, President Trump’s administration has taken certain executive actions that may promote the availability of alternative forms of health insurance outside PPACA’s requirements and otherwise affect the implementation of PPACA. We cannot predict how these changes to, or the potential repeal, replacement or further modification of, PPACA will affect our business, results of operations, cash flow, capital resources and liquidity, or whether we will be able to adapt successfully thereto.
We are similarly unable to guarantee that current U.K. laws, regulations and regulatory assessment methodologies will not be modified or replaced in the future. Additionally, there is a risk that budget constraints, public spending cuts (such as the cuts announced by the U.K. government in the 2010 Comprehensive Spending Review and implemented in the 2011 and 2012 government budgets) or other financial pressures could cause the NHS to reduce funding for the types of services that we provide. Such policy changes in the U.K. could lead to fewer services being purchased by publicly funded entities or material changes being made to their procurement practices, any of which could materially reduce our revenue. These and other future developments and amendments may negatively impact our operations, which could have a material adverse effect on our business, financial condition or results of operations. See “—Expanding our operations internationally poses additional risks to our business.”
Finally, the allocation of funding responsibility for adult social care will be subject to change over the next few years under the provisions of the Care Act 2014 with individuals identified as being required to pay for their own care under the relevant means test being required to take funding responsibility up to a specified lifetime monetary cap, with Local Authorities then becoming responsible for the continued funding of personal care, but not ‘daily living’ expenses. This will potentially place greater funding responsibility with public sector bodies over the longer term, which will potentially exacerbate the current funding challenges faced by such bodies.
The industry trend on value-based purchasing may negatively impact our revenue.
There is a trend in the healthcare industry toward value-based purchasing of healthcare services. These value-based purchasing programs include both public reporting of quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for care related to certain preventable adverse events. Many large commercial payors currently require hospitals to report quality data, and several commercial payors do not reimburse hospitals for certain preventable adverse events.
We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. We are unable at this time to predict how this trend will affect our results of operations, but it could negatively impact our revenue if we are unable to meet quality standards established by both governmental and private payers.
We operate in a highly competitive industry, and competition may lead to declines in patient volumes.
The healthcare industry is highly competitive, and competition among healthcare providers (including hospitals) for patients, physicians and other healthcare professionals has intensified in recent years. There are other healthcare facilities that provide behavioral and other mental health services comparable to those offered by our facilities in each of the geographical areas in which we operate. Some of our competitors are owned bytax-supported governmental agencies or bynon-profit corporations and may have certain financial advantages not available to us, including endowments, charitable contributions,tax-exempt financing and exemptions from sales, property and income taxes. Some of ourfor-profit competitors are local, independent operators or physician groups with strong established reputations within the surrounding communities, which may adversely affect our ability to attract a sufficiently large number of patients in markets where we compete with such providers. We also face competition from otherfor-profit entities, who may possess greater financial, marketing or research and development resources than us or may invest more funds in renovating their facilities or developing technology.
If our competitors are better able to attract patients, recruit and retain physicians and other healthcare professionals, expand services or obtain favorable managed care contracts at their facilities, we may experience a decline in patient volume and our results of operations may be adversely affected.
The NHS is the principal provider of secure mental healthcare services in the U.K., with approximately 70% of the total beds in secure mental healthcare services in the U.K. As the preferred provider, there is often a bias toward referrals to NHS, and therefore NHS facilities have maintained high occupancy rates. As a result of budget constraints, independent operators have emerged to satisfy the demand for mental health services not supplied by the NHS. In addition to the NHS, we face competition in the U.K. from independent sector providers and other publicly funded entities for individuals requiring care and for appropriate sites on which to develop or expand facilities in the U.K. Should we fail to compete effectively with our peers and competitors in the industry, or if the competitive environment intensifies, individuals may be referred elsewhere for services that we provide, negatively impacting our ability to secure referrals and limiting the expansion of our business.
The trend by insurance companies and managed care organizations to enter into sole-source contracts may limit our ability to obtain patients.
Insurance companies and managed care organizations in the U.S. are entering into sole-source contracts with healthcare providers, which could limit our ability to obtain patients since we do not offer the range of services required for these contracts. Moreover, private insurers, managed care organizations and, to a lesser extent, Medicaid and Medicare, are beginning tocarve-out specific services, including mental health and substance abuse services, and establish small, specialized networks of providers for such services at fixed reimbursement rates. Continued growth in the use ofcarve-out arrangements could materially adversely affect our business to the extent we are not selected to participate in such networks or if the reimbursement rate in such networks is not adequate to cover the cost of providing the service.
Our performance depends on our ability to recruit and retain quality psychiatrists and other physicians.
The success and competitive advantage of our facilities depends, in part, on the number and quality of the psychiatrists and other physicians on the medical staffs of our facilities and our maintenance of good relations with those medical professionals. Although we employ psychiatrists and other physicians at many of our facilities, psychiatrists and other physicians generally are not employees of our facilities, and, in a number of our markets, they have admitting privileges at competing hospitals providing acute or inpatient behavioral healthcare services. Such physicians (including psychiatrists) may terminate their affiliation with us at any time or admit their patients to competing healthcare facilities or hospitals. If we are unable to attract and retain sufficient numbers of quality psychiatrists and other physicians by providing adequate support personnel and facilities that meet the needs of those psychiatrists and other physicians, they may stop referring patients to our facilities and our results of operations may decline.
It may become difficult for us to attract and retain an adequate number of psychiatrists and other physicians to practice in certain of the communities in which our facilities are located. Our failure to recruit psychiatrists and other physicians to these communities or the loss of such medical professionals in these communities could make it more difficult to attract patients to our facilities and thereby may have a material adverse effect on our business, financial condition or results of operations. Additionally, our ability to recruit psychiatrists and other physicians is closely regulated. The form, amount and duration of assistance we can provide to recruited psychiatrists and other physicians is limited by the Stark Law, the Anti-Kickback Statute, state anti-kickback statutes, and related regulations.
Some of our employees are represented by labor unions and any work stoppage could adversely affect our business.
Increased labor union activity could adversely affect our labor costs. As of December 31, 2017, labor unions represented approximately 460 of our employees at five of our U.S. facilities through eight collective bargaining agreements. The Royal College of Nursing represents nursing employees at our facilities in the U.K. We cannot assure you that employee relations will remain stable. Furthermore, there is a possibility that work stoppages could occur as a result of union activity, which could increase our labor costs and adversely affect our business, financial condition or results of operations. To the extent that a greater portion of our employee base unionizes and the terms of any collective bargaining agreements are significantly different from our current compensation arrangements, it is possible that our labor costs could increase materially and our business, financial condition or results of operations could be adversely affected.
We depend on key management personnel, and the departure of one or more of our key executives or a significant portion of our local facility management personnel could harm our business.
The expertise and efforts of our senior executives and the chief executive officer, chief financial officer, medical directors, physicians and other key members of our facility management personnel are important to the success of our business. The loss of the services of one or more of our senior executives, including our U.K. senior management team, or of a significant portion of our facility management personnel could significantly undermine our management expertise and our ability to provide efficient, quality healthcare services at our facilities, which could harm our business.
We could face risks associated with, or arising out of, environmental, health and safety laws and regulations.
We are subject to various federal, foreign, state and local laws and regulations that:
• | regulate certain activities and operations that may have environmental or health and safety effects, such as the generation, handling and disposal of medical wastes; |
• | impose liability for costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and |
• | regulate workplace safety. |
Compliance with these laws and regulations could increase our costs of operation. Violation of these laws may subject us to significant fines, penalties or disposal costs, which could negatively impact our results of operations, financial condition or cash flows. We could be responsible for the investigation and remediation of environmental conditions at currently or formerly owned, operated or leased sites, as well as for associated liabilities, including liabilities for natural resource damages, third-party property damage or personal injury resulting from lawsuits that could be brought by the government or private litigants, relating to our operations, the operations of facilities or the land on which our facilities are located. We may be subject to these liabilities regardless of whether we operate, lease or own the facility, and regardless of whether such environmental conditions were created by us or by a prior owner or tenant, or by a third party or a neighboring facility whose operations may have affected such facility or land. That is because liability for contamination under certain environmental laws can be imposed on current or past owners, lessors or operators of a site without regard to fault. We cannot assure you that environmental conditions relating to our prior, existing or future sites or those of predecessor companies whose liabilities we may have assumed or acquired will not have a material adverse effect on our business, financial condition or results of operations.
State efforts to regulate the construction or expansion of healthcare facilities in the U.S. could impair our ability to operate and expand our operations.
A majority of the states in which we operate facilities in the U.S. have enacted certificate of need (“CON”)CON laws that regulate the construction or expansion of healthcare facilities, certain capital expenditures or changes in services or bed capacity. In giving approval for these actions, these states consider the need for additional or expanded healthcare facilities or services. Our failure to obtain necessary state approval could (i) result in our inability to acquire a targeted facility, complete a desired expansion or make a desired replacement, (ii) make a
31
facility ineligible to receive reimbursement under the Medicare or Medicaid programs or (iii) result in the revocation of a facility’s license or imposition of civil or criminal penalties, any of which could harm our business.
In addition, significant CON reforms have been proposed in a number of states that would increase the capital spending thresholds and provide exemptions of various services from review requirements. In the past, we have not experienced any material adverse effects from such requirements, but we cannot predict the impact of these changes upon our operations.
We may be unable to extend leases at expiration, which could harm our business, financial condition or results of operations.
We lease the real property on which a number of our facilities are located. Our lease agreements generally give us the right to renew or extend the term of the leases and, in certain cases, purchase the real property. These renewal and purchase rights generally are based upon either prescribed formulas or fair market value. Management expects to renew, extend or exercise purchase options with respect to our leases in the normal course of business; however, there can be no assurance that these rights will be exercised in the future or that we will be able to satisfy the conditions precedent to exercising any such renewal, extension or purchase options. Furthermore, the terms of any such options that are based on fair market value are inherently uncertain and could be unacceptable or unfavorable to us depending on the circumstances at the time of exercise. If we are not able to renew or extend our existing leases, or purchase the real property subject to such leases, at or prior to the end of the existing lease terms, or if the terms of such options are unfavorable or unacceptable to us, our business, financial condition or results of operations could be adversely affected.
Controls designed to reduce inpatient services may reduce our revenue.
Controls imposed by Medicare, Medicaid and commercial third-party payors designed to reduce admissions and lengths of stay, commonly referred to as “utilization review,” have affected and are expected to continue to affect our facilities. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required preadmission authorization and utilization review and by payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Efforts to impose more stringent cost controls are expected to continue. For example, PPACA expanded the potential use of prepayment review by Medicare contractors by eliminating certain statutory restrictions on its use. Utilization review is also a requirement of mostnon-governmental managed-care organizations and other third-party payors. Although we are
unable to predict the effect these controls and changes will have on our operations, significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on our financial condition and results of operations.
Additionally, the outsourcing of behavioral healthcare to the private sector is a relatively recent development in the U.K. There has been some opposition to outsourcing. While we anticipate that the NHS will continue to rely increasingly upon outsourcing, we cannot assure you that the outsourcing trend will continue. The absence of future growth in the outsourcing of behavioral healthcare services could have a material adverse impact on our business, financial condition and results of operations.
Although we have facilities in 39 states, the U.K. and Puerto Rico, we have substantial operations in the U.K., Pennsylvania, California and Arkansas, which makes us especially sensitive to regulatory, economic, environmental and competitive conditions and changes in those locations.
For the year ended December 31, 2017, our revenue in the U.K. represented approximately 36% of our total revenue. Revenue from Pennsylvania, California and Arkansas represented approximately 7%, 5% and 5% of our total revenue for the year ended December 31, 2017, respectively. This concentration makes us particularly sensitive to legislative, regulatory, economic, environmental and competition changes in those locations. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these locations could have a disproportionate effect on our overall business results. If our facilities in these locations are adversely affected by changes in regulatory and economic conditions, our business, financial condition or results of operations could be adversely affected.
In addition, some of our facilities are located in hurricane-prone areas. In 2017 and at other times in the past, hurricanes have had a disruptive effect on the operations of facilities and the patient populations in hurricane-prone areas. Our business activities could be significantly disrupted by a particularly active hurricane season or even a single storm, and our property insurance may not be adequate to cover losses from such storms or other natural disasters.
We are required to treat patients with emergency medical conditions regardless of ability to pay.
In accordance with our internal policies and procedures, as well as EMTALA, we provide a medical screening examination to any individual who comes to one of our hospitals seeking medical treatment (whether or not such individual is eligible for insurance benefits and regardless of ability to pay) to determine if such individual has an emergency medical condition. If it is determined that such person has an emergency medical condition, we provide such further medical examination and treatment as is required to stabilize the patient’s medical condition, within the facility’s capability, or arrange for the transfer of the individual to another medical facility in accordance with applicable law and the treating hospital’s written procedures. Our hospitals may face substantial civil penalties if we fail to provide appropriate screening and stabilizing treatment or fail to facilitate other appropriate transfers as required by EMTALA.
An increase in uninsured or underinsured patients or the deteriorationWe are subject to taxation in the collectability ofU.S., Puerto Rico and various state jurisdictions. Any adverse development in the accountstax laws of such patients could harmjurisdictions or any disagreement with our results of operations.
Collection of receivables from third-party payors and patients is critical to our operating performance. Our primary collection risks relate to uninsured patients and the portion of the bill that is the patient’s responsibility, which primarily includesco-payments and deductibles. We estimate our provisions for doubtful accounts based on general factors such as payor source, the aging of the receivables and historical collection experience. At December 31, 2017, our allowance for doubtful accounts represented approximately 12% of our accounts receivable balance as of such date. We routinely review accounts receivable balances in conjunction with these factors and other economic conditions that might ultimately affect the collectability of the patient accounts and make adjustments to our allowances as warranted. Significant changes in business office operations, payor mix, economic conditions or trends in federal and state governmental health coverage (including the repeal, replacement or modification of PPACA) could affect our collection of accounts receivable, cash flow and results of operations. If we experience unexpected increases in the growth of uninsured and underinsured patients or in bad debt expenses, our results of operations will be harmed.
A cyber security incident could cause a violation of HIPAA and other privacy laws and regulations or result in a loss of confidential data.
A cyber-attack that bypasses our information technology (“IT”) security systems causing an IT security breach, loss of PHI or other data subject to privacy laws, loss of proprietary business information, or a material disruption of our IT business systems,tax positions could have a material adverse impacteffect on our business, financial condition or results of operations. In addition, our future resultseffective tax rate could change materially as a result of operations, as well as our reputation, could be adversely impacted by theft, destruction, loss, or misappropriation of PHI, other confidential data or proprietary business information.changes in tax laws.
FailureWe are subject to maintain effective internal control over financial reportingtaxation in, accordance with Section 404and to the tax laws and regulations of, the Sarbanes-Oxley ActU.S., Puerto Rico and various state jurisdictions as a result of 2002 (the “Sarbanes-Oxley Act”),our operations and our corporate and financing structure. Adverse developments in these tax laws or regulations, or any change in position regarding the application, administration or interpretation thereof, in any applicable jurisdiction, could have a material adverse effect on our business.
We are required to maintain internal control overbusiness, financial reporting under Section 404condition or results of operations. In addition, the Sarbanes-Oxley Act. If we are unable to maintain adequate internal control over financial reporting, wetax authorities in any applicable jurisdiction may be unable to report our financial information on a timely basis, may suffer adverse regulatory consequencesdisagree with the tax treatment or violationscharacterization of NASDAQ listing rules and may breach the covenants under our financing arrangements. There could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliabilityany of our financial statements. If we or our independent registered public accounting firm identify any material weakness in our internal control over financial reporting in the future (including any material weakness in the controls of businesses we have acquired), their correction could require additional remedial measurestransactions, which, could be costly, time-consuming andif successfully challenged by such tax authorities, could have a material adverse effect on our business.business, financial condition or results of operations. Certain changes in the mix of our earnings between jurisdictions and assumptions used in the calculation of income taxes, among other factors, could have a material adverse effect on our overall effective tax rate.
We are responsible forGeneral Risk Factors
Provisions of our charter documents or Delaware law could delay or prevent an underfunded pension liability relatedacquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for stockholders to change management.
Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition of Partnershipsor other change in Care. In addition, wecontrol that stockholders may be requiredconsider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. This is because these provisions may prevent or frustrate attempts by stockholders to increase fundingreplace or remove our management. These provisions include:
• | a classified board of directors; |
• | a prohibition on stockholder action through written consent; |
• | a requirement that special meetings of stockholders be called only upon a resolution approved by a majority of our directors then in office; |
• | advance notice requirements for stockholder proposals and nominations; and |
• | the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. |
Section 203 of the pension plans and/Delaware General Corporation Law (the “DGCL”) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns or within the last three years has owned 15% of voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Although we have elected not to be subject to Section 203 of the DGCL, our amended and restated certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that Waud Capital Partners, L.L.C. (“WCP”), its affiliates and any investment fund managed by WCP will be deemed to have been approved by our board of directors, and thereby not subject to the restrictions set forth in our amended and restated certificate of incorporation that have the same effect as Section 203 of the DGCL. Accordingly, the
32
provision in our amended and restated certificate of incorporation that adopts a modified version of Section 203 of the DGCL may discourage, delay or prevent a change in control of us.
As a result of these provisions in our charter documents and Delaware law, the price investors may be willing to pay in the future for shares of our common stock may be limited.
Fluctuations in our operating results, quarter to quarter earnings and other factors, including factors outside our control, may result in significant decreases in the price of our common stock.
The stock markets experience volatility, in some cases unrelated to operating performance. These broad market fluctuations may adversely affect the trading price of our common stock and, as a result, there may be significant volatility in the market price of our common stock. If we are unable to operate our facilities as profitably as we have in the past or as our investors expect us to in the future, the market price of our common stock will likely decline when it becomes apparent that the market expectations may not be realized. In addition to our operating results, many economic and other factors outside of our control could have an adverse effect on the useprice of excess cash.
Partnershipsour common stock and increase fluctuations in Care isour quarterly earnings. These factors include certain of the sponsorrisks discussed herein, outcomes of political elections, demographic changes, operating results of other healthcare companies, changes in our financial estimates or recommendations of securities analysts, speculation in the press or investment community, the possible effects of war, terrorist and other hostilities, adverse weather conditions, climate change, the impact of a defined benefit pension plan (the Partnershipspandemic, epidemic, or outbreak of an infectious disease, managed care contract negotiations and terminations, changes in Care Limited Pension and Life Assurance Plan) that covers approximately 180 membersgeneral conditions in the U.K., most of whom are inactive and retired former employees. As of May 1, 2005, this plan was closed to new participants but then-current participants continue to accrue benefits, and effective May 2015, active participants no longer accrued benefits. As of December 31, 2017,economy or the net deficit recognized under U.S. GAAP in respect of this plan was £6.5 million.
Future sales of common stock by our existing stockholders may cause our stock price to fall.
The market price of our common stock could decline as a result of sales by us or our existing stockholders, particularly our largest stockholders, our directors and executive officers, in the market, or the perception that these sales could occur. These sales might also make it more difficult for us to sell equity securities at a time and price that we deem appropriate. Certain current and former members of our management and stockholders have demand and piggyback registration rights with respect to shares of our common stock beneficially owned by them. The presence of additional shares of our common stock trading in the public market, as a result of the exercise of such registration rights, may have an adverse effect on the market price of our securities.
If securities or industry analysts do not publish research or reports about our business, if they were to change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us. If one or more of these analysts cease coverage of us or fail to publish regular reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet their expectations, our stock price could decline.
We incur substantial costs as a result of being a public company.
As a public company, we incur significant legal, accounting, insurance and other expenses, including costs associated with public company reporting requirements. We incur costs associated with complying with the requirements of the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), and related rules implemented by the SEC and NASDAQ. Enacted in July 2010, the Dodd-Frank Act contains significant corporate governance and executive compensation-related provisions, some of which the SEC has implemented by adopting additional rules and regulations in areas such as executive compensation. The expenses incurred by public companies generally for reporting and corporate governance purposes have been increasing. Management expects these laws and regulations to increase our legal and financial compliance costs and to make some activities more time-consuming and costly, although management is currently unable to estimate these costs with any degree of certainty. These laws and regulations could make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.
Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for stockholders to change management.
Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. This is because these provisions may prevent or frustrate attempts by stockholders to replace or remove our management. These provisions include:
Section 203 of the Delaware General Corporation Law (“DGCL”) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person that together with its affiliates owns or within the last three years has owned 15% of voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Although we have elected not to be subject to Section 203 of the DGCL, our amended and restated certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that Waud Capital Partners, L.L.C. (“WCP”), its affiliates and any investment fund managed by WCP and any persons to whom WCP sells at least five percent (5%) of our outstanding voting stock will be deemed to have been approved by our board of directors, and thereby not subject to the restrictions set forth in our amended and restated certificate of incorporation that have the same effect as Section 203 of the DGCL. Accordingly, the provision in our amended and restated certificate of incorporation that adopts a modified version of Section 203 of the DGCL may discourage, delay or prevent a change in control of us.
As a result of these provisions in our charter documents and Delaware law, the price investors may be willing to pay in the future for shares of our common stock may be limited.
We do not anticipate paying any cash dividends in the foreseeable future.
We intend to retain our future earnings, if any, for use in our business or for other corporate purposes and do not anticipate that cash dividends with respect to common stock will be paid in the foreseeable future. Any decision as to the future payment of dividends will depend on our results of operations, financial position and such other factors as our board of directors, in its discretion, deems relevant. In addition, the terms of our debt substantially limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain for the foreseeable future.
Item 1B. Unresolved Staff Comments.
None.
33
Item 2. Properties.
The following table lists, by state or country, the number of behavioral healthcare facilities directly or indirectly owned and operated by us as ofat December 31, 2017:2022:
State | Facilities | Operated Beds |
| Facilities |
|
| Operated Beds |
| ||||||||
Alaska | 1 | — |
|
| 1 |
|
|
| — |
| ||||||
Arizona | 3 | 425 |
|
| 4 |
|
|
| 481 |
| ||||||
Arkansas | 7 | 713 |
|
| 6 |
|
|
| 785 |
| ||||||
California | 22 | 462 |
|
| 25 |
|
|
| 496 |
| ||||||
Delaware | 2 | 93 |
|
| 3 |
|
|
| 130 |
| ||||||
Florida | 6 | 482 |
|
| 12 |
|
|
| 481 |
| ||||||
Georgia | 5 | 332 |
|
| 9 |
|
|
| 390 |
| ||||||
Illinois | 1 | 164 |
|
| 2 |
|
|
| 252 |
| ||||||
Indiana | 8 | 303 |
|
| 10 |
|
|
| 337 |
| ||||||
Iowa | 1 | — |
|
| 2 |
|
|
| — |
| ||||||
Kansas | 1 | — |
|
| 1 |
|
|
| — |
| ||||||
Kentucky |
|
| 1 |
|
|
| — |
| ||||||||
Louisiana | 6 | 372 |
|
| 6 |
|
|
| 467 |
| ||||||
Maine | 4 | — |
|
| 5 |
|
|
| — |
| ||||||
Maryland | 3 | — |
|
| 3 |
|
|
| — |
| ||||||
Massachusetts | 13 | 120 |
|
| 14 |
|
|
| 263 |
| ||||||
Michigan | 6 | 343 |
|
| 4 |
|
|
| 346 |
| ||||||
Mississippi | 3 | 412 |
|
| 3 |
|
|
| 496 |
| ||||||
Missouri | 2 | 313 |
|
| 6 |
|
|
| 580 |
| ||||||
Montana | 1 | 108 | ||||||||||||||
Nevada | 4 | 144 |
|
| 3 |
|
|
| 134 |
| ||||||
New Hampshire | 2 | — |
|
| 2 |
|
|
| — |
| ||||||
New Jersey | 1 | — |
|
| 1 |
|
|
| — |
| ||||||
New Mexico | 2 | 207 |
|
| 1 |
|
|
| 46 |
| ||||||
North Carolina | 11 | 477 |
|
| 10 |
|
|
| 503 |
| ||||||
Ohio | 2 | 146 |
|
| 6 |
|
|
| 290 |
| ||||||
Oklahoma | 1 | 108 |
|
| 4 |
|
|
| 108 |
| ||||||
Oregon | 6 | — |
|
| 7 |
|
|
| — |
| ||||||
Pennsylvania | 31 | 1,413 |
|
| 29 |
|
|
| 1,729 |
| ||||||
Rhode Island | 2 | — |
|
| 2 |
|
|
| — |
| ||||||
South Carolina | 1 | 42 |
|
| 1 |
|
|
| 63 |
| ||||||
South Dakota | 1 | 126 |
|
| 1 |
|
|
| 126 |
| ||||||
Tennessee | 6 | 533 |
|
| 14 |
|
|
| 985 |
| ||||||
Texas | 4 | 397 |
|
| 5 |
|
|
| 567 |
| ||||||
Utah | 6 | 147 |
|
| 6 |
|
|
| 147 |
| ||||||
Vermont | 1 | — |
|
| 1 |
|
|
| — |
| ||||||
Virginia | 6 | 215 |
|
| 9 |
|
|
| 442 |
| ||||||
Washington | 6 | 135 |
|
| 9 |
|
|
| 137 |
| ||||||
West Virginia | 7 | — |
|
| 7 |
|
|
| — |
| ||||||
Wisconsin | 13 | 35 |
|
| 14 |
|
|
| 35 |
| ||||||
Puerto Rico |
|
| 1 |
|
|
| 172 |
| ||||||||
|
| 250 |
|
|
| 10,988 |
| |||||||||
International | ||||||||||||||||
Puerto Rico | 1 | 172 | ||||||||||||||
United Kingdom | 373 | 8,865 | ||||||||||||||
|
| |||||||||||||||
582 | 17,804 | |||||||||||||||
|
|
See “Business—“Item 1. Business— U.S. Operations” and “Business— U.K. Operations— Description of U.K. Facilities” for a summary description of our U.S. and U.K.the facilities that we own and lease. WeIn addition, we currently lease approximately 61,000 square feet of office space at 6100 Tower Circle, Franklin, Tennessee, for our corporate headquarters. Our headquarters and facilities are generally well maintained and in good operating condition.
34
We are, from timeInformation with respect to time, subject to various claimsthis item may be found in Note 20—Commitments and legal actions that ariseContingencies in the ordinary courseaccompanying notes to our consolidated financial statements beginning on Page F-1 of our business, including claims for damages for personal injuries, medical malpractice, breach of contract, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be coveredthis Annual Report on Form 10-K, which information is incorporated herein by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Under the federal False Claims Act, private parties have the right to bringqui tam,or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. In the opinion of management, we are not currently a party to any proceeding that would have a material adverse effect on our business, financial condition or results of operations.reference.
Item 4. Mine Safety Disclosures
Not applicable.
35
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Price Range of Common Stock
Our common stock is listed for trading on The NASDAQ Global Select Market under the symbol “ACHC.” The following table sets forth the high and low sales prices per share of our common stock as reported on The NASDAQ Global Select Market for the two most recent fiscal years:
High | Low | |||||||
Year ended December 31, 2016: | ||||||||
First Quarter | $ | 65.89 | $ | 49.77 | ||||
Second Quarter | $ | 65.00 | $ | 50.30 | ||||
Third Quarter | $ | 57.29 | $ | 46.99 | ||||
Fourth Quarter | $ | 50.18 | $ | 32.54 | ||||
Year ended December 31, 2017: | ||||||||
First Quarter | $ | 47.39 | $ | 32.69 | ||||
Second Quarter | $ | 49.99 | $ | 40.37 | ||||
Third Quarter | $ | 54.34 | $ | 44.26 | ||||
Fourth Quarter | $ | 48.35 | $ | 26.92 |
Stockholders
As of February 27, 2018,28, 2023, there were approximately 495541 holders of record of our common stock.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
During the three months ended December 31, 2017,2022, the Company withheld shares of Company common stock to satisfy employee minimum statutory tax withholding obligations payable upon the vesting of restricted stock, as follows:
Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs |
| Total Number of Shares Purchased |
|
| Average Price Paid per Share |
|
| Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |
|
| Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs |
| ||||||||||||||||
October 1 – October 31 | 590 | $ | 33.25 | — | — |
|
| 2,502 |
|
| $ | 82.34 |
|
|
| — |
|
|
| — |
| |||||||||||
November 1 – November 30 | 4,670 | $ | 29.42 | — | — |
|
| 1,151 |
|
| $ | 79.40 |
|
|
| — |
|
|
| — |
| |||||||||||
December 1 – December 31 | 893 | 31.83 | — | — |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
| ||||||||||||
| ||||||||||||||||||||||||||||||||
Total | 6,153 |
|
| 3,653 |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
|
Dividends
We have never declared or paid dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore we do not anticipate paying any cash dividends in the foreseeable future. Additionally, because we are a holding company, our ability to pay dividends on our common stock is limited by restrictions on the ability of our subsidiaries to pay dividends or make distributions to us, including restrictions under the terms of the agreements governing our indebtedness. Any future determination to pay dividends will be at the discretion of our board of directors, subject to compliance with covenants in current and future agreements governing our indebtedness (including our Amended and Restated SeniorNew Credit Facility and the indenture governing our Senior Notes), and will depend upon our results of operations, financial condition, capital requirements and other factors that our board of directors deems relevant.
Item 6. Selected Financial Data.[Reserved]
The selected financial data presented below for the years ended December 31, 2017, 2016 and 2015, and as36
Year Ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||||||
Income Statement Data: | ||||||||||||||||||||
Revenue before provision for doubtful accounts | $ | 2,877,234 | $ | 2,852,823 | $ | 1,829,619 | $ | 1,030,784 | $ | 735,109 | ||||||||||
Provision for doubtful accounts | (40,918 | ) | (41,909 | ) | (35,127 | ) | (26,183 | ) | (21,701 | ) | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Revenue | 2,836,316 | 2,810,914 | 1,794,492 | 1,004,601 | 713,408 | |||||||||||||||
Salaries, wages and benefits(1) | 1,536,160 | 1,541,854 | 973,732 | 575,412 | 407,962 | |||||||||||||||
Professional fees | 196,223 | 185,486 | 116,463 | 52,482 | 37,171 | |||||||||||||||
Supplies | 114,439 | 117,425 | 80,663 | 48,422 | 37,569 | |||||||||||||||
Rents and leases | 76,775 | 73,348 | 32,528 | 12,201 | 10,049 | |||||||||||||||
Other operating expenses | 331,827 | 312,556 | 206,746 | 110,654 | 80,572 | |||||||||||||||
Depreciation and amortization | 143,010 | 135,103 | 63,550 | 32,667 | 17,090 | |||||||||||||||
Interest expense, net | 176,007 | 181,325 | 106,742 | 48,221 | 37,250 | |||||||||||||||
Debt extinguishment costs | 810 | 4,253 | 10,818 | — | 9,350 | |||||||||||||||
Loss on divestiture | — | 178,809 | — | — | — | |||||||||||||||
(Gain) loss on foreign currency derivatives | — | (523 | ) | 1,926 | (15,262 | ) | — | |||||||||||||
Transaction-related expenses | 24,267 | 48,323 | 36,571 | 13,650 | 7,150 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Income from continuing operations, before income taxes | 236,798 | 32,955 | 164,753 | 126,154 | 69,245 | |||||||||||||||
Provision for income taxes | 37,209 | 28,779 | 53,388 | 42,922 | 25,975 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Income from continuing operations | 199,589 | 4,176 | 111,365 | 83,232 | 43,270 | |||||||||||||||
Income (loss) from discontinued operations, net of income taxes | — | — | 111 | (192 | ) | (691 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Net income | 199,589 | 4,176 | 111,476 | 83,040 | 42,579 | |||||||||||||||
Net loss attributable to noncontrolling interests | 246 | 1,967 | 1,078 | — | — | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Net income attributable to Acadia Healthcare Company, Inc. | $ | 199,835 | $ | 6,143 | $ | 112,554 | $ | 83,040 | $ | 42,579 | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Income from continuing operations per share basic | $ | 2.30 | $ | 0.07 | $ | 1.65 | $ | 1.51 | $ | 0.87 | ||||||||||
Income from continuing operations per share diluted | $ | 2.30 | $ | 0.07 | $ | 1.64 | $ | 1.50 | $ | 0.86 | ||||||||||
Balance Sheet Data (as of end of period): | ||||||||||||||||||||
Cash and cash equivalents | $ | 67,290 | $ | 57,063 | $ | 11,215 | $ | 94,040 | $ | 4,569 | ||||||||||
Total assets | 6,424,502 | 6,024,726 | 4,279,208 | 2,206,955 | 1,213,623 | |||||||||||||||
Total debt | 3,239,888 | 3,287,809 | 2,240,744 | 1,079,635 | 606,100 | |||||||||||||||
Total equity | 2,572,871 | 2,167,724 | 1,683,028 | 880,965 | 480,710 |
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations with our audited consolidated financial statements and notes thereto included elsewhere in this Annual Report onForm 10-K.
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form10-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements that address future results or occurrences. In some cases you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “would,” “should,” “could” or the negative thereof. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contained are forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors, many of which are outside of our control, which could cause our actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to:to, the following:
• | the impact of competition for staffing, labor shortages and higher turnover rates on our labor costs and profitability; |
• | the impact of increases in inflation and rising interest rates; |
• | compliance with laws and government regulations; |
• | our indebtedness, our ability to meet our debt obligations, and our ability to incur substantially more debt; |
• | the impact of payments received from the government and third-party payors on our revenue and results of operations; |
• | the impact of volatility in the global capital and credit markets, as well as significant developments in macroeconomic and political conditions that are out of our control; |
• | the impact of general economic and employment conditions, including increased construction and other costs due to inflation, on our business and future results of operations; |
• | difficulties in successfully integrating the operations of acquired facilities or realizing the potential benefits and synergies of our acquisitions and joint ventures; |
• | our ability to recruit and retain quality psychiatrists and other physicians, nurses, counselors and other medical support personnel; |
• | the occurrence of patient incidents, which could result in negative media coverage, adversely affect the price of our securities and result in incremental regulatory burdens and governmental investigations; |
• | the impact of claims brought against us or our facilities including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employee related claims; |
• | the impact of governmental investigations, regulatory actions and whistleblower lawsuits; |
• | any failure to comply with the terms of the Company’s corporate integrity agreement with the OIG; |
• | the impact of healthcare reform in the U.S.; |
• | our acquisition, joint venture and wholly-owned de novo strategies, which expose us to a variety of operational and financial risks, as well as legal and regulatory risks; |
• | the impact of state efforts to regulate the construction or expansion of healthcare facilities on our ability to operate and expand our operations; |
• | our ability to implement our business strategies; |
• | the impact of disruptions on our inpatient and outpatient volumes caused by pandemics, epidemics or outbreaks of infectious diseases, such as the COVID-19 pandemic; |
37
• | our dependence on key management personnel, key executives and local facility management personnel; |
• | our restrictive covenants, which may restrict our business and financing activities; |
• | the impact of adverse weather conditions and climate change, including the effects of hurricanes, wildfires and other natural disasters, and any resulting outmigration; |
• | the risk of a cyber-security incident and any resulting adverse impact on our operations or violation of laws and regulations regarding information privacy; |
• | our future cash flow and earnings; |
• | the impact of our highly competitive industry on patient volumes; |
• | our ability to cultivate and maintain relationships with referral sources; |
• | the impact of the trend for insurance companies and managed care organizations to enter into sole source contracts on our ability to obtain patients; |
• | the impact of value-based purchasing programs on our revenue; |
• | our potential inability to extend leases at expiration; |
• | the impact of controls designed to reduce inpatient services on our revenue; |
• | the impact of different interpretations of accounting principles on our results of operations or financial condition; |
• | the impact of environmental, health and safety laws and regulations, especially in locations where we have concentrated operations; |
• | the impact of laws and regulations relating to privacy and security of patient health information and standards for electronic transactions; |
• | the impact of a change in the mix of our earnings, adverse changes in our effective tax rate and adverse developments in tax laws generally; |
• | changes in interpretations, assumptions and expectations regarding recent tax legislation, including provisions of the CARES Act and additional guidance that may be issued by federal and state taxing authorities; |
• | failure to maintain effective internal control over financial reporting; |
• | the impact of fluctuations in our operating results, quarter to quarter earnings and other factors on the price of our securities; and |
• | those risks and uncertainties described from time to time in our filings with the SEC. |
Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date of this Annual Report on Form10-K. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.
Overview
Our business strategy is to acquire and develop behavioral healthcare facilities and improve our operating results within our facilities and our other behavioral healthcare operations. We strive to improve the operating results of our facilities by providing high-quality services, expanding referral networks and marketing initiatives while meeting the increased demand for behavioral healthcare services through expansion of our current locations as well as developing new services within existing locations. At December 31, 2017,2022, we operated 582250 behavioral healthcare facilities with approximately 17,80011,000 beds in 39 states the U.K. and Puerto Rico. During the year ended December 31, 2017,2022, we acquired one facility and added 750 new560 beds, (exclusiveconsisting of the acquisition), including 588290 added to existing facilities and 162270 added through the opening of one wholly-owned facility and two de novo facilities.joint venture facilities, and we opened seven CTCs. For the year ending December 31, 2018,2023, we expect to add more than 800 totalapproximately 300 beds exclusive of acquisitions.through additions to existing facilities, and we expect to open two wholly-owned facilities, two joint venture facilities and at least six CTCs.
We are the leading publicly traded pure-play provider of behavioral healthcare services with operations in the U.S. and the U.K. Management believes that we are positioned as a leading platform in a highly fragmented industry under the direction of an experienced management team that has significant industry expertise. Management expects to take advantage of several strategies that are more accessible as a result of
38
our increased size and geographic scale, including continuing a national marketing strategy to attract new patients and referral sources, increasing our volume ofout-of-state referrals, providing a broader range of services to new and existing patients and clients and selectively pursuing opportunities to expand our facility and bed count in the U.S. through acquisitions, wholly-owned de novo facilities, joint ventures and U.K.
On January 19, 2021, we completed the U.K. Sale pursuant to a Share Purchase Agreement in which we sold all of the securities of AHC-WW Jersey Limited, a private limited liability company incorporated in Jersey and a subsidiary of the Company, which constituted the entirety of our U.K. operations.The U.K. Sale resulted in approximately $1,525 million of gross proceeds before deducting the settlement of existing foreign currency hedging liabilities of $85 million based on the current GBP to USD exchange rate, cash retained by the buyer and transaction costs. We used the net proceeds of approximately $1,425 million (excluding cash retained by the buyer) along with cash from the balance sheet to reduce debt by $1,640 million during the first quarter of 2021. As a result of the U.K. Sale, we reported, for all periods presented, results of operations and cash flows of the U.K. operations as discontinued operations in the accompanying financial statements.
Acquisitions
2017 Acquisition
On November 13, 2017,7, 2022, we completed the acquisition of Aspire, an education facility with 36 bedsacquired four CTCs located in Scotland,Georgia from Brand New Start.
On December 31, 2021, we acquired the equity of CenterPointe for cash consideration of approximately $21.3$140 million.
2016 U.S. Acquisitions
On June 1, 2016, we completed The acquisition was funded through a combination of cash on hand and a $70.0 million draw on the Revolving Facility. At the time of the acquisition, of Pocono Mountain, anCenterPointe operated four acute inpatient psychiatric facilityhospitals with 108306 beds locatedand ten outpatient locations primarily in Henryville, Pennsylvania, for cash consideration of approximately $25.4 million.Missouri.
On May 1, 2016, we completed the acquisition of TrustPoint, an inpatient psychiatric facility with 100 beds located in Murfreesboro, Tennessee, for cash consideration of approximately $62.7 million.
On April 1, 2016, we completed the acquisition of Serenity Knolls, an inpatient psychiatric facility with 30 beds located in Forest Knolls, California, for cash consideration of approximately $10.0 million.
Priory
On February 16, 2016, we completed the acquisition of Priory for a total purchase price of approximately $2.2 billion, including cash consideration of approximately $1.9 billion and the issuance of 4,033,561 shares of our common stock to shareholders of Priory. Priory was the leading independent provider of behavioral healthcare services in the U.K. operating 324 facilities with approximately 7,100 beds at the acquisition date.
The CMA in the U.K. reviewed our acquisition of Priory. On July 14, 2016, the CMA announced that our acquisition of Priory was referred for a phase 2 investigation unless we offered acceptable undertakings to address the CMA’s competition concerns relating to the provision of behavioral healthcare services in certain markets. On July 28, 2016, the CMA announced that we had offered undertakings to address the CMA’s concerns and that, in lieu of a phase 2 investigation, the CMA would consider our undertakings.
On October 18, 2016, we signed a definitive agreement with BC Partners for the sale of 21 existing U.K. behavioral health facilities and one de novo behavioral health facility with an aggregate of approximately 1,000 beds. On November 10, 2016, the CMA accepted our undertakings to sell the U.K. Disposal Group to BC Partners and confirmed that the divestiture satisfied the CMA’s concerns about the impact of our acquisition of Priory on competition for the provision of behavioral healthcare services in certain markets in the U.K. As a result of the CMA’s acceptance of our undertakings, our acquisition of Priory was not referred for a phase 2 investigation. On November 30, 2016, we completed the sale of the U.K. Disposal Group to BC Partners for £320 million cash.
Revenue
Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and Local Authorities in England, Scotland and Wales); and (v) individual patients and clients. Revenue is recorded in the period in which services are provided at established billing rates less contractual adjustments based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.
Results of Operations
The following table illustrates our consolidated results of operations from continuing operations for the respective periods shown (dollars in thousands):
| Year Ended December 31, |
| ||||||||||||||||||||||||||||||||||||||||||||||
Year Ended December 31, |
| 2022 |
|
| 2021 |
|
| 2020 |
| |||||||||||||||||||||||||||||||||||||||
2017 | 2016 | 2015 | ||||||||||||||||||||||||||||||||||||||||||||||
Amount | % | Amount | % | Amount | % | |||||||||||||||||||||||||||||||||||||||||||
Revenue before provision for doubtful accounts | $ | 2,877,234 | $ | 2,852,823 | $ | 1,829,619 | ||||||||||||||||||||||||||||||||||||||||||
Provision for doubtful accounts | (40,918 | ) | (41,909 | ) | (35,127 | ) | ||||||||||||||||||||||||||||||||||||||||||
|
|
|
| Amount |
|
| % |
|
| Amount |
|
| % |
|
| Amount |
|
| % |
| ||||||||||||||||||||||||||||
Revenue | 2,836,316 | 100.0 | % | 2,810,914 | 100.0 | % | 1,794,492 | 100.0 | % |
|
| 2,610,399 |
|
|
| 100.0 | % |
|
| 2,314,394 |
|
|
| 100.0 | % |
|
| 2,089,929 |
|
|
| 100.0 | % | |||||||||||||||
Salaries, wages and benefits | 1,536,160 | 54.2 | % | 1,541,854 | 54.9 | % | 973,732 | 54.3 | % |
|
| 1,393,434 |
|
|
| 53.4 | % |
|
| 1,243,804 |
|
|
| 53.7 | % |
|
| 1,154,522 |
|
|
| 55.2 | % | |||||||||||||||
Professional fees | 196,223 | 6.9 | % | 185,486 | 6.6 | % | 116,463 | 6.5 | % |
|
| 158,013 |
|
|
| 6.1 | % |
|
| 136,739 |
|
|
| 5.9 | % |
|
| 120,489 |
|
|
| 5.8 | % | |||||||||||||||
Supplies | 114,439 | 4.0 | % | 117,425 | 4.2 | % | 80,663 | 4.5 | % |
|
| 100,200 |
|
|
| 3.8 | % |
|
| 90,702 |
|
|
| 3.9 | % |
|
| 87,241 |
|
|
| 4.2 | % | |||||||||||||||
Rents and leases | 76,775 | 2.7 | % | 73,348 | 2.6 | % | 32,528 | 1.8 | % |
|
| 45,462 |
|
|
| 1.7 | % |
|
| 38,519 |
|
|
| 1.7 | % |
|
| 37,362 |
|
|
| 1.8 | % | |||||||||||||||
Other operating expenses | 331,827 | 11.7 | % | 312,556 | 11.1 | % | 206,746 | 11.5 | % |
|
| 349,277 |
|
|
| 13.4 | % |
|
| 301,339 |
|
|
| 13.0 | % |
|
| 262,272 |
|
|
| 12.5 | % | |||||||||||||||
Income from provider relief fund |
|
| (21,451 | ) |
|
| (0.8 | )% |
|
| (17,900 | ) |
|
| (0.8 | )% |
|
| (32,819 | ) |
|
| (1.6 | )% | ||||||||||||||||||||||||
Depreciation and amortization | 143,010 | 5.0 | % | 135,103 | 4.8 | % | 63,550 | 3.5 | % |
|
| 117,769 |
|
|
| 4.5 | % |
|
| 106,717 |
|
|
| 4.6 | % |
|
| 95,256 |
|
|
| 4.6 | % | |||||||||||||||
Interest expense, net | 176,007 | 6.2 | % | 181,325 | 6.4 | % | 106,742 | 6.0 | % |
|
| 69,760 |
|
|
| 2.7 | % |
|
| 76,993 |
|
|
| 3.3 | % |
|
| 158,105 |
|
|
| 7.6 | % | |||||||||||||||
Debt extinguishment costs | 810 | 0.0 | % | 4,253 | 0.1 | % | 10,818 | 0.6 | % |
|
| — |
|
|
| 0.0 | % |
|
| 24,650 |
|
|
| 1.1 | % |
|
| 7,233 |
|
|
| 0.3 | % | |||||||||||||||
Loss on divestiture | — | — | % | 178,809 | 6.4 | % | — | — | % | |||||||||||||||||||||||||||||||||||||||
(Gain) loss on foreign currency derivatives | — | — | % | (523 | ) | — | % | 1,926 | 0.1 | % | ||||||||||||||||||||||||||||||||||||||
Transaction related expenses | 24,267 | 0.9 | % | 48,323 | 1.7 | % | 36,571 | 2.0 | % | |||||||||||||||||||||||||||||||||||||||
Loss on impairment |
|
| — |
|
|
| 0.0 | % |
|
| 24,293 |
|
|
| 1.0 | % |
|
| 4,751 |
|
|
| 0.2 | % | ||||||||||||||||||||||||
Transaction-related expenses |
|
| 23,792 |
|
|
| 0.9 | % |
|
| 12,778 |
|
|
| 0.6 | % |
|
| 11,720 |
|
|
| 0.6 | % | ||||||||||||||||||||||||
|
|
|
|
|
|
|
| 2,236,256 |
|
|
| 85.7 | % |
|
| 2,038,634 |
|
|
| 88.0 | % |
|
| 1,906,132 |
|
|
| 91.2 | % | |||||||||||||||||||
2,599,518 | 91.6 | % | 2,777,959 | 98.8 | % | 1,629,739 | 90.8 | % | ||||||||||||||||||||||||||||||||||||||||
Income from continuing operations, before income taxes | 236,798 | 8.4 | % | 32,955 | 1.2 | % | 164,753 | 9.2 | % | |||||||||||||||||||||||||||||||||||||||
Income from continuing operations before income taxes |
|
| 374,143 |
|
|
| 14.3 | % |
|
| 275,760 |
|
|
| 12.0 | % |
|
| 183,797 |
|
|
| 8.8 | % | ||||||||||||||||||||||||
Provision for income taxes | 37,209 | 1.3 | % | 28,779 | 1.0 | % | 53,388 | 3.0 | % |
|
| 94,110 |
|
|
| 3.6 | % |
|
| 67,557 |
|
|
| 2.9 | % |
|
| 40,606 |
|
|
| 1.9 | % | |||||||||||||||
|
|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||
Income from continuing operations | $ | 199,589 | 7.1 | % | $ | 4,176 | 0.2 | % | $ | 111,365 | 6.2 | % |
|
| 280,033 |
|
|
| 10.7 | % |
|
| 208,203 |
|
|
| 8.9 | % |
|
| 143,191 |
|
|
| 6.8 | % | ||||||||||||
|
|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||
Loss from discontinued operations, net of taxes |
|
| — |
|
|
| 0.0 | % |
|
| (12,641 | ) |
|
| (0.5 | )% |
|
| (812,390 | ) |
|
| (38.9 | )% | ||||||||||||||||||||||||
Net income (loss) |
|
| 280,033 |
|
|
| 10.7 | % |
|
| 195,562 |
|
|
| 8.4 | % |
|
| (669,199 | ) |
|
| (32.0 | )% | ||||||||||||||||||||||||
Net income attributable to noncontrolling interests |
|
| (6,894 | ) |
|
| (0.3 | )% |
|
| (4,927 | ) |
|
| (0.2 | )% |
|
| (2,933 | ) |
|
| (0.1 | )% | ||||||||||||||||||||||||
Net income (loss) attributable to Acadia Healthcare Company, Inc. |
|
| 273,139 |
|
|
| 10.4 | % |
|
| 190,635 |
|
|
| 8.2 | % |
|
| (672,132 | ) |
|
| (32.2 | )% |
We are encouraged by the favorable trends in our business and believe we are well positioned to capitalize on the expected growth in demand for behavioral health services. As with many other healthcare providers and other industries across the country, we are currently dealing with a tight labor market. While we experienced higher wage inflation in 2022 compared to previous years, we believe the diversity of our markets and service lines and our proactive focus helps us manage through this environment. We remain focused on ensuring that we have the level of staff to meet the demand in our markets across our 39 states and Puerto Rico.
39
The following table sets forth percent changes in same facility operating data for our continuing operations for the years ended December 31, 2022 and 2021 compared to the previous years:
|
| Year Ended December 31, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
U.S. Same Facility Results (a) |
|
|
|
|
|
|
|
|
Revenue growth |
| 9.2% |
|
| 10.9% |
| ||
Patient days growth |
| 2.5% |
|
| 4.3% |
| ||
Admissions growth |
| (1.0)% |
|
| 3.5% |
| ||
Average length of stay change (b) |
| 3.6% |
|
| 0.8% |
| ||
Revenue per patient day growth |
| 6.5% |
|
| 6.3% |
| ||
Adjusted EBITDA margin change (c) |
| 70 bps |
|
| 150 bps |
| ||
Adjusted EBITDA margin excluding income from provider relief fund (d) |
| 60 bps |
|
| 220 bps |
|
(a) | Results for the periods presented include facilities we have operated more than one year and exclude certain closed services. |
(b) | Average length of stay is defined as patient days divided by admissions. |
(c) | Adjusted EBITDA is defined as income before provision for income taxes, equity-based compensation expense, debt extinguishment costs, loss on impairment, transaction-related expenses, interest expense and depreciation and amortization. Management uses Adjusted EBITDA as an analytical indicator to measure performance and to develop strategic objectives and operating plans. Adjusted EBITDA is commonly used as an analytical indicator within the healthcare industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. |
(d) | For the years ended December 31, 2022, 2021 and 2020, excludes income from provider relief fund of $21.5 million, $17.9 million and $32.8 million, respectively. |
Year Ended December 31, 2017 Compared2022 compared to the Year Ended December 31, 20162021
Revenue.Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $24.4$296.0 million, or 0.9%12.8%, to $2.9 billion$2,610.4 million for the year ended December 31, 20172022 from $2.9 billion$2,314.4 million for the year ended December 31, 2016. The increase related primarily to2021. Same facility revenue generated during the year ended December 31, 2017 from the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory, offset by the reduction in revenue before provision for doubtful accounts related to the U.K. Divestiture of $154.7 million and the decline in the exchange rate between USD and GBP of $45.5 million. Same-facility revenue before provision for doubtful accounts increased by $138.2$210.9 million, or 5.5%9.2%, for the year ended December 31, 20172022 compared to the year ended December 31, 2016,2021, resulting from same-facilitysame facility growth in patient days of 3.6%2.5%, an increase in same facility revenue per day of 6.5% and an increase in same-facility revenue per daythe average length of 1.9%stay of 3.6%. Consistent with the same-facilitysame facility patient day growth in 2016,2021, the growth in same-facilitysame facility patient days for the year ended December 31, 20172022 compared to the year ended December 31, 20162021 resulted from the addition of beds to our existing facilities and ongoing demand for our services.
Provision for doubtful accounts. The provision for doubtful accounts was $40.9 million for the year ended December 31, 2017, or 1.4% of revenue before provision for doubtful accounts, compared to $41.9 million for the year ended December 31, 2016, or 1.5% of revenue before provision for doubtful accounts.
Salaries, wages and benefits. Salaries, wages and benefits (“SWB”) expense was $1.5 billion$1,393.4 million for the year ended December 31, 20172022 compared to $1.5 billion$1,243.8 million for the year ended December 31, 2016, a decrease2021, an increase of $5.7$149.6 million. SWB expense included $23.5$29.6 million and $28.3$37.5 million of equity-based compensation expense for the years ended December 31, 20172022 and 2016,2021, respectively. Excluding equity-based compensation expense, SWB expense was $1.5 billion,$1,363.8 million, or 53.3%52.2% of revenue, for the year ended December 31, 2017,2022, compared to $1.5 billion,$1,206.3 million, or 53.8%52.1% of revenue, for the year ended December 31, 2016. The slight decrease in SWB expense, excluding equity-based compensation expense, was primarily attributable to the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP offset by SWB expense incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory. Same-facility2021. Same facility SWB expense was $1.3 billion for the year ended December 31, 2017, or 50.9% of revenue compared to $1.3 billion for the year ended December 31, 2016, or 51.0% of revenue.
Professional fees. Professional fees were $196.2$1,208.4 million for the year ended December 31, 2017,2022, or 6.9%48.3% of revenue, compared to $185.5$1,112.4 million for the year ended December 31, 2016,2021, or 6.6%48.5% of revenue. The $10.7 million increase was primarily attributable professional fees incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory, and higher contract labor costs in our U.K. Facilities offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facility professional
Professional fees. Professional fees were $160.1$158.0 million for the year ended December 31, 2017,2022, or 6.2%6.1% of revenue, compared to $145.0$136.7 million for the year ended December 31, 2016,2021, or 5.9% of revenue.
Supplies.Supplies expense was $114.4 Same facility professional fees were $132.6 million for the year ended December 31, 2017,2022, or 4.0%5.3% of revenue, compared to $117.4$124.1 million, for the year ended December 31, 2016,2021, or 4.2%5.4% of revenue. The $3.0 million decrease was primarily attributable to the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP offset by supplies expense incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory. Same-facility supplies
Supplies. Supplies expense was $103.5 million for the year ended December 31, 2017, or 4.0% of revenue, compared to $100.2 million for the year ended December 31, 2016,2022, or 4.1%3.8% of revenue.
Rents and leases. Rents and leases were $76.8revenue, compared to $90.7 million for the year ended December 31, 2017,2021, or 2.7%3.9% of revenue, compared to $73.3revenue. Same facility supplies expense was $94.7 million for the year ended December 31, 2016,2022, or 2.6%3.8% of revenue. The $3.4 million increase was primarily attributablerevenue, compared to rents and leases incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory slightly offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facility rents and leases were $58.0$89.8 million for the year ended December 31, 2017,2021, or 2.2%3.9% of revenue, compared to $57.5revenue.
40
Rents and leases. Rents and leases were $45.5 million for the year ended December 31, 2016,2022, or 2.3%1.7% of revenue, compared to $38.5 million for the year ended December 31, 2021, or 1.7% of revenue. Same facility rents and leases were $37.0 million for the year ended December 31, 2022, or 1.5% of revenue, compared to $35.0 million for the year ended December 31, 2021, or 1.5% of revenue.
Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $331.8$349.3 million for the year ended December 31, 2017,2022, or 11.7%13.4% of revenue, compared to $312.6$301.3 million for the year ended December 31, 2016,2021, or 11.1%13.0% of revenue. The $19.2 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2016 Acquisitions, particularly the acquisition of Priory slightly offset by the reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP. Same-facilitySame facility other operating expenses were $297.8$314.9 million for the year ended December 31, 2017,2022, or 11.4%12.6% of revenue, compared to $273.3$290.0 million for the year ended December 31, 2016,2021, or 11.1%12.6% of revenue.
Income from provider relief fund. For the year ended December 31, 2022, we recorded $21.5 million of income from provider relief fund related to PHSSE Fund and ARP funds received in 2021 and 2022. For the year ended December 31, 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received in 2021 and 2020.
Depreciation and amortization. Depreciation and amortization expense was $143.0$117.8 million for the year ended December 31, 2017,2022, or 5.0%4.5% of revenue, compared to $135.1$106.7 million for the year ended December 31, 2016,2021, or 4.8%4.6% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2016 and 2017 and real estate acquired as part of the 2016 Acquisitions, particularly the acquisition of Priory, offset by reduction in expense related to the U.K. Divestiture and the decline in the exchange rate between USD and GBP.
Interest expense. Interest expense was $176.0$69.8 million for the year ended December 31, 20162022 compared to $181.3$77.0 million for the year ended December 31, 2016.2021. The decrease in interest expense was primarily athe result of the lower interest rates in connection with amendmentsa significant reduction to the Amended and Restated Senior Credit Facility and theoutstanding debt paydown on November 30, 2016 using proceeds from the U.K. Divestiture. Interest expense was also impacted by higher interest rates applicable to our variable rate debt, borrowings under the Amended and Restated Senior Credit Facility and the issuance of the 6.500% Senior Notes on February 16, 2016.
Debt extinguishment costs. Debt extinguishment costs for the year ended December 30, 2017 represent $0.5 million of charges and $0.3 ofnon-cash charges recorded in connection with the Third Repricing Amendment to the Amended and Restated Senior Credit Facility.U.K. Sale.
Debt extinguishment costs. Debt extinguishment costs for the year ended December 31, 2016 represent $1.1 million of cash charges and $3.2 million ofnon-cash charges recorded in connection with the TrancheB-2 Repricing Amendment and the Refinancing Amendment.
Loss on divestiture.As part of our divestitures in the U.K. and U.S., we recorded $178.8 million of loss on divestiture for the year ended December 31, 2016, which included an allocation of goodwill to the disposal groups of approximately $106.9 million, loss on the sale of properties of approximately $45.0 million, transaction-related expenses of approximately $26.8 million andwrite-off of intangible assets of approximately $0.1 million.
Gain on foreign currency derivatives. We entered into foreign currency forward contracts during the year ended December 31, 2016 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and the U.K. under our cash management and foreign currency risk management programs. Exchange rate changes between the contract date and the settlement date resulted in a gain on foreign currency derivatives of $0.5were $24.7 million for the year ended December 31, 2016.
Transaction-related expenses. Transaction-related expenses wereLoss on impairment. Loss on impairment was $24.3 million for the year ended December 31, 2017 compared to $48.32021. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.
Transaction-related expenses. Transaction-related expenses were $23.8 million for the year ended December 31, 2016.2022 compared to $12.8 million for the year ended December 31, 2021. Transaction-related expenses represent legal, accounting, termination, restructuring, management transition, acquisition and other similar costs incurred in the respective periods, primarily related to the 2016 Acquisitions, the U.K. Divestiture and the related integration efforts, as summarized below (in thousands):
Year Ended December 31, | ||||||||
2017 | 2016 | |||||||
Severance and contract termination costs | $ | 14,709 | $ | 12,415 | ||||
Legal, accounting and other fees | 9,558 | 21,058 | ||||||
Advisory and financing commitment fees | — | 14,850 | ||||||
|
|
|
| |||||
$ | 24,267 | $ | 48,323 | |||||
|
|
|
|
|
| Year Ended December 31, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Management transition costs |
| $ | 11,575 |
|
| $ | — |
|
Termination and restructuring costs |
|
| 6,476 |
|
|
| 5,343 |
|
Legal, accounting and other acquisition-related costs |
|
| 5,741 |
|
|
| 7,435 |
|
|
| $ | 23,792 |
|
| $ | 12,778 |
|
Discontinued Operations. Loss from discontinued operations for the year ended December 31, 2021 was $12.6 million.
Provision for income taxes. For the year ended December 31, 2017,2022, the provision for income taxes was $37.2$94.1 million, reflecting an effective tax rate of 15.7%25.2%, compared to $28.8$67.6 million, reflecting an effective tax rate of 87.3%24.5%, for 2016. The decrease in the effective tax rate for the year ended December 31, 2017 was primarily attributable to the Company’s estimate of theone-time tax benefit on revaluation of deferred tax items pursuant to the enactment of the Tax Act as well as changes in the foreign exchange rate between USD and GBP in 2017 and the disparity between the accounting treatment and the tax treatment of the U.K. Divestiture on November 30, 2016. The Company will continue to analyze the effects of the Tax Act on its financial statements and operations. Additional impacts from the enactment of the Tax Act will be recorded as they are identified during the measurement period as provided for in Staff Accounting Bulletin 118 (“SAB 118”).2021.
Year Ended December 31, 2016 Compared2021 compared to the Year Ended December 31, 20152020
Revenue.Revenue before provision for doubtful accounts. Revenue before provision for doubtful accounts increased $1.0 billion,$224.5 million, or 55.9%10.7%, to $2.9 billion for the year ended December 31, 2016 from $1.8 billion for the year ended December 31, 2015. The increase related primarily to revenue generated during the year ended December 31, 2016 from the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. The decrease in the GBP to USD exchange rate had an unfavorable impact on revenue before provision for doubtful accounts of $35.6$2,314.4 million for the year ended December 31, 2016. Same-facility2021 from $2,089.9 million for the year ended December 31, 2020. Same facility revenue before provision for doubtful accounts increased by $127.2$225.6 million, or 7.5%10.9%, for the year ended December 31, 20162021 compared to the year ended December 31, 2015, primarily2020, resulting from same-facilitysame facility growth in patient days of 7.2%4.3% and an increase in same facility revenue per day of 6.3%. Consistent with the same-facilitysame facility patient day growth in 2015,2020, the growth in same-facilitysame
41
facility patient days for the year ended December 31, 20162021 compared to the year ended December 31, 20152020 resulted from the addition of beds to our existing facilities and ongoing demand for our services.
Provision for doubtful accounts. The provision for doubtful accountsSalaries, wages and benefits. SWB expense was $41.9$1,243.8 million for the year ended December 31, 2016, or 1.5 % of revenue before provision for doubtful accounts,2021 compared to $35.1$1,154.5 million for the year ended December 31, 2015, or 1.9% of revenue before provision for doubtful accounts. The same-facility provision for doubtful accounts was $35.3 million for the year ended December 31, 2016, or 1.9% of revenue before provision for doubtful accounts, compared to $31.5 million for the year ended December 31, 2015, or 1.9% of revenue before provision for doubtful accounts.
Salaries, wages and benefits. Salaries, wages and benefits expense was $1.5 billion for the year ended December 31, 2016 compared to $973.7 million for the year ended December 31, 2015,2020, an increase of $568.1$89.3 million. SWB expense included $28.3$37.5 million and $20.5$22.5 million of equity-based compensation expense for the years ended December 31, 20162021 and 2015,2020, respectively. Excluding equity-based compensation expense, SWB expense was $1.5 billion,$1,206.3 million, or 53.8%52.1% of revenue, for the year ended December 31, 2016,2021, compared to $953.3$1,132.0 million, or 53.1%54.2% of revenue, for the year ended December 31, 2015. The $560.3 million increase in SWB expense, excluding equity-based compensation expense, was primarily attributable to SWB expense incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facility2020. Same facility SWB expense was $895.0$1,115.0 million for the year ended December 31, 2016,2021, or 50.2%48.5% of revenue, compared to $830.8$1,049.0 million for the year ended December 31, 2015,2020, or 50.0%50.6% of revenue.
Professional fees. Professional fees were $185.5$136.7 million for the year ended December 31, 2016,2021, or 6.6 %5.9% of revenue, compared to $116.5$120.5 million for the year ended December 31, 2015,2020, or 6.5%5.8% of revenue. The $69.0 million increase was primarily attributable to professional fees incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility professional fees were $92.8$123.3 million for the year ended December 31, 2016,2021, or 5.2%5.4% of revenue, compared to $95.0$108.0 million, for the year ended December 31, 2015,2020, or 5.7%5.2% of revenue.
Supplies.Supplies expense was $117.4$90.7 million for the year ended December 31, 2016,2021, or 4.2%3.9% of revenue, compared to $80.7$87.2 million for the year ended December 31, 2015,2020, or 4.5%4.2% of revenue. The $36.7 million increase was primarily attributable to supplies expense incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility supplies expense was $79.5$89.7 million for the year ended December 31, 2016,2021, or 4.5%3.9% of revenue, compared to $74.2$86.6 million for the year ended December 31, 2015,2020, or 4.5%4.2% of revenue.
Rents and leases. Rents and leases were $73.3$38.5 million for the year ended December 31, 2016,2021, or 2.6%1.7% of revenue, compared to $32.5$37.4 million for the year ended December 31, 2015,2020, or 1.8% of revenue. The $40.8 million increase was primarily attributable to rents and leases incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility rents and leases were $31.5$34.5 million for the year ended December 31, 2016,2021, or 1.8%1.5% of revenue, compared to $29.6$34.1 million for the year ended December 31, 2015,2020, or 1.8%1.6% of revenue.
Other operating expenses. Other operating expenses consisted primarily of purchased services, utilities, insurance, travel and repairs and maintenance expenses. Other operating expenses were $312.6$301.3 million for the year ended December 31, 2016,2021, or 11.1%13.0% of revenue, compared to $206.7$262.3 million for the year ended December 31, 2015,2020, or 11.5%12.5% of revenue. The $105.9 million increase was primarily attributable to other operating expenses incurred by the facilities acquired in our 2015 and 2016 Acquisitions, particularly the acquisition of Priory. Same-facilitySame facility other operating expenses were $202.6$286.2 million for the year ended December 31, 2016,2021, or 11.4%12.4% of revenue, compared to $188.4$256.0 million for the year ended December 31, 2015,2020, or 11.3%12.3% of revenue.
Income from provider relief fund. For the year ended December 31, 2021, we recorded $17.9 million of income from provider relief fund related to PHSSE Fund funds received in 2021 and 2020. For the year ended December 31, 2020, we recorded $32.8 million of income from provider relief fund related to $34.9 million of PHSSE Fund funds received from April through December 2020. Our recognition of this income in the fourth quarter of 2020 was based on revised guidance in the CAA enacted in December 2020.
Depreciation and amortization. Depreciation and amortization expense was $135.1 million for the year ended December 31, 2016, or 4.8% of revenue, compared to $63.6 million for the year ended December 31, 2015, or 3.5% of revenue. The increase in depreciation and amortization was attributable to depreciation associated with capital expenditures during 2015 and 2016 and real estate acquired as part of the 2015 and 2016 Acquisitions, particularly the acquisition of Priory.
Interest expense. Interest expense was $181.3 million for the year ended December 31, 2016 compared to $106.7 million for the year ended December 31, 2015. The increase in interest expense was primarily a result2021, or 4.6% of borrowings under the Amended and Restated Senior Credit Facility, the issuance of the 5.625% Senior Notes on February 11, 2015 and September 21, 2015 and the issuance of the 6.500% Senior Notes on February 16, 2016.
Debt extinguishment costs. Debt extinguishment costs for the year ended December 31, 2016 represent $1.1 million of cash charges and $3.2 million ofnon-cash charges recorded in connection with the TrancheB-2 Repricing Amendment and the Refinancing Amendment. Debt extinguishment costs for the year ended December 31, 2015 represent $7.5 million of cash charges and $3.3 million ofnon-cash charges recorded in connection with the repayment of $97.5 million of 12.875% Senior Notes.
Loss on divestiture.As part of our divestitures in the U.K. and U.S., we recorded $178.8 million of loss on divestiture for the year ended December 31, 2016, which included an allocation of goodwillrevenue, compared to the disposal groups of approximately $106.9 million, loss on the sale of properties of approximately $45.0 million, transaction-related expenses of approximately $26.8 million andwrite-off of intangible assets of approximately $0.1 million.
(Gain) loss on foreign currency derivatives. We entered into foreign currency forward contracts during the years ended December 31, 2016 and 2015 in connection with (i) acquisitions in the U.K. and (ii) certain transfers of cash between the U.S. and the U.K. under our cash management and foreign currency risk management programs. Exchange rate changes between the contract date and the settlement date resulted in a gain on foreign currency derivatives of $0.5$95.3 million for the year ended December 31, 2016, compared to a loss2020, or 4.6% of $1.9revenue.
Interest expense. Interest expense was $77.0 million for the year ended December 31, 2015.
Transaction-related expenses. Transaction-related expenses were $48.32021 compared to $158.1 million for the year ended December 31, 2016 compared2020. The decrease in interest expense was primarily the result of a significant reduction to $36.6outstanding debt in connection with the U.K. Sale.
Debt extinguishment costs. Debt extinguishment costs were $24.7 million for the year ended December 31, 2015.2021 and represented $6.3 million of cash charges and $18.4 million of non-cash charges in connection with the redemption of the 5.625% Senior Notes and the 6.500% Senior Notes and the termination of the Prior Credit Facility. Debt extinguishment costs were $7.2 million for the year ended December 31, 2020 and represented $1.4 million of cash charges and $5.8 million of non-cash charges recorded in connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, the issuance of the 5.000% Senior Notes and the Fourth Repricing Facilities Amendment.
Loss on impairment. Loss on impairment was $24.3 million for the year ended December 31, 2021. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage. Loss on impairment of $4.8 million for the year end December
42
31, 2020 represents a non-cash long-lived asset impairment charge of $4.2 million and $0.6 million related to indefinite-lived asset impairment related to closed facilities in the U.S.
Transaction-related expenses. Transaction-related expenses were $12.8 million for the year ended December 31, 2021 compared to $11.7 million for the year ended December 31, 2020. Transaction-related expenses represent legal, accounting, termination, restructuring, strategic review and other similar costs incurred in the respective periods, primarily related to the 2015 and 2016 Acquisitions, as summarized below (in thousands):
Year Ended December 31, | ||||||||
2016 | 2015 | |||||||
Legal, accounting and other fees | $ | 21,058 | $ | 17,768 | ||||
Advisory and financing commitment fees | 14,850 | 10,337 | ||||||
Severance and contract termination costs | 12,415 | 8,466 | ||||||
|
|
|
| |||||
$ | 48,323 | $ | 36,571 | |||||
|
|
|
|
|
| Year Ended December 31, |
| |||||
|
| 2021 |
|
| 2020 |
| ||
Legal, accounting and other acquisition-related costs |
| $ | 7,435 |
|
| $ | 8,252 |
|
Termination and restructuring costs |
|
| 5,343 |
|
|
| 3,468 |
|
|
| $ | 12,778 |
|
| $ | 11,720 |
|
Discontinued Operations. Loss from discontinued operations for the year ended December 31, 2021 was $12.6 million compared to loss from discontinued operations of $812.4 million for the year ended December 31, 2020. The year ended December 31, 2020 included a loss on sale of $867.3 million related to the U.K. operations and a non-cash long-lived asset impairment charge of $20.2 million related to the decision to close certain U.K. elderly care facilities.
Provision for income taxes. For the year ended December 31, 2016,2021, the provision for income taxes was $28.8$67.6 million, reflecting an effective tax rate of 87.3%24.5%, compared to $53.4$40.6 million, reflecting an effective tax rate of 32.4%22.1%, for 2015.the year ended December 31, 2020. The changeincrease in the effective tax rate for the year ended December 31, 2016 is2021 was primarily attributable to the disparity between the accounting treatmentour recognition of a deferred tax liability as a result of a change in our previous permanent reinvestment assertion and thenon-recurring impacts of U.S. and U.K. tax treatment of the U.K. Divestiture on November 30, 2016.
Liquidity and Capital Resources
Cash provided by continuing operating activities for the year ended December 31, 20172022 was $401.3$380.6 million compared to $371.7$374.2 million for the year ended December 31, 2016. The2021. Operating cash flows for the year ended December 31, 2022 included net government relief funds paid of approximately $39.1 million, which consisted of $19.4 million of payroll tax deferral payments and repayment of $20.1 million of Medicare advance payments offset by net receipts of $0.4 million of provider relief fund payments. Operating cash flows were impacted by an increase in earnings, a reduction in cash provided by continuing operating activities was primarily attributable topaid for interest and an increase in tax payments during the year ended December 31, 2022. Operating cash provided by continuing operating activities from our 2016 Acquisitionsflows for the year ended December 31, 2021 included government relief funds paid of approximately $38.1 million, which consisted of $19.4 million of payroll tax deferral payments and repayment of $25.1 million of Medicare advance payments, offset by the U.K. Divestiture and the decline in the exchange rate between USD and GBP.net receipts of $6.4 million of provider relief fund payments. Days sales outstanding as ofat December 31, 20172022 was 3844 compared to 34 as of42 at December 31, 2016. As of December 31, 2017 and December 31, 2016, we had working capital of $94.2 million and $85.1 million, respectively.2021.
Cash used in continuing investing activities for the year ended December 31, 20172022 was $336.5$305.8 million compared to $660.4cash provided by continuing investing activities of $1,013.1 million for the year ended December 31, 2016.2021. Cash used in continuing investing activities for the year ended December 31, 20172022 primarily consisted of $274.2payments of $296.1 million of cash paid for capital expenditures, and $41.1$9.5 million of cash paid for real estate.acquisitions and $7.2 million of cash paid for other, offset by proceeds from the sale of property and equipment of $7.1 million. Cash paid for capital expenditures for the year ended December 31, 2017 consisted of $70.82022 was $296.1 million, consisting of routine or maintenance capital expenditures and $203.4of $60.5 million ofand expansion capital expenditures.expenditures of $235.6 million. We define expansion capital expenditures as those that increase the capacity of our facilities or otherwise enhance revenue. Routine or maintenance capital expenditures, including information technology capital expenditures, were approximately 2.5%2% of revenue for the year ended December 31, 2017.2022. Cash used inprovided by continuing investing activities for the year ended December 31, 20162021 primarily consisted of $683.5proceeds from the U.K. Sale of $1,511.0 million, proceeds from the sale of cash paid for acquisitions, $307.5property and equipment of $3.5 million offset by $244.8 million of cash paid for capital expenditures, and $40.8$139.0 million of cash paid for real estate acquisitions, partially offset by$84.8 million of settlement of foreign currency derivatives, $31.4 million of cash received on divestiturespaid for purchase of $373.3finance lease and $1.4 million of cash paid for other. Cash paid for capital expenditures for the year ended December 31, 2021 was $244.8 million, consisting of routine or maintenance capital expenditures of $41.8 million and expansion capital expenditures of $203.0 million.
Cash used in continuing financing activities for the year ended December 31, 20172022 was $60.1$110.9 million compared to cash provided by financing activities of $358.8$1,636.5 million for the year ended December 31, 2016.2021. Cash used in continuing financing activities for the year ended December 31, 20172022 primarily consisted of principal payments on revolving credit facility of $95.0 million, principal payments on long-term debt of $34.8$18.6 million, repaymentrepurchase of long-term debtshares for payroll tax witholdings, net of $22.5proceeds from stock option exercises of $6.2 million, acquisition of ownership interests from noncontrolling partners of $5.5 million and common stock withheld for minimum statutory taxesdistributions to noncontrolling partners in joint ventures of $3.5$1.0 million, offset by contributions from noncontrolling partners in joint ventures of $15.4 million and other of $0.1 million. Cash provided by
43
used in continuing financing activities for the year ended December 31, 20162021 primarily consisted of repayment of long-term debt borrowings of $1.5 billion, borrowings on our revolving credit facility of $179.0$2,227.9 million, and an issuance of common stock of $685.1 million, partially offset by repayment of assumed Priory debt of $1.4 billion, paymentprincipal payments on revolving credit facility of $337.0 million, repayment of long-term debt of $200.6$330.0 million, principal payments on long-term debt of $49.9$8.0 million, payment of debt issuance costs of $36.6$8.0 million, other of $6.9 million and commondistributions to noncontrolling partners in joint ventures of $1.6 million, offset by borrowing on long-term debt of $425.0 million, borrowings on revolving credit facility of $500.0 million, repurchase of shares for payroll tax withholdings, net of proceeds from stock withheld for minimum statutory taxesoption exercises of $8.8$16.3 million and contributions from noncontrolling partners in joint ventures of $4.5 million.
We had total available cash and cash equivalents of $67.3$97.6 million, $57.1$133.8 million and $11.2$378.7 million as ofat December 31, 2017, 20162022, 2021 and 2015,2020, respectively, of which approximately $20.4$3.7 million, $41.4$20.1 million and $9.2$17.0 million was held by our foreign subsidiaries, respectively. Our strategic plan does not require the repatriation of foreign cash in order to fund our operations in the U.S., and it is our current intention to permanently reinvest our foreign cash and cash equivalents outside of the U.S. On December 22, 2017, the Tax Act was enacted into law. The Tax Act provides for significant changes to the U.S. tax code that impact businesses. Effective January 1, 2018, the Tax Act reduces the U.S. federal tax rate for corporations from 35% to 21% for U.S. taxable income and requires aone-time remeasurement of deferred taxes to reflect their value at a lower tax rate of 21%. While we are still evaluating the full impact of the legislation, we expect the substantial reduction of the federal corporate tax rate to benefit our financial results and cash flow in future periods. We believe the change will not result in a U.S. tax liability on those foreign earnings which have not previously been repatriated to the U.S., with future foreign earnings potentially not subject to U.S. income taxes when repatriated.
Amended and Restated SeniorNew Credit Facility
We entered into a credit agreement establishing the New Credit Facility on March 17, 2021. The New Credit Facility provides for a $600.0 million Revolving Facility and a $425.0 million Term Loan Facility with each maturing on March 17, 2026 unless extended in accordance with the terms of the New Credit Facility. The Revolving Facility further provides for (i) up to $20.0 million to be utilized for the issuance of letters of credit and (ii) the availability of a swingline facility under which we may borrow up to $20.0 million.
As a part of the closing of the New Credit Facility on March 17, 2021, we (i) refinanced and terminated the Prior Credit Facility and (ii) financed the redemption of all of the outstanding 5.625% Senior Notes.
We had $521.6 million of availability under the Revolving Facility and had standby letters of credit outstanding of $3.4 million related to security for the payment of claims required by our workers’ compensation insurance program at December 31, 2022.
During the third quarter of 2021, we repaid $60.0 million of the initial $160.0 million balance outstanding on the Revolving Facility. During the fourth quarter of 2021, we had a draw of $70.0 million on the Revolving Facility related to the CenterPointe acquisition. During the year ended December 31, 2022, we repaid $95.0 million of the balance outstanding on the Revolving Facility.
The New Credit Facility requires quarterly principal repayments for the Term Loan Facility of $5.3 million for March 31, 2023 to March 31, 2024, $8.0 million for June 30, 2024 to March 31, 2025, $10.6 million for June 30, 2025 to December 31, 2025, with the remaining principal balance of the Term Loan Facility due on the maturity date of March 17, 2026.
We have the ability to increase the amount of the Senior Facilities, which may take the form of increases to the Revolving Facility or the Term Loan Facility or the issuance of one or more incremental term loan facilities (collectively, the “Incremental Facilities”), upon obtaining additional commitments from new or existing lenders and the satisfaction of customary conditions precedent for such Incremental Facilities. Such Incremental Facilities may not exceed the sum of (i) the greater of $480.0 million and an amount equal to 100% of the Consolidated EBITDA (as defined in the New Credit Facility) of the Company and its Restricted Subsidiaries (as defined in the New Credit Facility) (as determined for the four fiscal quarter period most recently ended for which financial statements are available), and (ii) additional amounts so long as, after giving effect thereto, the Consolidated Senior Secured Net Leverage Ratio (as defined in the New Credit Facility) does not exceed 3.5 to 1.0.
Subject to certain exceptions, substantially all of our existing and subsequently acquired or organized direct or indirect wholly-owned U.S. subsidiaries are required to guarantee the repayment of our obligations under the New Credit Facility. Borrowings under the Senior Facilities bear interest at a floating rate, which will initially be, at our option, either (i) adjusted LIBOR plus 1.375% or (ii) an alternative base rate plus 0.375% (in each case, subject to adjustment based on the Company’s consolidated total net leverage ratio). An unused fee initially set at 0.20% per annum (subject to adjustment based on the Company’s consolidated total net leverage ratio) is payable quarterly in arrears based on the actual daily undrawn portion of the commitments in respect of the Revolving Facility.
The interest rates and the unused line fee on unused commitments related to the Senior Facilities are based upon the following pricing tiers:
Pricing Tier |
| Consolidated Leverage Ratio |
| Eurodollar Rate Loans |
|
| Base Rate Loans |
|
| Commitment Fee |
| |||
1 |
| ≥ 4.50:1.0 |
|
| 2.250 | % |
|
| 1.250 | % |
|
| 0.350 | % |
2 |
| <4.50:1.0 but ≥ 3.75:1.0 |
|
| 2.000 | % |
|
| 1.000 | % |
|
| 0.300 | % |
3 |
| <3.75:1.0 but ≥ 3.00:1.0 |
|
| 1.750 | % |
|
| 0.750 | % |
|
| 0.250 | % |
4 |
| <3.00:1.0 but ≥ 2.25:1.0 |
|
| 1.500 | % |
|
| 0.500 | % |
|
| 0.200 | % |
5 |
| <2.25:1.0 |
|
| 1.375 | % |
|
| 0.375 | % |
|
| 0.200 | % |
44
The New Credit Facility contains customary representations and affirmative and negative covenants, including limitations on the Company’s and its subsidiaries’ ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay junior indebtedness and enter into affiliate transactions, in each case, subject to customary exceptions. In addition, the New Credit Facility contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any consecutive four fiscal quarter period, a consolidated total net leverage ratio of not more than 5.0 to 1.0 and an interest coverage ratio of at least 3.0 to 1.0. The New Credit Facility also includes events of default customary for facilities of this type and upon the occurrence of such events of default, among other things, all outstanding loans under the Senior Facilities may be accelerated and/or the lenders’ commitments terminated. At December 31, 2022, the Company was in compliance with such covenants.
Prior Credit Facility
We entered into a credit agreement establishing a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, we entered into an amended and restated credit agreement establishing the Amended and RestatedPrior Credit AgreementFacility, which amended and restated the Senior Secured Credit Facility. We have amended the Amended and RestatedPrior Credit AgreementFacility from time to time as described in our prior filings with the SEC.
On February 6, 2015,April 21, 2020, we entered into the SeventhThirteenth Amendment to our Amended and Restatedthe Prior Credit Agreement.Facility. The SeventhThirteenth Amendment added Citibank, N.A. as an “L/C Issuer” underamended the Amended and Restated Credit AgreementConsolidated Leverage Ratio in orderthe prior covenant to permitincrease such leverage ratio for the rolloverrest of CRC’s existing letters of credit into the Amended and Restated Credit Agreement and increased both the Company’s Letter of Credit Sublimit and Swing Line Sublimit to $20.0 million.2020.
On February 11, 2015,November 13, 2020, we entered into the First IncrementalFourth Repricing Facilities Amendment to our Amended and Restatedthe Prior Credit Agreement.Facility. The First IncrementalFourth Repricing Facilities Amendment activated a new $500.0 million incremental TrancheB-1 Facility that was added toextended the Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-1 Facility were used to fund a portionmaturity date of each of the purchase price for our acquisitionprior revolving line of CRC.
On April 22, 2015, we entered into an Eighth Amendment to our Amendedcredit and Restated Credit Agreement. The Eighth Amendment changed the definition of “Change of Control” in part to remove a provision whose purpose was, when calculating whether a majority of incumbent directors have approved new directors, that any incumbent director that became a director as a result of a threatened or actual proxy contest was not counted in such calculation.
On January 25, 2016, we entered into the Ninth Amendment to our Amended and Restated Credit Agreement. The Ninth Amendment modified certain definitions and provides increased flexibility to us in terms of our financial covenants. Our baskets for permitted investments were also increased to provide increased flexibility for us to invest innon-wholly owned subsidiaries, joint ventures and foreign subsidiaries. As a result of the Ninth Amendment, we may invest innon-wholly owned subsidiaries and joint ventures up to 10.0% of our and our subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 12.5% of our and our subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. We may also invest in foreign subsidiaries that are not loan parties up to 10% of our and our subsidiaries’ total assets in any consecutive four fiscal quarter period, and up to 15% of our and our subsidiaries’ total assets during the term of the Amended and Restated Credit Agreement. The foregoing permitted investments are subject to an aggregate cap of 25% of our and our subsidiaries’ total assets in any fiscal year.
On February 16, 2016, we entered into the Second Incremental Facility Amendment to our Amended and Restated Credit Agreement. The Second Incremental Amendment activated a new $955.0 million incremental Term Loan B facility and added $135.0 million to the Term Loan A facility to our Amended and Restated Senior Secured Credit Facility, subject to limited conditionality provisions. Borrowings under the TrancheB-2 Facility were used to fund a portion of the purchase price for the acquisition of Priory and the fees and expenses for such acquisition and the related financing transactions. Borrowings under the TLA Facility were usedfrom November 30, 2021 to pay downNovember 30, 2022. The Fourth Repricing Facilities Amendment also (1) replaced the majorityrevolving line of our $300.0credit in an aggregate committed amount of $500.0 million revolving credit facility.
On May 26, 2016, we entered into a TrancheB-1 Repricing Amendmentwith an aggregate committed amount of approximately $459.0 million and (2) replaced the TLA Facility aggregate outstanding principal amount of approximately $352.4 million with an aggregate principal amount of approximately $318.9 million. The interest rate margin applicable to both facilities remained unchanged from the prior facilities, and the commitment fee applicable to the Amended and Restated Credit Agreement. The TrancheB-1 Repricing Amendment reducednew revolving line of credit also remained unchanged from the Applicable Rate with respect to the TrancheB-1 Facility from 3.5% to 3.0% in the caseprior revolving line of Eurodollar Rate loans and 2.5% to 2.0% in the case of Base Rate Loans.
On September 21, 2016, we entered into a TrancheB-2 Repricing Amendment to the Amended and Restated Credit Agreement. The TrancheB-2 Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-2 Facility from 3.75% to 3.00% in the case of Eurodollar Rate loans and 2.75% to 2.00% in the case of Base Rate Loans.credit. In connection with the TrancheB-2Fourth Repricing Facilities Amendment, we recorded a debt extinguishment charge of $3.4$1.0 million, including the write-off of discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of income.operations at December 31, 2020.
On November 22, 2016,January 5, 2021, we entered intomade a Tenth Amendmentvoluntary payment of $105.0 million on the Tranche B-4 Facility. On January 19, 2021, we used a portion of the net proceeds from the U.K. Sale to repay the Amended and Restated Credit Agreement. The Tenth Amendment, among other things, (i) amendedoutstanding balances of $311.7 million of the negative covenant regarding dispositions, (ii) modified the collateral package to release any real property with a fair market value of less than $5.0 million and (iii) changed certain investment, indebtedness and lien baskets.
On November 30, 2016, we entered into a Refinancing Facilities Amendment to the Amended and Restated Credit Agreement. The Refinancing Amendment increased our line of credit on our revolving credit facility to $500.0 million from $300.0 million and reduced our TLA Facility to $400.0and $767.9 million from $600.6 million. In addition,of the Refinancing Amendment extendedTranche B-4 Facility. As a part of the maturity date forclosing of the Refinancing Facilities to November 30,New Credit Facility on March 17, 2021, from February 13, 2019,we refinanced and lowered our effective interest rate on our line of credit on our revolving credit facility and TLAterminated the Prior Credit Facility by 50 basis points. In. At March 31, 2021, in connection with the Refinancing Amendment,termination of the Prior Credit Facility, we recorded a debt extinguishment charge of $0.8$10.9 million, including thewrite-off of discount and deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statements of income.
On May 10, 2017, we entered into the Third Repricing Amendment to the Amended and Restated Credit Agreement. The Third Repricing Amendment reduced the Applicable Rate with respect to the TrancheB-1 Facility and the TrancheB-2 Facility from 3.0% to 2.75% in the case of Eurodollar Rate loans and 2.0% to 1.75% in the case of Base Rate Loans. In connection with the Third Repricing Amendment, we recorded a debt extinguishment charge of $0.8 million, including the discount andwrite-off of deferred financing costs, which was recorded in debt extinguishment costs in the consolidated statementsstatement of operations.
We had $493.4 million of availability under the revolving line of credit and had standby letters of credit outstanding of $6.6 million related to security for the payment of claims required by our workers’ compensation insurance program as of December 31, 2017. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing. The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our TLA Facility of $5.0 million for March 31, 2018 to December 31, 2019, $7.5 million for March 31, 2020 to December 31, 2020, and $10.0 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. We are required to repay the TrancheB-1 Facility in equal quarterly installments of $1.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-1 Facility due on February 11, 2022. We are required to repay the TrancheB-2 Facility in equal quarterly installments of approximately $2.4 million on the last business day of each March, June, September and December, with the outstanding principal balance of the TrancheB-2 Facility due on February 16, 2023. On December 29, 2017, the Company made an additional payment of $22.5 million, including $7.7 million on the TrancheB-1 Facility and $14.8 million on the TrancheB-2 Facility.
Borrowings under the Amended and Restated Credit Agreement are guaranteed by each of our wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of our and such subsidiaries’ assets. Borrowings with respect to the TLA Facility and our revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $40.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.75% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.75% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at December 31, 2017. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As of December 31, 2017, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.75%. In addition, we are required to pay a commitment fee on undrawn amounts under our revolving credit facility.
The interest rates and the unused line fee on unused commitments related to the Pro Rata Facilities are based upon the following pricing tiers:
Pricing Tier | Consolidated Leverage Ratio | Eurodollar Rate Loans | Base Rate Loans | Commitment Fee | ||||||||||
1 | < 3.50:1.0 | 1.75 | % | 0.75 | % | 0.20 | % | |||||||
2 | >3.50:1.0 but < 4.00:1.0 | 2.00 | % | 1.00 | % | 0.25 | % | |||||||
3 | >4.00:1.0 but < 4.50:1.0 | 2.25 | % | 1.25 | % | 0.30 | % | |||||||
4 | >4.50:1.0 but < 5.25:1.0 | 2.50 | % | 1.50 | % | 0.35 | % | |||||||
5 | >5.25:1.0 | 2.75 | % | 1.75 | % | 0.40 | % |
Eurodollar Rate Loans with respect to the TrancheB-1 Facility bear interest at the TrancheB-1 Facility Applicable Rate (as defined below) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans bear interest at the TrancheB-1 Facility Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “TrancheB-1 Facility Applicable Rate” means, with respect to Eurodollar Rate Loans, 3.0%, and with respect to Base Rate Loans, 2.0%. The TrancheB-2 Facility bears interest as follows: Eurodollar Rate Loans bear interest at the Applicable Rate (as defined in the Amended and Restated Credit Agreement) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period) and Base Rate Loans bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Applicable Rate” means, with respect to Eurodollar Rate Loans, 3.0%, and with respect to Base Rate Loans, 2.0%.
The lenders who provided the TrancheB-1 Facility and TrancheB-2 Facility are not entitled to benefit from the Company’s maintenance of its financial covenants under the Amended and Restated Credit Agreement. Accordingly, if we fail to maintain its financial covenants, such failure shall not constitute an event of default under the Amended and Restated Credit Agreement with respect to the TrancheB-1 Facility or the TrancheB-2 Facility until and unless the Amended and Restated Senior Credit Facility is accelerated or the commitment of the lenders to make further loans is terminated.
The Amended and Restated Credit Agreement requires us and our subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and consolidated senior secured leverage ratio. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. We may be required to pay all of our indebtedness immediately if we default on any of the numerous financial or other restrictive covenants contained in any of our material debt agreements. Set forth below is a brief description of such covenants, all of which are subject to customary exceptions, materiality thresholds and qualifications:
|
| ||||
|
As of December 31, 2017, the Company was in compliance with all of the above covenants.
Senior Notes
6.125% Senior Notes Due 2021
On March 12, 2013, we issued $150.0 million of 6.125%5.500% Senior Notes due 2021.2028
On June 24, 2020, we issued $450.0 million of the 5.500% Senior Notes due 2028. The 6.125%5.500% Senior Notes mature on March 15, 2021July 1, 2028 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year.
5.125% Senior Notes due 2022
On July 1, 2014, we issued $300.0 million of 5.125% Senior Notes due 2022. The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125%5.500% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.year, commencing on January 1, 2021.
5.625%5.000% Senior Notes due 20232029
On February 11, 2015,October 14, 2020, we issued $375.0$475.0 million of 5.625% Senior Notes due 2023. On September 21, 2015, we issued $275.0 million of additional 5.625%the 5.000% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, we have outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625%5.000% Senior Notes mature on FebruaryApril 15, 20232029 and bear interest at a rate of 5.625%5.000% per annum, payable semi-annually in arrears on FebruaryApril 15 and AugustOctober 15 of each year.
6.500%year, commencing on April 15, 2021. We used the net proceeds of the 5.000% Senior Notes due 2024
On February 16, 2016, we issued $390.0to prepay approximately $453.3 million of 6.500%the outstanding borrowings on the Tranche B-3 Facility and used the remaining net proceeds for general corporate purposes and to pay related fees and expenses in connection with the offering. In connection with the 5.000% Senior Notes, due 2024. The 6.500% Senior Notes mature on March 1, 2024we recorded a debt extinguishment charge of $2.9 million, including the write-off of discount and bear interest at a ratedeferred financing costs of 6.500% per annum, payable semi-annuallythe Tranche B-3 Facility, which was recorded in arrears on March 1 and September 1debt extinguishment costs in the consolidated statement of eachoperations for the year beginning on September 1, 2016.ended December 31, 2020.
The indentures governing the Senior Notes contain covenants that, among other things, limit the Company’sour ability and the ability of itsour restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’sour assets; and (vii) create liens on assets.
45
The Senior Notes issued by the Companyus are guaranteed by each of the Company’sour subsidiaries that guarantee the Company’sguaranteed our obligations under the Amended and Restated SeniorNew Credit Facility. The guarantees are full and unconditional and joint and several.
The CompanyWe may redeem the Senior Notes at itsour option, in whole or part, at the dates and amounts set forth in the indentures.
9.0% and 9.5% Revenue Bonds5.625% Senior Notes due 2023
On NovemberFebruary 11, 2012,2015, we issued $375.0 million of the 5.625% Senior Notes. On September 21, 2015, we issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, we had outstanding an aggregate of $650.0 million of the 5.625% Senior Notes. The 5.625% Senior Notes were to mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On March 17, 2021, we redeemed the 5.625% Senior Notes.
6.500% Senior Notes due 2024
On February 16, 2016, we issued $390.0 million of the 6.500% Senior Notes. The 6.500% Senior Notes were to mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016. On March 1, 2021, we redeemed the 6.500% Senior Notes.
Redemption of 5.625% Senior Notes and 6.500% Senior Notes
On January 29, 2021, we issued conditional notices of full redemption providing for the redemption in full of $650 million of the 5.625% Senior Notes and $390 million of the 6.500% Senior Notes to the holders of such notes.
On March 1, 2021, we satisfied and discharged the indentures governing the 6.500% Senior Notes. In connection with the acquisitionredemption of the 6.500% Senior Notes, we recorded debt extinguishment costs of $10.5 million, including $6.3 million cash paid for breakage costs and the write-off of deferred financing costs of $4.2 million in the consolidated statement of operations.
On March 17, 2021, we satisfied and discharged the indentures governing the 5.625% Senior Notes. In connection with the redemption of the 5.625% Senior Notes, we recorded debt extinguishment costs of $3.3 million, including the write-off of deferred financing and premiums costs in the consolidated statement of operations.
6.125% Senior Notes due 2021
On March 12, 2013, we issued $150.0 million of the 6.125% Senior Notes. The Pavilion6.125% Senior Notes were to mature on March 15, 2021 and bear interest at HealthPark, LLC (“Park Royal”),a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. On June 24, 2020, we assumedredeemed the 6.125% Senior Notes.
5.125% Senior Notes due 2022
On July 1, 2014, we issued $300.0 million of the 5.125% Senior Notes. The 5.125% Senior Notes were to mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year. On June 24, 2020, we redeemed the 5.125% Senior Notes.
Redemption of 6.125% Senior Notes and 5.125% Senior Notes
On June 10, 2020, we issued conditional notices of full redemption providing for the redemption in full of the 6.125% Senior Notes and the 5.125% Senior Notes on the Redemption Date, in each case at the Redemption Price. On June 24, 2020, we satisfied and discharged the indentures governing the 6.125% Senior Notes and the 5.125% Senior Notes by irrevocably depositing with a trustee sufficient funds equal to the Redemption Price for the 6.125% Senior Notes and the 5.125% Senior Notes and otherwise complying with the terms in the indentures relating to the satisfaction and discharge of the 6.125% Senior Notes and the 5.125% Senior Notes. In connection with the redemption of the 6.125% Senior Notes and the 5.125% Senior Notes, we recorded a debt extinguishment charge of $3.3 million, including the write-off of the deferred financing and other costs in the consolidated statement of operations for the year ended December 31, 2020.
Other long-term debt
During the year ended December 31, 2021, we repaid other long-term debt of $23.0 million. The fair market value of the debt assumed was $25.6$3.3 million, and resultedwhich is reflected in a debt premium balance being recorded as of the acquisition date. The debt consisted of $7.5 million and $15.5 million of Lee County (Florida) Industrial Development Authority Healthcare Facilities Revenue Bonds, Series 2010 with stated interest rates of 9.0% and 9.5%, respectively. The 9.0% bondsfinancing activities in the amountconsolidated statement of $7.5 million have a maturity datecash flows.
46
Contractual Obligations
The following table presents a summary of contractual obligations (dollars in thousands):
Payments Due by Period | ||||||||||||||||||||
Less Than 1 Year | 1-3 Years | 3-5 Years | More Than 5 Years | Total | ||||||||||||||||
Long-term debt(1) | $ | 199,973 | $ | 405,354 | $ | 1,508,021 | $ | 2,006,944 | $ | 4,120,292 | ||||||||||
Operating leases | 69,613 | 124,712 | 107,691 | 835,369 | 1,137,385 | |||||||||||||||
Purchase and other obligations(2) | 4,307 | 7,404 | 33,899 | 27,085 | 72,695 | |||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total obligations and commitments | $ | 273,893 | $ | 537,470 | $ | 1,649,611 | $ | 2,869,398 | $ | 5,330,372 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
| Payments Due by Period |
| |||||||||||||||||
|
| Less Than 1 Year |
|
| 1-3 Years |
|
| 3-5 Years |
|
| More Than 5 Years |
|
| Total |
| |||||
Long-term debt (a) |
| $ | 97,302 |
|
| $ | 216,197 |
|
| $ | 481,468 |
|
| $ | 973,000 |
|
| $ | 1,767,967 |
|
Operating lease liabilities (b) |
|
| 32,818 |
|
|
| 54,714 |
|
|
| 31,631 |
|
|
| 62,653 |
|
|
| 181,816 |
|
Finance lease liabilities |
|
| 990 |
|
|
| 2,096 |
|
|
| 2,269 |
|
|
| 21,821 |
|
|
| 27,176 |
|
Total obligations and commitments |
| $ | 131,110 |
|
| $ | 273,007 |
|
| $ | 515,368 |
|
| $ | 1,057,474 |
|
| $ | 1,976,959 |
|
(a) | Amounts include required principal and interest payments. The projected interest payments reflect interest rates in place on our variable-rate debt |
(b) | Amounts |
Off-Balance Sheet Arrangements
As ofAt December 31, 2017,2022, we had standby letters of credit outstanding of $6.6$3.4 million related to security for the payment of claims as required by our workers’ compensation insurance program.
Market Risk
Interest Rate Risk
Our interest expense is sensitive to changes in market interest rates. Our long-term debt outstanding at December 31, 20172022 was composed of $1.5 billion$914.3 million of fixed-rate debt and $1.7 billion$450.2 million of variable-rate debt with interest based on LIBOR plus an applicable margin. A hypothetical 10% increase in interest rates (which would equate to a 0.42% higher rateBased on our variable rate debt) would decrease our net income and cash flows by $5.0 million on an annual basis based upon our borrowing level at December 31, 2017.2022, a hypothetical 1% increase in interest rates would decrease our pretax income on an annual basis by approximately $4.5 million.
Foreign Currency Risk
The functional currency forWe expect our U.K. facilities is the British pound or GBP. Our revenue and earnings are sensitivevariable-rate debt to changes in the GBP to USD exchange ratetransition from the translation of our earnings into USD at exchange rates that may fluctuate. Based upon the level of our U.K. operations relativeLIBOR plus an appliable margin to the CompanySecured Overnight Financing Rate (“SOFR”) during 2023. SOFR was chosen as the recommended risk-free reference rate by the Alternative Reference Rates Committee and is a whole, a hypothetical 10% change (which would equatebroad measure of the cost of borrowing cash overnight collateralized by U.S. Treasury securities. The Federal Reserve Bank of New York started to an increase or decreasepublish SOFR in the exchange rate of 0.13) would cause a change in our net income of $10.1 million for the year ended December 31, 2017.
In May 2016, we entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency exchange risk by effectively converting a portion of our fixed-rate USD denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate,GBP-denominated debt of £449.3 million. The cross currency swap agreements limit the impact of changes in the exchange rate on our cash flows and leverage. Following the Brexit vote, the GBP dropped to its lowest level against the USD in more than 30 years. If the exchange rate remains low, our results of operations will be negatively impacted in future periods.April 2018.
Critical Accounting Policies
Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses included in the financial statements. Estimates are based on historical experience and other available information, the results of which form the basis of such estimates. While management believes our estimation processes are reasonable, actual results could differ from our estimates. The following accounting policies are considered critical to the portrayal of our financial condition and operating performance and involve highly subjective and complex assumptions and assessments:
Revenue and Accounts Receivable
Our revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and adolescent residential treatment. We receive payments from the following sources for services rendered in our facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by CMS; (iv) public funded sources in the U.K. (including the NHS, CCGs and local authorities in England, Scotland and Wales); and (v)(iv) individual patients and clients. Revenue is recorded inWe determine the period in which services are provided attransaction price based on established billing rates lessreduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on amounts reimbursable by Medicare or Medicaid under provisions of cost or prospective reimbursement formulas or amounts due from other third-party payors at contractually determined rates.
The following table presents revenue by payor typecontractual agreements, discount policies and as a percentage of revenue before provision for doubtful accounts for the years ended December 31, 2017, 2016 and 2015 (in thousands):
Year Ended December 31, | ||||||||||||||||||||||||
2017 | 2016 | 2015 | ||||||||||||||||||||||
Amount | % | Amount | % | Amount | % | |||||||||||||||||||
Commercial | $ | 569,242 | 19.8 | % | $ | 534,468 | 18.7 | % | $ | 423,077 | 23.1 | % | ||||||||||||
Medicare | 281,270 | 9.8 | % | 266,868 | 9.4 | % | 214,125 | 11.7 | % | |||||||||||||||
Medicaid | 796,375 | 27.7 | % | 725,508 | 25.4 | % | 609,805 | 33.3 | % | |||||||||||||||
NHS | 937,595 | 32.6 | % | 1,021,888 | 35.8 | % | 356,965 | 19.5 | % | |||||||||||||||
Self-Pay | 249,978 | 8.7 | % | 268,160 | 9.4 | % | 174,850 | 9.6 | % | |||||||||||||||
Other | 42,774 | 1.4 | % | 35,931 | 1.3 | % | 50,797 | 2.8 | % | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Revenue before provision for doubtful accounts | 2,877,234 | 100.0 | % | 2,852,823 | 100.0 | % | 1,829,619 | 100.0 | % | |||||||||||||||
Provision for doubtful accounts | (40,918 | ) | (41,909 | ) | (35,127 | ) | ||||||||||||||||||
|
|
|
|
|
| |||||||||||||||||||
Revenue | $ | 2,836,316 | $ | 2,810,914 | $ | 1,794,492 | ||||||||||||||||||
|
|
|
|
|
|
The following tables present a summary of our aging of accounts receivable as of December 31, 2017 and 2016:
December 31, 2017
Current | 30-90 | 90-150 | >150 | Total | ||||||||||||||||
Commercial | 15.3 | % | 8.7 | % | 3.2 | % | 6.9 | % | 34.1 | % | ||||||||||
Medicare | 9.4 | % | 1.6 | % | 0.5 | % | 1.1 | % | 12.6 | % | ||||||||||
Medicaid | 19.8 | % | 6.4 | % | 2.5 | % | 5.2 | % | 33.9 | % | ||||||||||
NHS | 7.0 | % | 3.4 | % | 0.2 | % | 0.0 | % | 10.6 | % | ||||||||||
Self-Pay | 1.8 | % | 1.4 | % | 1.4 | % | 3.2 | % | 7.8 | % | ||||||||||
Other | 0.3 | % | 0.3 | % | 0.2 | % | 0.2 | % | 1.0 | % | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total | 53.6 | % | 21.8 | % | 8.0 | % | 16.6 | % | 100.0 | % |
December 31, 2016
Current | 30-90 | 90-150 | >150 | Total | ||||||||||||||||
Commercial | 15.8 | % | 8.5 | % | 3.0 | % | 5.3 | % | 32.6 | % | ||||||||||
Medicare | 12.0 | % | 1.6 | % | 0.8 | % | 1.2 | % | 15.6 | % | ||||||||||
Medicaid | 18.7 | % | 6.5 | % | 2.9 | % | 5.5 | % | 33.6 | % | ||||||||||
NHS | 5.1 | % | 3.4 | % | 0.6 | % | 0.4 | % | 9.5 | % | ||||||||||
Self-Pay | 1.8 | % | 1.5 | % | 1.5 | % | 3.3 | % | 8.1 | % | ||||||||||
Other | 0.1 | % | 0.1 | % | 0.1 | % | 0.3 | % | 0.6 | % | ||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total | 53.5 | % | 21.6 | % | 8.9 | % | 16.0 | % | 100.0 | % |
Medicaid accounts receivable as of December 31, 2017 and 2016 included approximately $0.9 million and $1.2 million, respectively, of accounts pending Medicaid approval.
Allowance for Contractual Discountshistorical experience. Implicit price concessions are based on historical collection experience.
We derive a significant portion of our revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided in ourthe Company’s inpatient facilities and cost settlement provisions. Management estimates the allowance for contractual discountstransaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from our estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management.
47
Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. In the opinion of management, adequate provision has been made for any adjustments and final settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on ourthe Company’s financial condition or results of operations. Our cost report receivablespayables were $9.0$13.7 million and $7.4$6.5 million atas of December 31, 20172022 and 2016,2021, respectively, and were included in other current assets inliabilities on the consolidated balance sheets. Management believes that these receivables are properly stated and are not likely to be settled for a significantly different amount.sheet. The net adjustments to estimated cost report settlements resulted in increasesan increase to revenue of $0.2$0.1 million $0.7for the year ended December 31, 2022, compared to decreases to revenue of $5.4 million and $1.9$1.3 million for the years ended December 31, 2017, 20162021 and 2015,2020, respectively.
Management believes that we are in substantial compliance with all applicable lawsThe following table presents revenue by payor type and regulationsas a percentage of revenue for continuing operations for the years ended December 31, 2022, 2021 and is not aware2020 (in thousands):
|
| Year Ended December 31, |
| |||||||||||||||||||||
|
| 2022 |
|
| 2021 |
|
| 2020 |
| |||||||||||||||
|
| Amount |
|
| % |
|
| Amount |
|
| % |
|
| Amount |
|
| % |
| ||||||
Commercial |
| $ | 788,895 |
|
|
| 30.2 | % |
| $ | 684,292 |
|
|
| 29.6 | % |
| $ | 596,698 |
|
|
| 28.5 | % |
Medicare |
|
| 394,227 |
|
|
| 15.1 | % |
|
| 364,598 |
|
|
| 15.8 | % |
|
| 330,070 |
|
|
| 15.8 | % |
Medicaid |
|
| 1,319,600 |
|
|
| 50.6 | % |
|
| 1,147,884 |
|
|
| 49.6 | % |
|
| 1,037,852 |
|
|
| 49.7 | % |
Self-Pay |
|
| 76,050 |
|
|
| 2.9 | % |
|
| 93,425 |
|
|
| 4.0 | % |
|
| 98,302 |
|
|
| 4.7 | % |
Other |
|
| 31,627 |
|
|
| 1.2 | % |
|
| 24,195 |
|
|
| 1.0 | % |
|
| 27,007 |
|
|
| 1.3 | % |
Revenue |
| $ | 2,610,399 |
|
|
| 100.0 | % |
| $ | 2,314,394 |
|
|
| 100.0 | % |
| $ | 2,089,929 |
|
|
| 100.0 | % |
The following tables present a summary of any material pending or threatened investigations involving allegations of wrongdoing. Compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties and exclusion from the Medicare and Medicaid programs.
Allowance for Doubtful Accounts
Our ability to collect outstanding patient receivables from third-party payors is critical to our operating performance and cash flows. The primary collection risk with regard to patient receivables relates to uninsured patient accounts or patient accounts for which primary insurance has paid, but the portion owed by the patient remains outstanding. We estimate uncollectible accounts and establish an allowance for doubtful accounts in order to adjust accounts receivable to estimated net realizable value. In evaluating the collectabilityaging of accounts receivable we consider a number of factors, including the age of the accounts, historical collection experience, current economic conditions,at December 31, 2022 and other relevant factors. Accounts receivable that2021:
December 31, 2022
|
| Current |
|
| 30-90 |
|
| 90-150 |
|
| >150 |
|
| Total |
| |||||
Commercial |
|
| 18.0 | % |
|
| 5.3 | % |
|
| 2.8 | % |
|
| 8.4 | % |
|
| 34.5 | % |
Medicare |
|
| 11.5 | % |
|
| 1.7 | % |
|
| 0.7 | % |
|
| 1.4 | % |
|
| 15.3 | % |
Medicaid |
|
| 31.7 | % |
|
| 4.5 | % |
|
| 2.6 | % |
|
| 4.7 | % |
|
| 43.5 | % |
Self-Pay |
|
| 1.2 | % |
|
| 1.4 | % |
|
| 1.2 | % |
|
| 2.6 | % |
|
| 6.4 | % |
Other |
|
| 0.2 | % |
|
| 0.0 | % |
|
| 0.0 | % |
|
| 0.1 | % |
|
| 0.3 | % |
Total |
|
| 62.6 | % |
|
| 12.9 | % |
|
| 7.3 | % |
|
| 17.2 | % |
|
| 100.0 | % |
December 31, 2021
|
| Current |
|
| 30-90 |
|
| 90-150 |
|
| >150 |
|
| Total |
| |||||
Commercial |
|
| 20.1 | % |
|
| 6.2 | % |
|
| 2.6 | % |
|
| 8.2 | % |
|
| 37.1 | % |
Medicare |
|
| 11.3 | % |
|
| 1.7 | % |
|
| 0.5 | % |
|
| 2.0 | % |
|
| 15.5 | % |
Medicaid |
|
| 28.6 | % |
|
| 3.5 | % |
|
| 2.0 | % |
|
| 5.6 | % |
|
| 39.7 | % |
Self-Pay |
|
| 1.3 | % |
|
| 1.4 | % |
|
| 1.4 | % |
|
| 3.0 | % |
|
| 7.1 | % |
Other |
|
| 0.1 | % |
|
| 0.1 | % |
|
| 0.2 | % |
|
| 0.2 | % |
|
| 0.6 | % |
Total |
|
| 61.4 | % |
|
| 12.9 | % |
|
| 6.7 | % |
|
| 19.0 | % |
|
| 100.0 | % |
Insurance
We are determined to be uncollectible based on our policies are written off to the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on our results of operations and cash flows.
Insurance
The Company is subject to medical malpractice and other lawsuits due to the nature of the services the Company provides.we provide. A portion of the Company’sour professional liability risk isrisks are insured through a wholly-owned insurance subsidiary. The Company’s wholly-owned insurance subsidiary insures the Companyproviding coverage for professional liability losses up to $78.0$10.0 million per claim through August 31, 2022 and $5.0 million and $10.0 million for certain other claims thereafter. We have obtained reinsurance coverage from a third party to cover claims in excess of those limits. The reinsurance policy has a coverage limit of $75.0 million or $70.0 million for certain other claims in the aggregate. TheOur reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance subsidiary has obtained reinsurance with unrelated commercial insurers for professional liability risks of $75.0 millionpolicies in excess of a retention level of $3.0 million.place. The reserve for professional and general liability risks was estimated based on historical claims, prior settlements and judgments, demographic factors, industry trends, severity factors, and other actuarial assumptions. The estimated accrual for professional and general liabilities could be significantly affected should current and future occurrences differ from historical claim trends and
48
expectations. While claims are monitored closely when estimating professional and general liability accruals, the complexity of the claims and wide range of potential outcomes often hampers timely adjustments to the assumptions used in these estimates. We recorded an unfavorable adjustment of $5.9 million to our estimated liability for self-insured professional and general liability claims during the year ended December 31, 2022, relating to the settlement or expected settlement of certain prior year claims relating primarily to the 2017 to 2018 period. The professional and general liability reserve was $55.0$103.6 million as ofat December 31, 2017,2022, of which $22.8$12.1 million was included in other accrued liabilities and $32.2$91.5 million was included in other long-term liabilities. The professional and general liability reserve was $52.3$87.8 million as ofat December 31, 2016,2021, of which $11.7$11.9 million was included in other accrued liabilities and $40.6$75.9 million was included in other long-term liabilities. The Company estimatesWe estimate receivables for the portion of professional and general liability reserves that are recoverable under the Company’sour insurance policies. Such receivable was $22.7$37.8 million as ofat December 31, 2017,2022, of which $17.6$10.2 million was included in other current assets and $5.1$27.6 million was included in other assets, and such receivable was $25.9$37.9 million as ofat December 31, 2016,2021, of which $6.5$10.8 million was included in other current assets and $19.4$27.1 million was included in other assets.
The Company’sOur statutory workers’ compensation program is fully insured with a $0.5 million deductible per accident. The workers’ compensation liability was $18.5$24.2 million as ofat December 31, 2017,2022, of which $10.0$12.0 million was included in accrued salaries and benefits and $8.5$12.2 million was included in other long-term liabilities, and such liability was $16.6$23.6 million as ofat December 31, 2016,2021, of which $10.0$12.0 million was included in accrued salaries and benefits and $6.6$11.6 million was included in other long-term liabilities. The reserve for workers compensation claims was based upon independent actuarial estimates of future amounts that will be paid to claimants. Management believes that adequate provisions have been made for workers’ compensation and professional and general liability risk exposures.
Property and Equipment and Other Long-Lived Assets
Property and equipment are recorded at cost. Depreciation is calculated on the straight-line basis over the estimated useful lives of the assets, which typically range from 10 to 50 years for buildings and improvements, three to seven years for equipment and the shorter of the lease term or estimated useful lives for leasehold improvements. When assets are sold or retired, the corresponding cost and accumulated depreciation are removed from the related accounts and any gain or loss is recorded in the period of sale or retirement. Repair and maintenance costs are expensed as incurred. Depreciation expense was $143.0$117.8 million, $134.8$106.7 million and $63.0$95.3 million for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.
The carrying values of long-lived assets are reviewed for possible impairment whenever events, circumstances or operating results indicate that the carrying amount of an asset may not be recoverable. If this review indicates that the asset will not be recoverable, as determined based upon the undiscounted cash flows of the operating asset over the remaining useful lives,life, the carrying value of the asset will be reduced to its estimated fair value. Fair value estimates are based on independent appraisals, market values of comparable assets or internal evaluations of future net cash flows. During the second quarter of 2021, we opened a 260-bed replacement facility in Pennsylvania and recorded a non-cash property impairment charge of $23.2 million for the existing facility. Additionally, during the third quarter of 2021, we recorded a $1.1 million non-cash property impairment charge for one facility in Louisiana resulting from hurricane damage.
We performed an impairment review of long-lived assets in the fourth quarter of 2022 and 2021 and recorded no impairment. The impairment review of long-lived assets in the fourth quarter of 2020 indicated the carrying amounts of certain of our long-lived assets may not be recoverable. This created a non-cash impairment of $4.2 million for the year ended December 31, 2020, which was recorded in loss on impairment on our consolidated statements of operations.
Goodwill and Indefinite-Lived Intangible Assets
Our goodwill and other indefinite-lived intangible assets, which consist of licenses and accreditations, trade names and certificates of need intangible assets that are not amortized, are evaluated for impairment annually during the fourth quarter or more frequently if events indicate that the carrying value of a reporting unit may not be recoverable. We have
As of our annual impairment tests on October 1, 2022 and October 1, 2021, we had one reporting unit, behavioral health services. The fair value of our behavioral health services reporting unit substantially exceeded its carrying value, and therefore no impairment was recorded.
During the second quarter of 2021, we sold one outpatient facility for $4.3 million and recorded a write down of $1.8 million of goodwill and $0.2 million of intangible assets related to the disposition. During the fourth quarter of 2021, we sold one outpatient facility for $1.5 million and recorded a write down of $0.7 million of goodwill and $0.1 million of intangibles related to the disposition.
49
As of our annual impairment test on October 1, 2020, we had two operating segments U.S. Facilities and U.K. Facilities, for segment reporting purposes, U.S. facilities and U.K. facilities, each of which representsrepresented a reporting unit for purposes of the Company’sour goodwill impairment test. Potential
Our annual goodwill impairment and other indefinite-lived intangible assets test performed as of October 1, 2020 considered recent financial performance, including the impacts of COVID-19 on certain portions of the U.K. business. The 2020 impairment test of the U.K. facilities indicated carrying value of the reporting unit exceeded the estimated fair value and resulted in a non-cash loss on impairment of the remaining goodwill of the U.K. facilities of $356.2 million. The non-cash loss on impairment is noted for a reporting unit if its carrying value exceedsincluded in loss on sale within discontinued operations in the consolidated statement of operations. As of our impairment test on October 1, 2020, the fair value of the reporting unit. For aour U.S facilities reporting unit with potential impairment of goodwill, we determine the implied fair value of goodwill. If thesubstantially exceeded its carrying value, of goodwill exceeds its implied fair value, an impairment loss is recorded. Our annual impairment tests of goodwill and other indefinite-lived intangibles in 2017, 2016 and 2015 resulted intherefore no impairment charges.
Income Taxes
We use the asset and liability method of accounting for income taxes. Under this method, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carryforwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, as applicable, based on tax rates and laws in the respective tax jurisdiction enacted as of the balance sheet date.
We review our deferred tax assets for recoverability and establish a valuation allowance based on historical taxable income, projected future taxable income, applicable tax strategies, and the expected timing of the reversals of existing temporary differences. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
We report a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense.
We also haveestablished accruals for taxes and associated interest that may become payable in future years as a result of audits by tax authorities. We accrue for tax contingencies when it is more likely than not that a liability to a taxing authority has been incurred and the amount of the contingency can be reasonably estimated. Although weWe believe that the positions taken on previously filed tax returns are reasonable we neverthelessand have not established tax and interest reserves in recognition that various taxing authorities may challenge the positions taken by us resulting in additional liabilities for taxes and interest. These amounts are reviewed as circumstances warrant and adjusted as events occur that affect our potential liability for additional taxes, such as lapsing of applicable statutes of limitations, conclusion of tax audits, additional exposure based on current calculations, identification of new issues, release of administrative guidance, or rendering of a court decision affecting a particular tax issue.
Financial Accounting Standards Board Accounting Standards Codification 740 requires us to recognize the effect
50
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.Risk
Information with respect to this Item is provided under the caption “Market Risk” under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Item 8. Financial Statements and Supplementary Data.Data
Information with respect to this Item is contained in our consolidated financial statements beginning on PageF-1 of this Annual Report onForm 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.Disclosure
None.
Item 9A. Controls and Procedures.Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, our management conducted an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined inRules 13a-15(e) and15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on this evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
Reports on Internal Control Over Financial Reporting
Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we have included a report of management’s assessment of the design and operating effectiveness of our internal controls as part of this report. Our independent registered public accounting firm also reported on the effectiveness of internal control over financial reporting. Management’s report and the independent registered public accounting firm’s report are included in our consolidated financial statements beginning on pageF-1 of this report under the captions entitled “Management’s Report on Internal Control Over Financial Reporting” and “Report of Independent Registered Public Accounting Firm.”
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the quarter ended December 31, 20172022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
51
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Directors
The information with respect to our directors set forth under the caption “Election of Directors” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Audit and Risk Committee
The information with respect to our Audit and Risk Committee and our audit committee financial experts serving on the Audit and Risk Committee is set forth under the caption “Corporate Governance – Committees of the Board of Directors – Audit and Risk Committee” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Executive Officers
The information with respect to our executive officers set forth under the caption “Management – Executive Officers” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Section 16(a) Compliance
The information with respect to compliance with Section 16(a) of the Exchange Act set forth under the caption “Security Ownership of Certain Beneficial Owners and Management—Delinquent Section 16(a) Beneficial Ownership Reporting Compliance”Reports” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Stockholder Nominees
The information with respect to the procedures by which stockholders may recommend nominees to the Boardboard of Directorsdirectors set forth under the caption “Corporate Governance – Nomination of Directors – Nominations by Our Stockholders” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Corporate Governance Documents
We have adopted a Code of Conduct that applies to all of our directors, officers and employees and a Code of Ethics for Senior Financial Officers. These documents, as well as the charters of the Audit and Risk Committee, Compensation Committee, Compliance Committee, and Nominating and Governance Committee, are available on our website at www.acadiahealthcare.com on the Investors webpage under the caption “Corporate Governance.” Upon the written request of any person, we will furnish, without charge, a copy of any of these documents. Requests should be directed to Acadia Healthcare Company, Inc., 6100 Tower Circle, Suite 1000, Franklin, Tennessee 37067, Attention: Christopher L. Howard, Esq. We intend to disclose any amendments to our Code of Ethics and any waiver from a provision of our code, as required by the SEC, on our website.
Item 11. Executive Compensation
The information with respect to the compensation of our executive officers set forth under the captions “Executive Compensation” and “Compensation Discussion and Analysis” and the information set forth under the captions “Director Compensation,” “Corporate Governance – Compensation Committee Interlocks and Insider Participation,” and “Compensation Committee Report” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
52
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information with respect to security ownership of certain beneficial owners and management and related stockholder matters set forth under the caption “Security Ownership of Certain Beneficial Owners and Management” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Equity Compensation Plan Information
The following table provides information as ofat December 31, 20172022 with respect to compensation plans (including individual compensation arrangements) under which shares of Common Stock are authorized for issuance:
Plan Category | Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights | Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans(1) | Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights |
|
| Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights |
|
| Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (a) |
| ||||||||||||||
Equity Compensation Plans Approved by Stockholders(2) | 2,491,252 | (3) | $ | 53.44 | 4,498,687 | ||||||||||||||||||||
Equity Compensation Plans Not Approved by Stockholders(4) | 15,000 | $ | 5.64 | — | |||||||||||||||||||||
|
| ||||||||||||||||||||||||
Equity Compensation Plans Approved by Stockholders (b) |
| 3,298,279 |
| (c) |
|
| $ | 46.27 |
|
|
| 3,133,811 |
| ||||||||||||
Equity Compensation Plans Not Approved by Stockholders |
| — |
|
|
| $ | — |
|
|
| — |
| |||||||||||||
Total | 2,506,252 | $ | 47.89 | 4,498,687 |
| 3,298,279 |
|
|
|
|
|
|
|
| 3,133,811 |
| |||||||||
|
|
(a) | Excludes shares to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units. |
(b) | Represents securities issued or available for issuance under the Acadia Healthcare Company, Inc. Incentive Compensation Plan. |
(c) | Includes |
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information with respect to certain relationships and related transactions and director independence set forth under the captions “Certain Relationships and Related Transactions” and “Corporate Governance – Independence of the Board of Directors” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
The information with respect to the fees paid to and services provided by our principal accountants set forth under the caption “Ratification of Appointment of Independent Registered Public Accounting Firm” in our Definitive Proxy Statement for the Annual Meeting of Stockholders to be held May 3, 201818, 2023 is incorporated herein by reference.
53
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(a) The following documents are filed as part of this Annual Report on Form10-K:
The consolidated financial statements required to be included in Part II, Item 8, Financial Statements and Supplementary Data, begin on PageF-1 and are submitted as a separate section of this report.
|